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Abstract
Introduction
This thesis describes the aetiology, pathology, diagnosis and management of children
with constipation. In particular, it describes a condition, slow transit constipation,
which represents a form of chronic childhood constipation that is not readily
responsive to conventional treatment.
Hypothesis and aims
Firstly this thesis hypothesises that quality of life is affected by slow transit
constipation when subjects are compared to healthy age matched controls. Secondly,
it proposes to ascertain whether or not nuclear scintigraphy represents a reliable
means of assessing colonic motility. Thirdly, it seeks to determine whether or not
transcutaneous electrical stimulation (in the form of interferential therapy) has the
ability to alter either the clinical symptoms, quality of life or colonic transit of
children with slow transit constipation. Lastly, this thesis aims to look at a subgroup
of children with slow transit constipation managed by antegrade continence enemas
delivered via an appendix stoma, and determine whether or not colonic activity,
measured by a manometric catheter inserted via their appendicostomy, is affected by
transcutaneous inferential therapy.
Methods
Study 1 - Children (8-18yrs) with symptoms of constipation and proven slow transit
constipation on nuclear scintigraphy, with symptoms for >2years unresponsive to
conventional dietary, medical and behavioural therapies, were recruited from
xxvi
gastrointestinal and surgical out-patient clinics. Control subjects were recruited from
a local scout jamboree. QoL was assessed using the PedsQL tool that consists of
parallel parent and child reported scores. Physical, psychosocial and total quality of
life scores were compared using Wilcoxon matched pairs and Mann Whitney tests.
Study 2 - Children (8-18yrs) with symptoms of constipation for >2years
unresponsive to conventional dietary, medical and behavioural therapies, who had
had 2 nuclear transit studies performed on separate occasions were recruited from
gastrointestinal and surgical out-patient clinics. Geometric centres of radioactivity
were compared at 6, 24, 30 and 48hrs. The GC at each time point for the initial and
repeat studies were compared by parametric statistical analysis (paired t-test).
Study 3 - Children (8-18yrs) with symptoms of constipation and proven slow transit
constipation on nuclear scintigraphy, with symptoms for >2years unresponsive to
conventional dietary, medical and behavioural therapies, were recruited from
gastrointestinal and surgical out-patient clinics. Children were randomised to receive
either real or placebo interferential therapy consisting of 12 treatment sessions over a
4 week period. Frequency of defecation, soiling and abdominal pain were assessed
before, during and after intervention. Quality of life scores (PedsQL, Holschneider
and Templeton) and gastrointestinal transit time (nuclear scintigraphy) were also
evaluated before and after treatment. Data were analysed using independent sample
and paired t tests. Where the data were not normally distributed, either Mann
Whitney or Wilcoxon matched pairs testing was performed.
Study 4 - Children (8-18yrs) with symptoms of constipation and proven slow transit
constipation on nuclear scintigraphy, with symptoms for >2years unresponsive to
conventional dietary, medical and behavioural therapies, with pre-existing appendix
stomas were recruited from gastrointestinal and surgical out-patient clinics. Subjects
received the same intervention as described in study 3 with all participants receiving
real interferential therapy. Colonic activity was assessed pre- and post-intervention
by colonic manometry - the catheter having been inserted in an antegrade fashion via
the appendicostomy. Data were analysed using paired t tests.
Results
Study 1 - Subjects with slow transit constipation (n=51) described significantly
poorer quality of life than age matched controls (n=79). This was so for total child
reported (p = < 0.0001) and parent reported (p < 0.0001) scores. Reported scores for
subjects with slow transit constipation were comparable to other chronic disease
states.
Study 2-7 children were recruited in whom 2 nuclear transit studies had been
performed. There was no statistical difference between the 2 studies when
comparing mean geometric centre of radioactivity at 6hrs (p = 0.161), 24hrs (p =
0.780), 30hrs (p = 0.947) and 48hrs (p = 0.615).
Study 3-35 children were recruited, 18 of whom were randomised to receive real
interferential therapy. There were no statistical differences between the 2 groups.
There was no change in frequency of defecation or soiling. There was a small
improvement in episodes of abdominal pain in the group that received real treatment
(p = 0.05). There appeared to be a decrease in colonic transit time as measured by
nuclear scintigraphy after intervention with real interferential therapy. There was a
significant difference in the post-intervention GC between the 2 treatment arms at 24
(p = 0.004), 30 (p = 0.02) and 48 (p = 0.002) hours. Comparing the 2 treatment
groups before and after intervention there was no change in quality of life scores.
When looking at each individual treatment arm, children described a significant
improvement in their quality of life (PedsQL scores) after real interferential therapy
(p = 0.005).
Study 4-5 children underwent colonic manometry before and after treatment with
inferential therapy. There was a small increase in antegrade colonic activity
following intervention p = 0.03. No other measured parameters were affected
(amplitude, duration, velocity and regional linkage). There was no statistical
difference in their frequency of episodes of defecation, soiling or abdominal pain.
Conclusion
This thesis concludes that quality of life is adversely affected by slow transit
constipation and that evaluation of quality of life should be part of routine
assessment of children with constipation. It also proposes that nuclear scintigraphy
represents a reliable means of assessing colonic transit in states of colonic inertia
such as slow transit constipation. Lastly, having demonstrated varied subjective and
objective responses to its application, it proposes that further evaluation is required to







Constipation is one of the most common conditions affecting western society. Its
prevalence is between 5 and 30%, depending on the diagnostic criteria utilised
Gastrointestinal motility is affected by genetic, organic, environmental and
psychological factors. Many different aetiological factors can result in the common
features of decreased bowel frequency or impaired rectal evacuation or recurrent
faecal soiling. The diagnosis of constipation requires careful history-taking,
thorough examination and individually tailored investigation.
1.2 Constipation in children
Constipation occurs in around 3% of children and accounts for 3-5% of visits to
paediatricians and 10-25% of referrals to gastroenterologists 2-5. A positive family
history can be found in 28-50% of constipated children and a higher incidence has
been reported in monozygotic than dizygotic twins. The peak incidence of
constipation occurs at the time of toilet training (between 2 and 4 years of age), with
an increased prevalence in boys.
1.3 Definition of constipation
There is much discrepancy concerning the definition of constipation. In part this is
due to the wide range of what is perceived as a normal stooling pattern. Definitions
can be based on stool frequency, stool consistency, ease of defecation and associated
symptoms such as soiling, bloating and abdominal pain. Although it is often
accepted that there is no precise definition of constipation that encompasses all
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people, the North American Society for Pediatric Gastroenterology, Hepatology and
Nutrition (NASPGHAN) describes it as a "delay or difficulty in defecation present
for 2 weeks or more" 6. More recently, the Paris Consensus on Childhood
Constipation Terminology (PACCT) group 7 has defined chronic constipation in
children as the occurrence of 2 or more of the following characteristics during the
previous 8 weeks:
• Less than 3 stools per week
• More than one episode of faecal incontinence per week
• Large stools in the rectum or palpable on abdominal examination
• Passing of very large stools that obstruct the toilet
• Retentive posturing and withholding behaviour
• Painful defecation
Faecal incontinence is defined as "the passage ofstools in an inappropriate place"
and has been chosen as a term to replace "encopresis" or "soiling". It can be either
organic (caused by an identifiable neurochemical, neuroendocrinologic or structural
anomaly) or functional in origin with functional faecal incontinence being further
classified as (i) constipation-associated: the passage ofstools in inappropriate places
by a child with a mental age of 4 years or older where the behaviour is associated
with constipation or (ii) non-retentive: the passage of stools in inappropriate places
by a child with a mental age of 4 years or older who shows no evidence of
constipation by history and /or examination.
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A normal bowel habit is defined by NASPGHAN as "having between 3 movements a
week and 3 movements a day with stools that are brown or golden brown and
formed, with a texture similar to peanut butter, and a size and shape similar to a
sausage" 6. The frequency of stooling will also vary with age and, in babies, how
they are fed 8 (Table 1):
Table 1 - Age related frequency of stooling in children.
• 0-3 months (breast fed) 5-40 motions/week
• 0-3 months (formula fed) 5-20
• 6-12 months 5-28
• 1-3 years 4-21
• >3 years 3-14
1.4 Normal defecation
Defecation is the act or process by which solid or semisolid waste material (faeces) is
eliminated from the digestive tract via the anus. It is a complex process that requires
precise co-ordination of contraction and relaxation of both voluntary and involuntary
muscles. The rectum acts as a temporary storage facility for the faecal material. It is
about 12 cm long, and although at its commencement its calibre is similar to that of
the sigmoid colon, near its termination it is dilated to form the rectal ampulla.
Defecation is usually stimulated by rectal distension that is detected by stretch
receptors situated in the wall of the rectal ampulla. It has also been suggested that
sensory receptors in the pelvic floor relay signals to the brain when stool first arrives
in the rectum 9. The firing of the stretch receptors in the ampulla initially triggers the
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'recto-anal inhibitory reflex'. This involves relaxation of the internal anal sphincter
in association with contraction of the external anal sphincter and the puborectalis
segment of levator ani. As stretching increases, and the 'defecation threshold
volume' is reached, an urge to defecate is perceived. The rectum shortens and
widens (the anorectal angle increases from 90-110° to 135 °) as puborectalis relaxes
and evacuation occurs by rectal wall peristalsis accompanied by an increase in intra¬
abdominal pressure. The act of defecation is made easier by appropriate posture.
Leaning forward whilst seated with the feet supported lengthens the anal opening and
widens the anorectal angle.
1.5 Aetiology of childhood constipation
Constipation is either organic or functional in origin, with the majority of children
having no organic basis for their symptoms 4. Organic causes of childhood
constipation include congenital anatomic or structural defects, metabolic and
endocrine disorders, neurological disorders, connective tissue disorders,
gastrointestinal disorders, cystic fibrosis and medications (Table 2). Any child with
ongoing constipation should have an organic cause for their constipation excluded
before a diagnosis of functional constipation is made.
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Table 2 - Causes of constipation in children.
Congenital anatomic or structural defects





abnormal abdominal musculature - prune belly, gastroschisis, Down's
syndrome






multiple endocrine neoplasia type 2B
Chronic intestinal pseudo-obstruction
Cystic fibrosis




damage to the spinal cord - meningomyelocele, trauma, surgery, tumours,







Cow milk intolerance or other food allergies
Other causes
colonic dysmotility (Slow Transit Constipation - STC)




















Functional constipation is diagnosed in those children where there is no objective
evidence of an underlying pathological condition and is defined by the Rome III
criteria (Table 3) 10 11. The majority of children with functional constipation have a
dietary cause for their constipation, functional faecal retention (FFR) or both.
Children with FFR exhibit a stool-withholding pattern of defecation. It is believed
that this pattern develops due to previous painful defecating experiences that lead to
voluntary withholding of faeces in order to avoid further painful defecation 4 6. It is
estimated that up to 63% of children with constipation and soiling have had a history
of painful defecation which began when they were under 3 years of age 12.
Alternatively, the initial insult can be as a result of toilet training, changes in routine
or diet, stressful events, intercurrent illness, perianal irritation (nappy rash or group
A, p-haemolytic streptococcus infection), unavailability/dislike of toilets or
postponement of defecation due to lack of interest or attention 6. This manner of
stooling results in prolonged faecal colonic stasis, with increased reabsorption of
faecal fluid, and leads to an increase in the size and consistency of the stools.
Overflow diarrhoea or soiling is the result of watery faecal matter trickling around
retained, hardened faeces. With time the rectum becomes accustomed to the constant
stimulus of a faecal mass and the normal urge to defecate is lost. This decrease in
rectal sensation also means that the child is often unaware of the unintentional
passage of faecal matter.
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Table 3 - Rome III criteria for diagnosis of functional constipation10.
Diagnostic Criteria for Functional Constipation (Rome III)
Must include two or more of the following in a child with a developmental age of at
least four years
Two or fewer defecations in the toilet per week
At least one episode of faecal incontinence per week
History of retentive posturing or excessive volitional stool retention
History of painful or hard bowel movements
History of a large faecal mass in the rectum
History of large diameter stools that may obscure the toilet
Criteria must be fulfilled at least once per week for at least two months before
diagnosis
1.6 Idiopathic constipation
Children with no obvious organic cause for their constipation should be managed by
a combination of dietary changes, laxatives and/or stool softeners and/or bulking
agents and behavioural modification and toilet training. Toilet posture education and
pelvic floor muscle training by a physiotherapist should be considered. Seventy
percent of children presenting with constipation will respond to this treatment
strategy within 2 years 1314.
1.7 Treatment-resistant constipation
Thirty percent of children with constipation fail to respond to medical management.
They are said to have treatment-resistant or "chronic" constipation. Until recently it
was believed that most children with treatment-resistant constipation had a functional
or behavioural basis for their symptoms 15. This is now not the case, with a definite
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population of children with chronic constipation having been shown to have a novel
condition called slow transit constipation (STC).
1.8 Slow transit constipation (STC)
Idiopathic slow transit constipation (STC) describes a clinical syndrome
characterised by intractable constipation that is not readily responsive to laxatives,
diet or a change in lifestyle 16. It is characterised by delayed colonic transit without
an underlying systemic disorder or pelvic floor dysfunction. Although it was initially
described in young women of reproductive age 1718 it has now been recognised as a
condition affecting children of all ages 19. Up to 50-60% of children with chronic
treatment-resistant constipation may have slow colonic transit 20. Recently, it has
been suggested that STC may be part of a pan-enteric disorder as alterations in
oesophageal motility 21, gastric emptying 21 22 and small bowel motility 23 24 25 have
been observed in some patients with STC.
1.9 The pathology of slow transit constipation
It is believed that in children with STC, the primary defect lies within the enteric
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nervous system (ENS) . Both clinical and manometric data suggest that the
abnormal motility associated with STC should be considered as neuropathic in nature
26. The gastrointestinal tract contains its own nerve cell bodies which form an
intrinsic network that is connected to the central nervous system via the vagal,
coeliac and pelvic nerves. Enteric neurons have cell bodies within ganglia that lie in
the myenteric or submucosal plexuses. The cell bodies have processes that penetrate
the muscle layers where they release their neurotransmitters. Acetylcholine (ACh)
9
and tachykinins (including substance P) cause gastrointestinal muscular contraction
whilst relaxation is initiated by the release of vasoactive intestinal peptide (VIP),
nitric oxide (NO) and ATP.
Some studies have suggested that some patients with STC have an element of
97 90
subclinical autonomic neuropathy " , in particular, selective small fibre
neuropathies 28. The same authors hypothesise that STC occurring in women post
childbirth, or following pelvic surgery, may be as a result of pelvic nerve injury and
that in a subgroup of people, STC should be considered a disorder of pelvic
29
autonomic nerves .
Most studies using conventional histological methods to examine the colon in
subjects with STC have failed to identify consistent abnormalities of the ENS 31"33.
Outdated methods employing silver staining techniques report a reduction in the total
number of argyrophilic neurones along with some morphological and axonal
abnormalities 34. It was with the advent of immunohistochemistry that abnormalities
in the enteric neurotransmitters and neuropeptides (substance P, vasoactive intestinal
peptide (VIP) nitric oxide synthase (NOS), neuropeptide Y and 5-HT) were first
reported, however findings have been inconsistent with decreased, increased and
unchanged levels all being described 20 35-40. Although these findings could suggest
that alterations of enteric neurotransmitters do not play a major role in the
pathophysiology of STC, it is more likely that STC represents a heterogeneous group
of disorders with the same end result - delayed colonic transit.
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Although they were discovered in 1893 41, it is only relatively recently that the true
importance of interstitial cells of Cajal (ICC) is finally being recognised. ICC are
found in the tunica muscularis throughout the gastrointestinal tract and lie between
enteric nerve terminals and smooth muscle 42 45 (Figure 1). Although their precise
role has remained undetermined for several decades, it is now thought that they act as
a conduit for active transmission of electrical slow waves as well as serving as
gastrointestinal pacemaker cells. A loss of ICC has been demonstrated in a range of




Figure 1 - Old and new models of neuromuscular transmission in the
gastrointestinal tract, (a) Old two cell model. Action potentials travelling
along nerve fibres caused release of neurotransmitter from varicosities.
Transmitter diffused across extracellular space and bound to receptors on
muscle cells inducing contraction or relaxation, (b) New three cell model.
Interstitial cells of Cajal have receptors for transmitters and are connected to




among the smooth muscle cells. Transmitter released from nerve fibres
binds to receptors on ICC, modifying excitation with changes conveyed to
adjacent ICC and muscle cells by electrical conduction. ICC also act as
pacemaker cells generating and conducting rhythmic electrical activity that
produces slow waves. AP - action potential; ICC - interstitial cells of Cajal;
SMC - smooth muscle cell; ® - transmitter; ■ - receptor20.
1.10 Diagnosis
1.10.1 Clinical
Medical history and physical examination are essential when diagnosing constipation
and a thorough ante-natal/birth/post-natal history should be obtained (Table 4). It is
important to clarify what each individual family defines as "constipation" by
determining the occurrence of specific symptoms and their frequency. Essential
information includes an accurate gastrointestinal and general medical assessment as
well as a developmental and psychosocial evaluation. Delayed first passage of
meconium, frequent soiling, passage of large soft stools, abdominal distension and
bloating are all common features associated with STC.
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Table 4 - Model of history taking and examination in a child with
constipation.
Demographics General appearance
Age Failure to thrive
Sex
Routine observations
Presenting symptoms Height and weight
Frequency of defecation Pulse
Behaviour associated with defecation Blood pressure
Consistency of stools
Soiling General examination
Pain (abdominal, rectal or other) Including cardiovascular and





Toilet training Abdominal mass - including
Onset and duration of symptoms faecaloma
Palpable bowel loops
Previous diagnoses and treatments
Neurological and spinal
Current treatment examination
Lower limb - tone, reflexes and
Peri-natal history power
Any ante-natal concerns/diagnoses Sacral dimple/sacral hair tuft
Gestation Obvious spinal deformity
Birth condition (need for ITU/special care) Muscle (especially buttock)
Time of passage of meconium wasting
Developmental history Anal inspection
Growth and attainment of developmental Site
markers Visible stool (skin and clothing)
Skin condition
Past medical historv Perianal skin tags
Hospital admissions (medical and surgical) Anal fissure
Urinary symptoms
Hypothyroidism associated symptoms Rectal examination
Anal wink
Dietary historv Anal tone
Pain
Medications Presence/consistency of stool
Immunisations Pelvic mass





Gastrointestinal and other significant illnesses
(including thyroid disease, cystic fibrosis,
coeliac disease, neurological conditions,
connective tissue disorders, diabetes)
Psychosocial history
Age appropriate quality of life assessment
A thorough physical examination is essential in the initial assessment of a child with
constipation (Table 4). This should include a general examination as well as an
abdominal examination and external examination of the perineum and perianal area.
A rectal examination should be performed by an appropriately experienced
. . 20
practitioner .
Blood samples should be obtained for coeliac disease screening and thyroid function
testing. A high percentage of eosinophils in the white cell differential of a full blood
count can be seen in cases of cows' milk protein intolerance 20.
1.10.2 Radiological
1.10.2.1 Abdominal X-ray
Plain abdominal x-rays have debatable value in the assessment of constipation 55. If
faecal impaction or loading is obvious on rectal or abdominal examination then little
more information can be attained by means of a plain x-ray. On rare occasions an x-
ray is useful to identify a vertebral anomaly (e.g. sacral agenesis and Currarino
Syndrome). Abdominal x-rays can be used to assess the presence and degree of
abdominal loading, especially in obese subjects or in those in whom a rectal
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examination is refused or inappropriate, however interpretation can be subjective and
x-ray timing in relation to defecation can be misleading.
1.10.2.2 Transit Studies (Overview)
Colonic transit time takes between 1-3 days during which time there is extensive
mixing of stool. The quantification of transit time demonstrates the presence of
constipation and provides an objective evaluation of faecal clearance. Transit time
has traditionally been measured using plastic, non-absorbable radio-opaque markers
with transit time in different regions being determined by the ingestion of different
shaped markers over 3-6 days 56~59. Studies measuring normal transit in children give
the upper range of total colonic transit from 46-62 hr 60. Transit rates in children less
than 5 years old are faster, whilst children aged 6 years or more have a range of
transit and frequency of defecation similar to adults. This mode of assessment of
gastrointestinal transit time is widely available and until recently has been considered
the gold standard. However, it has now been recognised that indigestible solid
particles do not move with a meal, and may not be handled by the colon in the same
manner as stool 61. Consequently, gastrointestinal transit is increasingly being
investigated using scintigraphy (nuclear transit study) 62-70. A tracer dose of
technetium, or gallium, in 20ml of milk is ingested and images obtained at 0-2 hours
to assess gastric emptying and a further image at 6 hours to ascertain whether or not
the tracer has reached the colon. Subsequently, images are obtained at 24, 30 and 48
hours to document transit through the colon. The colonic transit index can be
obtained based on the geometric mean of intestinal activity at 6, 24, 30 and 48 hours
(and 72 hours for adults) post-ingestion of tracer. By this means, patients with small
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bowel, right, left or pan-colonic (STC) or pan-intestinal transit deficits can be
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Figure 2 - Nuclear transit studies demonstrating (a) slow transit
constipation (STC) and (b) functional faecal retention (FFR) 20.
1.10.3 Rectal Mucosal Biopsy
In cases of intractable constipation with a history of delayed passage of meconium or
symptoms since birth, a diagnosis of Hirschsprung's disease needs to be eliminated
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by performing a rectal mucosal biopsy. Biopsy specimens are obtained from approx
3cm above the anal verge and should be deep enough to include adequate submucosa
71
. A diagnosis of Hirschsprung's disease is supported by an absence of ganglion
cells, usually in the presence of hypertrophied extrinsic nerve fibres, with a marked
increase in acetylcholinesterase activity in the lamina propria and muscularis mucosa
72. A rectal biopsy is also useful in identifying those children with a food allergy, as
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recognised by increased eosinophils in the mucosa .
1.10.4 Laparoscopic Colonic Biopsies
Recently, in those children with proximal colonic delay demonstrated by their transit
study, laparoscopic seromuscular biopsies are being performed in association with
rectal biopsy, in some centres, in an attempt to identify any consistent histological
anomalies. Biopsies are collected from the hepatic flexure, midtransverse colon,
splenic flexure and sigmoid colon without the need for suturing the defect 73.
Specimens are processed for immunofluorescence histochemistry and are stained for
substance P, VIP, NOS or cKit (a marker ICC). It has been proposed that some
children with STC have a form of intestinal neuronal dysplasia (IND), which
represents an abnormality of intestinal innervation that is more subtle than
Hirschsprung's disease and can be diagnosed by abnormal immunohistochemistry 73"
75
1.10.5 Colonic Manometry
Colonic manometry involves the in vivo measurement of changes in intraluminal
pressure within the colon. A multi-channel water-perfusion or solid-state pressure
17
recording catheter is sited in the colon in either a retrograde manner via colonoscopy,












Figure 3 - Abdominal radiograph showing an antegradely inserted 8
channel manometry catheter passing percutaneously through the
appendix (App) to the rectum (Rec) with the position of the side holes
shown 76.
Colonic contractile activity produces changes in intraluminal pressure seen as a
deviation from the baseline. Contractions can be non-propagating or propagating
with propagating contractions being in either an antegrade or retrograde direction
(Figure 4). High amplitude contractions (>116mmHg) are thought to represent mass
movement within the colon. Standards for colonic manometry in children have been
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defined and parameters measured 77. Expected frequency of propagating sequences,
ratio of antegrade to retrograde contractions, frequency of high amplitude














































Figure 4 - Colonic manometry showing (a) an antegrade propagating
sequence and (b) a retrograde propagating sequence 76.
1.11 Differential diagnosis
1.11.1 Hirschsprung's Disease (HD)
This represents a congenital condition where there is abnormal innervation
(aganglionosis - absent parasympathetic ganglion cells) of the bowel that results in
difficulty stooling. It has an approximate incidence of 1:5,000 live births 71. HD is
associated with a chromosomal abnormality in 12% of cases with an additional 18%
7R
of cases having other congenital anomalies . HD is characterized by the absence
of intrinsic ganglion cells in the submucosal and myenteric plexuses of the enteric
nervous system that is thought to result from premature migration arrest of neural
7Q
crest cells in the hindgut between 5 and 12 weeks of gestation . There is a wide
variation in the possible length of affected bowel, with the disease mostly affecting
the distal-most part of the rectum then spreading proximally. The aganglionic bowel
is in a constant state of spasm, causing a functional obstruction. HD that has a short
aganglionic segment, involving the anal canal, +/- rectum, +/- sigmoid colon, is 5
times more common in males than in females. However, the less common, long
segment HD is equally common in males and females and is more likely to have a
positive family history 71.
Cases of HD most commonly present in the neonatal period with delay in the passage
of meconium (>48 hours after birth), bilious vomiting and non-tender abdominal
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distension. Rectal examination with a probe classically causes explosive
decompression of meconium through the tight anal sphincters 71.
Plain abdominal radiographs show marked gaseous distension of the bowel proximal
to the affected segment (Figure 5). A diagnosis of HD can sometimes be made with
a lower gastrointestinal (GI) contrast study. There may be constriction of the
segment of bowel affected by the HD tapering through a transition zone to a
distended megacolon. However, contrast studies in association with ultrashort- or
long-segment disease may appear normal. HD is definitively diagnosed by suction
rectal biopsy where a lack of ganglion cells in the affected bowel, along with
increased acetylcholinesterase (AChE) staining, is indicative of the condition 71.
Figure 5 - Abdominal radiograph in neonate with Hirschsprung's
Disease 71.
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Initial management consists of decompression of the bowel either by regular trans¬
anal washouts or the formation of a defunctioning sigmoid colostomy. Definitive
treatment involves performing a "pull-through" operation where the normally
innervated bowel is brought down and sutured to the anus at the level of the anal
valves 71.
1.11.2 Chronic intestinal pseudo-obstruction (CIP)
Chronic intestinal pseudo-obstruction (CIP) is an intestinal motility disorder that
manifests as episodes of intestinal obstruction without mucosal or structural evidence
of mechanical blockage and is thought to be as a result of injury to the neural control
80mechanisms responsible for intestinal peristalsis . There are a variety of known
causes of CIP (Table 5) although it most commonly occurs secondary to conditions
that impair neuromuscular function. In addition to affecting either the small or the
large intestine, CIP can also involve the oesophagus, stomach, ureters and bladder.
The clinical features of CIP are dependent on the organs affected, the duration and
severity of illness, any co-morbidities and the degree of resultant nutritional
80
compromise . Early on in the disease, intermittent symptoms of bloating, nausea,
pain and erratic defecation are often attributed to recurrent gastrointestinal upset.
Symptoms then commonly become more chronic with additional severe, acute
exacerbations occurring at irregular intervals, and frequently without identifiable
triggers, that often require hospitalisation for intravenous fluid therapy, analgesia and
nutritional support80.
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Table 5 - Causes of chronic intestinal pseudo-obstruction (CIP) 80.
Primary chronic intestinal pseudo-obstruction
Visceral myopathy (familial or sporadic)
Visceral neuropathy (familial or sporadic)
Normal histology variant (sporadic only)

































Patients should be assessed as for any other cause of constipation/change in bowel
habit, with a full history, examination and appropriately tailored investigations. In
the first instance, plain abdominal radiographs and contrast studies are important to
exclude obstruction. It may then be appropriate to perform oesophageal/duodenal/
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small bowel/colonic or anorectal manometry and/or a gastrointestinal transit study to
identify any patterns of abnormal motility.
CIP is usually managed by a combination of medical therapy (pharmacological
agents that increase intestinal motility) and nutritional support but occasionally
requires surgical intervention (endoscopic placement of venting tubes and/or feeding
81tubes or stomas for intestinal decompression) . Providing adequate oral intake is
the biggest problem associated with CIP. Low lactose, low fat and low residue diets
have all been proposed as a means of reducing intestinal symptoms. In some
patients, symptoms can be so severe that that they require total parenteral nutrition
(TPN) in order to maintain an adequate caloric and fluid intake. Complications
related to TPN are the commonest cause of death in children with CIP 81.
1.11.3 Intestinal neuronal dysplasia
First described by Meier-Rouge in 1971, intestinal neuronal dysplasia (IND) was
initially depicted as a colonic, pseudo-Hirschsprung disorder characterised by
hyperganglionosis 82. It has now been recognised as a condition that can affect any
part of the GI tract and has been classified into 2 clinical and histochemical subtypes,
83A and B . Type A is a rare condition characterised by congenital hypoplasia or
aplasia of the sympathetic adrenergic innervation of the intestine. Patients present as
infants with diarrhoea, bloody stools and colonic spasticity. In contrast, in the more
common type B disease it is the enteric plexus that is primarily affected and presents
as intestinal dysmotility, chronic constipation and/or pseudo-obstruction in the first 3
years of life 83.
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The aetiology of IND type B remains largely unclear, however it is proposed that it is
caused by a reaction of the ENS to intestinal obstruction or inflammatory disease
84either in the foetal or post-natal period . There is a high incidence of associated
anomalies in patients with IND, with one series describing a rate of 30.5%,
increasing to 80% when only cases of diffuse disease (cf. rectocolonic) were
considered 85. Associated anomalies include intestinal malrotation, megacystis,
congenital short small bowel, hypertrophic pyloric stenosis, necrotising enterocolitis,
mental retardation, short stature, facial dysmorphia, Down's syndrome, intestinal
atresia, diffuse intestinal angiomatosis, histiocytosis, microvillus agenesis and
oc
hearing loss .
Diagnosis is often made by histochemical analysis of tissue obtained by rectal
suction biopsy. Scharli and Meier-Ruge initially described diagnostic criteria based
on the following histochemical findings: (i) increased AchE activity in the lamina
propria, (ii) hyperplasia ("giant ganglia") within the submucosal plexus, (iii)
heterotopia of neurone cells in the lamina propria mucosa, and (iv) increased AchE
oz:
activity in the circular muscle layer . These were modified by Borchard et al who
state that obligatory histochemical findings are (i) hyperplasia of the submucosal
86
plexus and (ii) increased AchE activity around submucosal vessels .
Despite these specific diagnostic criteria, there is much debate surrounding IND,
with many clinicians remaining unconvinced about its existence 87_9°. A prospective
study looked at the interobserver reliability of three pathologists with respect to the
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aforementioned histochemical features, and thus final diagnosis, of IND in rectal
biopsy specimens from symptomatic children aged 4 days to 15 years 91. The authors
found that although there was no discrepancy amongst the pathologists in cases
where there was aganglionosis (HD, k = 1), there was, however, high interobserver
variability in those cases without aganglionosis where a diagnosis of either normal or
IND was made (k values close to those expected by chance). The authors concluded
that some of the previously documented histological 'abnormalities' may in fact be
features of normal immature bowel and recommended that rectal biopsies in children
should only be used to confirm, or refute, a diagnosis of HD.
oo
This conclusion is supported by Lumb et al who believe that up to 95% of
constipation in children is due to FFR and that IND simply provides concerned
parents with a hollow diagnosis. They also believe that finding giant ganglia within
the submucosal plexus may be a normal variant rather than a pathological finding 89
and report finding giant ganglia in 76-78 % of normal colonic specimens resected for
colonic carcinoma. They conclude that following observations that homeobox Enx
(HoxllLl) knockout mice appear to have similar colonic features to those seen in
IND type B 92, identifying a human homologue for this mouse gene may circumvent
any current histological diagnostic difficulties.
1.11.4 Hypoganglionosis
Hypoganglionosis refers to a condition whereby functional intestinal obstruction
occurs in association with histochemical findings of fewer intestinal ganglion cells
within the myenteric plexus 93. However, as with IND, there remains extensive
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scepticism concerning its existence as a true clinical entity 94. As yet, the exact
histological criteria for diagnosing hypoganglionosis have not been established and
very few articles have been published using morphometric examinations. Taguchi et
al 95 have recently suggested that two forms of hypoganglionosis exist; congenital
and acquired. They reported a series of twenty four cases of functional intestinal
obstruction (excluding HD) requiring either small and/or large bowel resection.
Thirteen cases had immature ganglion cells, characterised by either normal or
increased numbers of ganglion cells with small nuclei. Seven cases had congenital
hypoganglionosis where both the number and size of the ganglion were reduced in
association with a decrease in the size of Auerbach's plexus. Four cases had
acquired hypoganglionosis with decreased numbers of ganglion cells in association
with preservation of the size of Auerbach's plexus. The cases of congenital
hypoganglionosis had ongoing problems post resection requiring a combination of
partial enteral and continuous parenteral nutrition for survival, whereas the cases of
acquired hypoganglionosis all improved. These findings suggest that two separate
clinical hypoganglionotic conditions exist, with clinical outcome intimately related to
histochemical features.
1.12 Medical management of constipation
Seventy percent of children with constipation will respond to "conventional
management" within two years 1314. Conventional management consists of dietary
modification, laxatives and/or stool softeners and/or bulking agents and behavioural
modification and toilet training. Before any medical therapy is initiated it is essential
to adequately educate the family, and child, with regards to the pathogenesis of
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constipation. It is important for everyone to understand that soiling as a result of
overflow incontinence is neither a wilful and defiant action nor a result of bad
parenting. It may be necessary to repeat educative measures several times during a
management program before they are adequately accepted and understood 6.
1.12.1 Dietary modification
The most common dietary cause of constipation is a low fibre diet. The American
Dietetic Society recommends daily intake of 20-35g of fibre, however the current
average American daily intake is just 5-14g 96. Within the GI tract, soluble fibre
dissolves easily in water and takes on a soft, gel like texture whilst insoluble fibre
passes through in an almost unchanged state. By behaving in this way, fibre acts as a
natural stool softener and bulking agent. There are good data to suggest that
increasing dietary fibre intake is beneficial in the treatment of childhood constipation
6 97 98-100
Although an increased fluid intake will not in itself relieve constipation, it is
commonly believed that an increased intake of water can provide some symptomatic
benefit. An increased water intake is thought to increase faecal water content and
produce stools that are softer and easier to pass. Although increasing fluid intake is
widely practiced, data are anecdotal and controlled trials have been unable to
demonstrate any measurable difference in stool consistency 101 102.
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1.12.2 Disimpaction
Before regular maintenance therapy can be commenced it is essential to relieve any
distal obstructing faeces by means of disimpaction. Faecal impaction is defined as "a
hard mass in the lower abdomen identified during physical examination" or "a
dilated rectum filled with a large amount of stool found during rectal examination" or
"excessive stool in the colon identified by abdominal radiography" 103. Disimpaction
can either be performed medically, using high dose oral laxatives or rectal therapies,
or manually 6. There have been no randomised trials comparing the efficacy of
different methods so the choice of treatment should be tailored to the individual
following discussion with the patient and family. Once the impaction has been
removed then the treatment concentrates on prevention of recurrence 6.
1.12.3 Laxatives
1.12.3.1 Bulk forming laxatives (psyllium, methylcellulose, polvcarbophil)
Taken with water, these laxatives provide additional fibre intake and increase water
content and bulk volume of the stool in order to decrease colonic transit time and
improve stool consistency 104. Side effects include bloating and abdominal pain.
1.12.3.2 Emollient laxatives (mineral oil)
Mineral oil decreases faecal water absorption producing softer stools. Anal seepage
may occur following initial use and lipoid pneumonia has been described following
aspiration 6 l04.
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1.12.3.3 Hyperosmolar laxatives (lactulose, polyethylene glycol, sorbitol
(70%), glycerine, magnesium hydroxide, magnesium citrate)
Sorbitol and lactulose are sugars that are poorly absorbed but hydrolysed by coliform
bacteria to lactic, acetic and formic acids. These acid metabolites promote
accumulation of fluid within the colon that results in the formation of soft stools.
Side effects include bloating, abdominal pain, hypernatraemia and increased
flatulence. Magnesium hydroxide and magnesium citrate stimulate the release of
cholecystokinin (CCK) which then stimulates gastrointestinal water secretion and
motility. Their use should be cautioned in infants as they are susceptible to
magnesium overload 6 104. Polyethylene glycol (PEG3350, Movicol®, Movicol
Paediatric Plain®) is a flexible, water-soluble polymer that is used to create high
osmotic pressures. It appears to be superior to other osmotic agents as it is not
hydrolysed by coliform bacteria resulting in decreased abdominal bloating and
flatulence. As it does not contain any electrolytes, salt and water absorption are not a
concern, particularly in patients with cardiac or renal disease 6 104. Currently,
Movicol Paediatric Plain® is the recommended oral agent for the management of
faecal impaction in children (Table 6).
Table 6 - Suggested Movicol Paediatric Plain® regime for oral
management of faecal impaction 105.
Number of Movicol Paediatric Plain® sachets
Age (years) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
2-5 2 4 4 6 6 8 8
6-11 4 6 8 10 12 12 12
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1.12.3.4 Stimulant laxatives (senna, aloe, castor oil, bisacodvl, glycerine
suppositories)
Stimulant laxatives act by altering fluid and electrolyte transport, gastrointestinal
motility or both. Senna and aloe contain anthraquinone, a naturally occurring
polycyclic aromatic hydrocarbon that alters the absorption and secretion of water in
the terminal ileum and colon and causes potassium retention. Its mechanism of
action is unknown. Anthraquinones are widely used in the industrial industry as dyes
and a side effect of their use in humans can be discoloration of the colonic mucosa
(melanosis coli (Figure 6)). This appearance is harmless and reversible upon
cessation of use 106. Bisacodyl stimulates gastrointestinal peristalsis and also alters
transmucosal active fluid and electrolyte transport. As with the anthraquinones its
• • 107mechanism of action remains unknown . Bisacodyl is not tolerated in many
subjects due to severe abdominal cramps and the dose should be titrated with
tolerance 6 l04. Glycerine is a hyperosmotic stimulant laxative that increases stool
water content and also provokes local muscle contraction.
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Figure 6 - Endoscopic picture of colonic wall exhibiting melanosis
col106i.
1.12.3.5 Increased chloride (CD secreting agents (prostaglandin E1 (PGE1),
CI" channel activators (Lubiprostone®)
Chloride channels are pore-forming proteins that allow the transport of chloride ions
across cell membranes. Chloride channels help to maintain the resting membrane
potential of skeletal muscle, assist with the depolarisation of smooth muscle, regulate
postsynaptic transmission, maintain intracellular pH and moderate cell volume and
fluid transport 108. Several of these actions are critical in maintaining normal
gastrointestinal epithelial cell function. Important chloride channels in the GI tract
include the cystic fibrosis transmembrane conductance regulator (CFTR) channel
32
(single pore, cAMP regulated) and the CIC group (9 subtypes) of chloride channels
(two pore, voltage dependent).
Lubiprostone, derived from a metabolite of PGE1, is a selective CIC-2 chloride
channel activator 109. CIC-2 channels are located on the apical cell membrane of
human gastrointestinal cells and are found throughout the stomach, small intestine
and colon (Figure 7). When CIC-2 channels are activated, there is an efflux of
chloride through the channels into the gastrointestinal lumen. This causes the
concomitant passage of sodium ions and water, via the paracellular pathway, in order
to maintain electrical neutrality and isotonic equilibrium respectively. These actions
add fluid to stool and promote increased gastrointestinal transit through stimulation













Figure 7 - Intestinal expression of chloride channels. The CFTR and
CIC-2 channels are located on the apical (luminal) side of the gastrointestinal
epithelial cell. Although not a chloride channel, the Na+/K+/2CF co-
transporter is one of the major pathways for the movement of chloride from
the bloodstream into the cell. This co-transporter is present on the
basolateral (abluminal) cell membrane of intestinal epithelial cells.
1.12.4 Behavioural modification and toilet training
Education is an important basis for the treatment of constipation. In order that
children, and their parents, respond to treatment it is essential that they understand
the commonness of their condition and are given plenty of reassurance and support.
Habit training involves teaching a child to defecate regularly. Toileting programs
should be developed in association with both the child and their parents in order to
ensure maximum compliance. Ideally children should be encouraged to sit on the
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toilet for 5-10 minutes after each meal. This takes advantage of the naturally
occurring gastro-colic reflex. Children should be encouraged to keep a toileting
diary with suitable praise for compliance, successful passage of a stool in the toilet
and soiling free days. In addition, appropriate toileting posture and muscle co¬
ordination should be assessed and corrected by a trained physiotherapist6 55
Some children with FFR have abnormal defecation dynamics demonstrable by
anorectal manometry. The most notable abnormality is paradoxical external anal
sphincter contraction during attempted defecation (anismus) no. Biofeedback
training aims to eliminate anismus by visually and aurally reinforcing repeated
external anal sphincter relaxation until a recognisable sensation is achieved without
the need for feedback. Although some studies have been encouraging 111-115 others
have been unable to demonstrate any benefit116-119.
1.13 Surgical management of constipation
Until recently surgical management of chronic treatment-resistant constipation
consisted mostly of bowel resection with or without formation of a stoma 120-124.
Now, however, a less invasive approach is regularly being taken with the formation
of a continent appendix stoma as first described by Malone for the management of
incontinence associated with spina bifida 125"128. The appendix is brought through the
anterior abdominal wall, usually in either the right iliac fossa or at the umbilicus, and
sutured to the skin to form an appendicostomy 125. Antegrade continence enemas
(ACE) are then performed via the stoma to flush faeces from the caecum to the
rectum 125. When the colon is intermittently (every 2-3 days) washed out in this
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manner it remains relatively empty and continence and soiling are improved.
Washouts can be performed via intermittent stomal catheterisation or via an
indwelling device (Figure 8).
Figure 8 - Chait button in appendix stoma 128.
1.14 Complications
1.14.1 Disease related
Ineffective treatment can lead to faecal impaction that may require either medical or
surgical disempaction. Constant soiling, if poorly managed, can result in perianal
erythema and, in severe cases, excoriation 129.
1.14.2 Laxatives
There is widespread belief that chronic use of laxatives can lead to tolerance,
habituation and even colonic damage and these misconceptions often lead to
inappropriate prescribing practices. When used appropriately there are relatively few





Intolerable stool leakage from an appendicostomy or stomal stenosis can both
necessitate stomal revision 126.
1.14.4 Psychosocial
One of the biggest and least recognised complications of chronic constipation is the
associated psychological insult. Chronic abdominal pain and constant faecal soiling
can lead to disrupted peer relationships, undue family stress and social ostracism.
Behavioural problems, which may be extreme, may be the cause in some patients,
but more frequently are the result of years of living with constipation 130.
1.15 Evaluation of colonic transit
In order to determine what is abnormal in terms of colonic transit it is essential to
understand what is normal. Several methods have been employed to assess
gastrointestinal transit, with the most popular current techniques being radio-opaque
marker and nuclear scintigraphic studies.
1.15.1 Radio-opaque marker studies
Radio-opaque marker studies involve the ingestion of plastic markers and subsequent
tracking of their passage through the gastrointestinal tract. Their use is advocated in
both adult and paediatric populations with several methods being described. Initially
Hinton et al 131 described a technique that involved the ingestion of radio-opaque
markers followed by x-ray of the stools until all markers were recovered. Following
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this, practice changed with methods being introduced that followed the internal
passage of the markers by process of serial abdominal radiograph. These techniques
used a combination of bolus or repeated ingestion of markers paired with single or
multiple radiographs. Arhan et al employed a technique that involved a single
ingestion of markers followed by abdominal radiographs at 24-hr intervals until
complete evacuation. This method was subsequently simplified by Metcalf et al 56
who administered subjects different-shaped markers on 3 consecutive days before
performing a solitary abdominal radiograph on day 4. Although this method
decreases radiographic exposure, it is felt that it underestimates colon transit time in
patients with a transit time of greater than 72 hrs 60. Most recently, Gutierrez et al 132
have described a technique that involves the ingestion of different shaped plastic
markers for 6 days, with subsequent attainment of an abdominal radiograph on day 7.
This method ensures that radiation exposure is low whilst maintaining the ability to
assess both segmental and prolonged gastrointestinal transit.
1.15.2 Nuclear scintigraphy
Nuclear scintigraphy, or radioisotope gastrointestinal transit studies, have the ability
to provide an accurate assessment of both global and segmental colonic transit time.
Radiolabeled material is ingested (traditionally 99m-Technetium, 67-Gallium citrate
or Ill-Indium) and its passage through the gastrointestinal tract followed by the
acquisition of sequential gamma camera images (see Figure 2, page 16). Taking
multiple images (up to 5 days post ingestion of radioisotope) allows estimates of
1 OO
gastric emptying and both small bowel and regional colonic transit to be made
Images can be assessed both by visual interpretation and by determining the
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geometric centre (GC) of radioisotopic activity 134. The gastrointestinal tract is
divided into regions of interest (ROI) and each is given a number. Different studies
divide the colon into varying numbers of ROI (between 4-99 are described 65 133 135~
142 Figure 9). The geometric centre for any scintigraphic image is an objective
figure, not a time in hours, and is dependent upon the number of regions of interest
that the colon is divided into.
For each image, the fraction of administered activity in each ROI is multiplied by the
region number (n) and then all are added to give the GC:
i
GC = X fraction of activity in ROIn x n
n
Studies can be reported in terms of total colonic or regional transit time (hrs) 143 144
137
, GC at set time points (traditionally a combination of 6, 8, 24, 30, 48, 72 and 96
hrs) 65 133135-142 or % of retained/excreted activity 135141.
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Figure 9 - Colon is divided in 6 ROi (1 = Small bowel, 2 = Ascending
colon, 3 = Transverse colon, 4 = Descending colon, 5 = Rectosigmoid
and 6 = Excreted) 69.
A worked example for the calculation of the geometric centre of activity is shown in
Figure 10. This figure represents a scintigraphic image taken at 6hrs. The
radiolabeled material has reached the colon, but there is still some residual matter in
the small bowel. 10% of measured activity remains within the small bowel (ROI =
1); 70% of activity is recorded in the ascending colon (ROI = 2) and the remaining
20% of activity has progressed into the transverse colon (ROI = 3). There is no
activity in regions of interest 4-6). This gives the following calculation:
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GC = (1 x 0.1) + (2 x 0.7) + (3 x 0.2) + (4 x 0) + (5 x 0) + (6 x 0)
= 0.1 + 1.4 + 0.6
= 2.1
Therefore it can be said for this example that at 6 hours, the geometric centre of




Figure 10 - Worked example of calculation of GC of activity for
scintigraphic image at 6hrs. Diagram represents colon with the regions of
interest (RO!) - 1-6 - indicated. The percentage of total radiolabelled activity
is shown (10, 70 and 20% in regions 1, 2 and 3 respectively).
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Although nuclear scintigraphy has been used in adults for some time, it has only been
employed to assess gastrointestinal transit time in children since the late 1990's 69 l43.
1.15.3 'Normal' colonic transit
Unfortunately there are no reports of normative data for children measured with
scintigraphy with normal values of colonic transit time in children having to be either
estimated from adult and paediatric plastic marker studies (Tables 7 and 8) or
extrapolated from adult nuclear transit studies (Table 9). As studies have shown that
marker studies appear to show similar transit rates in children and young adults 60 141
145"147, it is felt that it is reasonable to use scintigraphic data from adults to predict
normative values in children and adolescents.
Table 7 - Summary of review of studies evaluating colonic transit time
in healthy paediatric controls employing either radio opaque marker
techniques 148.
















Constipation - Total colonic
transit time (TCTT) (mean ±
SD) 58.3 ± 17.4 hrs (right colon
15.9 ± 12.4 hrs, left colon 14.7
± 13.4 hrs, recto sigmoid colon
17.2 ± 16.2 hrs)
Healthy - TCTT (mean ± SD)
30.2 ± 13.1 hrs (right colon 5.7
±3.9 hrs, left colon 7.9 ± 7.8
hrs, recto sigmoid colon 15.5 ±










Adult mean TCTT 38.9 hrs
(right colon 13.8 hrs, left colon











1 lhrs), upper limit of normal
(mean ± SD) 93 hrs
Child mean TCTT 28.8 hrs
(right colon 7.7 hrs, left colon
8.7 hrs, recto sigmoid colon
12.4 hrs), upper limit of normal













Mean TCTT 39.6 hrs (7.2-86.4
hrs, "upper limit of normal"
(95th percentile) 84 hrs)
Mean ascending colonic transit
time (CTT) 5.5 hrs (0-14.4 hrs,
95th percentile 14.2 hrs)
Mean transverse CTT 10.9 hrs
(0-33.6 hrs, 95th percentile 33.1
hrs)
Mean descending CTT 6.1 hrs
(0-21.6 hrs, 95th percentile 20.6
hrs)
Mean recto sigmoid CTT 18.2













TCTT (mean ± SD) 25.0 ±3.7
hrs, upper limit of normal (mean











TCTT (mean ± SD) 29.08 ±8.3
hrs (right colon 7.25 ± 5.75 hrs,
left colon 6.6 ± 6.2 hrs, recto
sigmoid colon 14.96 ± 8.7 hrs),


















Constipated - TCTT (mean ±
SD) 59.9 ±5.4 hrs (right colon
15.9 ± 2.3 hrs, left colon 18.9 ±
2.3 hrs, recto sigmoid colon
25.0 ±2.6 hrs)
Healthy - TCTT (mean ± SD)
37.8 ±6.2 hrs (right colon 10.8
±3.5 hrs, left colon 12.2 ± 2.7
hrs, recto sigmoid colon 14.7 ±
2.1 hrs), upper limit of normal
(mean + 2 SD) 50.2 hrs
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As all of the studies employ widely different methods to both carry out and report
their investigations, ascertaining what indeed construes 'normal' colonic transit is a
somewhat difficult task. When looking at the studies that have used radio-opaque
markers to assess colonic transit in normal children 58 60 132 149151, mean total colonic
transit time (TCTT) is reported as being from 25 ±3.7 hrs (mean ± SD) 150 to 39.6
hrs (mean, range 7.2-86.4 hrs) 60 with upper limits of normal described as being
anywhere between 32.4 hrs 150 and 84 hrs 60. Similar diversity is seen when looking
at the corresponding adult plastic marker studies 56 58 131 152153. When reviewing the
scintigraphic studies, it is very difficult to apply the findings to a normative
population. Studies that report transit in terms of GC do not provide one with a
quantitative time value for 'normal' colonic transit; therefore, unless one is using the
same protocol, with the same number of ROI, the values are somewhat meaningless.
Those studies that do report in terms of mean colonic transit time 137 143 144 describe
normal values of between 22.3 ±4.8 hrs (mean ± SD) 143 and 41.1 (range 14-80 hrs)
144
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Table 8 - Summary of review of studies evaluating colonic transit time
in healthy adult controls employing radio opaque marker techniques148.

















Constipation (+ faecal soiling) -
Gastrointestinal transit time
(GITT) (mean ± SD) 58 ±14.3hr
(range 36-86 hrs)
Constipation (- faecal soiling) -
GITT (mean ± SD) 61.1 ± 15 hr
(range 36-96 hrs)
Healthy GITT (mean ± SD)










ray (day 4 and
7)
TCTT (mean ± SD) 34.4 ±
16.2hrs (right colon 6.9 ± 7.8
hrs, left colon 9.1 ± 10.3 hrs,



















Adult mean TCTT 38.9 hrs
(right colon 13.8 hrs, left colon
14.1 hrs, recto sigmoid colon
1 lhrs)
Child mean TCTT 28.8 hrs
(right colon 7.7 hrs, left colon
8.7 hrs, recto sigmoid colon
12.4 hrs), upper limit of normal














TCTT (mean ± SE) 35.0 ± 2.1
hrs (right colon 11.3 ± 1.1 hrs,
left colon 11.4 ± 1.4 hrs, recto
sigmoid colon 12.4 ± 1.1 hrs)












All subjects passed first marker
within 66hrs, all except one
passed 80% within 114 hrs
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Table 9 - Summary of review of studies evaluating colonic transit time
in healthy adult controls employing nuclear scintigraphic techniques148.
Name Population Method Findings


















Healthy - mean GC @ 6hrs - 2;
24hrs - 3.5; 48hrs - 5 and 72hrs
-6.5
Constipation cf. healthy - No
difference in right sided transit,















By 48 hrs, 70.7% ± 9.1% (mean
± SEM) had been excreted.
Rapid emptying of caecum and
ascending colon - half emptying












TCTT (mean ± SD) 22.3 ±4.8
hrs (right colon 5.4 ± 3.0 hrs,
left colon 7.1 ± 3.4 hrs, recto










Images @ 6, 8
and 24 hrs (5
ROI)
Colonic filling @ 6hrs (mean ±
SE) - 44 ± 8 %; GC @ 8 hrs -
1.4 ±0.1 and 24 hrs - 2.6 ± 0.3

















No movement of isotope over
10-15 mins until bisacodyl
introduced
Healthy - hepatic flexure to
rectum time 1-10 mins (mean
5.3 mins)
Constipated - hepatic flexure to
rectum time 14-25 mins with no
movement at 2 hrs in 2 patients











Mouth to caecum (mean ± SD)
-5.4 ±2.2 hrs
Caecum to hepatic flexure - 5.3
±3.7 hrs
Caecum to splenic flexure - 12.1
±8.2 hrs
Caecum to recto sigmoid - 19.6
± 12.0 hrs
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2,4, 6, 24 and
48 hrs (4 ROI)
Colonic filling @ 6hrs (mean ±
SEM) - 71 ± 5 %; GC @ 24 hrs










Images at 18 -
72 hrs (7 ROI)
GC @ 24 hrs (lower and upper
95% confidence intervals) -
1.97-6.76,48hrs - 3.6-7.0 and
72 hrs-6.26-7.0







24 and 48 hrs
(5 ROI)
GC @ 8 hrs (mean) - 1.48,24










and 48 hrs (10
ROI)
GC @ 24 hrs (mean ± SEM) -
4.24 ± 0.53 and 48 hrs - 6.22 ±
0.22











% distribution @ 24 hrs (mean
± SE): ascending colon - 22 ± 7,
transverse colon - 34 ± 8,
descending colon - 7 ± 2,
rectosigmoid colon - 5 ± 3,
stool - 32 ± 10
% distribution @ 48 hrs (mean
± SE): ascending colon - 5 ± 2,
transverse colon - 30 ± 10,
descending colon - 4 ± 2,
rectosigmoid colon - 3 ± 1,










48, 72 and 96
hrs (99 ROI)
Mean activity position of
isotope @ 24 hrs - 68.4 (F),
84.5 (M); 48 hrs - 94.7 (F), 96.7
(M); 72 hrs-98.5 (F),98.1 (M)
and 96 hrs - 98.9 (F), 98.7 (M)












Colonic mean transit time -41.1
(range 14.0-80.0) hrs
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1.15.4 Abnormal colonic transit
Beninga et al 19 set a value of CTT >100 hrs for the definition of children with STC
based on the upper limit (mean + 2 SD) from the work of Corazziari et al 150.
Although this study contains data from non-constipated subjects, this arbitrary figure
is derived from the upper limit of total gastrointestinal transit time (TGITT) (not in
fact CTT as Beninga states) of a subset of children with constipation and a TGITT >
33hrs. By deriving a value for slow colonic transit in this manner, Beninga provides
an inflated estimate of what is likely to be truly abnormal 19.
When colonic transit is assessed by scintigraphic methods, rather than an arbitrary
figure being applied as to what constitutes delayed total transit, a more detailed
picture of regional transit can be formed 69. By determining the distribution of
activity at 48hrs, children can be divided into those with right sided and transverse
colonic retention (i.e. true STC) and those in whom the delay occurs at the
retosigmoid junction (FFR) 69.
1.16 Evaluation of colonic motility
In the past, colonic motility has remained largely unevaluated due both to the relative
inaccessibility of the colon and the lack of an appropriate animal model. Unlike
most animals, the human colon does not exhibit a cyclical, easily recognisable motor
pattern which adds to the difficulty in interpretation of colonic motor activity 155.
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1.16.1 Normal colonic motility (in adults)
The interdigestive pattern of motor activity seen in the upper gastrointestinal tract
does not occur in the colon. Instead, non-cyclical motor activity is exhibited
consisting of quiescent periods sporadically interspersed with non-propagating and
propagating contractions, producing an irregular passage of colonic luminal contents
155. Contractions can be defined as being either tonic or phasic. Tonic contractions
last more than 30 seconds and often have the shorter phasic contractions
superimposed on them. Contractions can be in either an aboral (antegrade) or oral
(retrograde) direction, producing a mixing of colonic contents and allowing adequate
absorption of water and electrolytes 155.
High amplitude propagating sequences (HAPS) are a feature of normal colonic
motility. HAPS are defined as colonic propagating sequences where the amplitude in
at least one recording channel exceeds 116mmHg 76 155 As with normal propagating
sequences, HAPS can occur in either an antegrade or retrograde (high amplitude
retrograde propagating sequence - HARPS) direction, although HARPS are thought
to rarely occur in states of health. HAPS have been found to originate most
commonly in the proximal colon with associated distal propagation. It is not clear
what initiates them, however most HAPS are associated with colonic mass
movement including the passage of faeces or wind 155. An increased frequency of
HAPS is seen in the post-prandial period and following waking 76. Direct colonic
instillation of Bisacodyl has the ability to induce HAPS identical in terms of
amplitude, length of propagation and velocity to those seen in normal physiological
states; its mechanism of action is poorly understood 156
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Different studies report differing expected frequencies of HAPS in 'normal' adults
ranging from 2 per 24 hrs 157 up to 10 per 24 hrs I55. These differences can be
explained by widely dissimilar study protocols involving a variation of: recording
catheter (solid vs. water perfused), bowel cleansing (preparation vs. no preparation),
length of recording (6 hrs up to 24 hrs), catheter position (proximal caecal vs. distal
rectosigmoidal recording) definition of HAPS (>80mmHg 77 158 - >200mmHg 159)
patient position (recumbent vs. ambulatory) and data interpretation (visual vs.
automated).
Some colonic cyclic activity does exist in the region distal to the rectosigmoid
junction, however it is not related to the cyclical activity displayed in the upper
intestine 160. It is described as the rectal motor complex (RMC) and is part of normal
colonic motility in adults. 3 patterns of cyclical rectal activity have been observed
160: (i) runs of powerful phasic contractions with a frequency of 2-3/minute, lasting
for 3-10 minutes and recurring at an interval of 92 + 1.9 (mean ± SEM) minutes
during the day and 56 ± 1.7 (mean ± SEM) minutes during the night; (ii) isolated
prolonged contractions lasting for 10-20 seconds and seen mainly during waking;
and (iii) clusters of contractions occurring at a frequency of 5-6/minute lasting for 1-
2 minutes and seen predominantly during the post-prandial period. The
physiological role of the RMC remains unknown 16°.
Since, apart from obvious propagating sequences and the RMC, colonic activity
often does not represent any obvious motility pattern, motor activity is also
quantitatively described in terms of a motility index (MI). This involves measuring
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the activity under the curve from pressure tracings. In this way, colonic motor
responses to physiological stimuli such as eating and waking can be more accurately
evaluated 155.
It is normal in adults to see an increase in the motility index after eating - the so
called gastrocolonic reflex 161. An increase in colonic activity is seen within 20-40
minutes of commencing eating with late and early components occurring at 20 and
• 162
60 minutes respectively. This response is most prominent in the distal colon " and
its magnitude is proportional to the fat contents of the ingested food, with a higher
content evoking an increased response 163. In controlled circumstances, a fat content
of >40%/meal is used to stimulate this colonic response to food.
1.16.2 Child vs. adult normal motility
Due to obvious ethical considerations, the majority of colonic manometric recordings
from children are of a short duration, only involve the lower, more accessible, colon
and have been performed on abnormal colons 77158. A lot of what is 'known' about
paediatric colonic motility has been extrapolated from adult studies and there is
subsequently a variation is what is currently perceived as both 'normal' and
'abnormal' 7677 158.
Like their adult counterparts, children demonstrate increased colonic motility in
response to eating and waking however, their post-prandial response is more rapid,
shorter lasting and characterised mainly by an increased frequency of HAPS 77158. in
addition, children are thought to have more frequent HAPS than adults and which are
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more often associated with the urge to defecate or an act of defecation. Children also
exhibit a diurnal variation in colonic activity with a decrease in motor activity seen
during sleep.
1.16.3 Abnormal colonic motility associated with STC
Both adults and children with STC have been shown to exhibit a lower frequency of
7f\ 77 1 SR 1 f\A
antegrade propagating sequences and lack the degree of response to eating
and waking seen in states of health. There is however much debate as to the ability
of both adults and children with STC to generate HAPS. Some centres believe a lack
of normal physiological HAPS in combination with an absence of HAPS in response
to colonic instillation of Bisacodyl to be a diagnostic feature of subjects with STC 77
158. Other centres have recorded HAPS in both adult 164 and paediatric 76 STC
colons. These studies have found that although some subjects with STC appear to
possess the ability to generate high pressure activity, the frequency of such events (as
with the low pressure propagating sequences) is significantly decreased. This degree
of diversity in the manometric findings can be attributed to either different study
protocols or different diagnostic criteria for STC (based on radiological
investigations) or may reflect the fact that subjects with STC represent an as yet
unrecognised heterogeneous group of colonic pathologies.
1.17 Summary
Constipation is a common childhood condition with a spectrum of severity that
ranges from solitary, self-limiting attacks of 'acute' constipation through to long¬
standing, treatment-resistant chronic constipation. Although the majority of children
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will respond to conventional management, there are some for whom constipation
represents a debilitating condition that is unresponsive to current therapy. Although
the cause of their constipation remains unknown, it is now widely believed that their
disease may have a hidden or unrecognised organic origin and that they may have a
variety of underlying pathologies that produce a similar clinical picture.
It is important to identify this group of children, through appropriate investigations,
in order to attempt to meet their needs and provide them with appropriate support
and treatment. Novel diagnostic techniques, such as nuclear transit studies and
colonic manometry, are no longer being considered as purely research tools and are
becoming more widely available and more commonly accepted as standard practice.
By employing such techniques as part of routine clinical work-up, children with
abnormal colonic motility can be identified and diagnosed early in their clinical
course before true chronicity is established.
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2. Electrical Stimulation as a Treatment Modality for
Gastrointestinal Disorders
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2. Electrical Stimulation as a Treatment Modality for Gastrointestinal
Disorders
2.1 Introduction
Scientific enquiry into the phenomena known as magnetism and electricity is
centuries old. Many have dedicated their life's work to expounding the effects and
potential applications. The time and place of their discovery, and indeed their first
therapeutic use, remain unknown, however historical literature is scattered with
colourful accounts of their existence. Throughout the Middle Ages it was believed
that magnets had wondrous powers: they were used to cure baldness, to purify
wounds, to treat gout and arthritis, and were even thought to have aphrodisiacal
qualities!
In 1743, Johann Gottlob Kruger (1715-1759) suggested that electric current could
induce changes in the body that would restore or maintain health 165. He based this
principle on the fact that the application of an electrical current seemed to increase
the blood flow to the area. Around the same time, Benjamin Franklin (1706-1790)
166
as part of his studies into the application of electricity, began treating paralysed
patients with thrice-daily shocks to their affected extremities. He found that although
the patients' limbs seemed to strengthen somewhat, the sessions were painful and the
benefits were short-lived.
In 1760, possibly inspired by Franklin's work, John Wesley (1704-1791) 167, an
English clergyman, established free medical clinics in Bristol and London and
offered electrification in the belief that it could be used to treat a number of ailments
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(Table 10). This concept of electrotherapy was further explored by Guillaume
Benjamin Amand Duchenne (1806-1875), the French neurologist, in the 1800's 168.
He developed his use of faradism (the application of a faradic current of electricity
for therapeutic or diagnostic purposes) by building his own electrical box-like
machine (Figure 11). He regularly carried this with him on his rounds, using it to
stimulate the muscles and nerves of his patients (Figure 12). Duchenne was the first
to describe several nervous and muscular disorders and to suggest possible
electrically modulated therapeutic options.
Table 10 - The Desideratum, or Electricity made Plain and Useful by a
Lover of Mankind and of Common Sense 168.
Disorders in Which Wesley Thought Electrification to be of Use
Agues King's Evil
St. Anthony's Fire Knots in the Flesh
Blindness, even from a Gurra Serena Lameness, Leprosy
Blood extravasated Mortification (dead flesh)
Bronchocele Palpitation of the Heart
Chlorosis Pain in the back, in the Stomach
Coldness in the feet Palsy, Pleurisy
Consumption Rheumanism, Ring worms
Contractions of the limbs Sciatica, Shingles, Sprain
Cramp Surfeit (excessive eating)
Deafness, Dropsy Swellings of all kinds
Epilepsy Throat sore
Feet violently disorded Toe hurt
Felons Tooth - Ache











Figure 11 - Electrisation apparatuses used by Dr. Duchenne
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Figure 12 - Self-portrait of Dr. G.B. Duchenne using his electrisation
apparatus, 1862 168.
By the mid nineteenth century, the use of electrical devices had become popular
throughout Europe and the United States.
Over the past century the popularity of electrical therapy has fluctuated immensely.
Although there are many who believe in the benefit of its clinical application, there
remain those who are unconvinced as to its clinical value. A lot of the scepticism is
related to the ambiguity concerning the proposed mechanisms of action involved in
the application of any type of electrical therapy. Many theories have evolved over
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the years as to the potential effects of electrical stimulation on human tissues, but in
truth they remain speculations rather than facts.
2.2 Types of electrical stimulation
2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
There currently exist several types of electrical therapy that differ both in their use of
current and their mode of delivery. Most people are familiar with the concept of
Transcutaneous Electrical Nerve Stimulation or TENS, as it is more popularly known
169 xens was initially used in the 1960's and introduced into clinical practice the
concept that pain may be relieved by peripheral stimulation that can take the form of
rubbing, vibration, heat, cold or, in the case of TENS, electrical stimulation. The
electric stimulus is delivered at variable current strengths, pulse rates and pulse
widths. The waveform is biphasic in order to avoid the electrolytic and iontophoretic
effects of a unidirectional current. TENS is traditionally categorised into 3 forms 169:
high-frequency, low-frequency and pulsed (burst). The most conventional form of
TENS is high-frequency. The stimulus is delivered at a frequency >10Hz (usually
40-150Hz) but at a low current intensity, between 10-30mA, which is below a level
producing pain. The pulse duration is short, typically around 50 microseconds.
Low-frequency TENS delivers a stimulus of <10Hz (usually l-10Hz), at a high
current intensity, close to the tolerance limit of the patient. It is often uncomfortable
and many patients cannot tolerate it. Pulsed TENS, uses low-intensity stimuli fired
in high-frequency bursts. N0 particular advantage of this method over conventional
TENS has been described 169
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2.2.2 Interferential therapy (IFT)
Interferential therapy (IFT) is a form of electrical stimulation that involves the
transcutaneous application, via electrodes, of two crossed, slightly out of phase,
medium-frequency currents. This produces an amplitude-modulated current effect
within the tissues l7°. As with TENS, the frequency, amplitude and pulse width of
the output waveforms can be regulated. Conventionally, currents within the range of
3,900 to 4,100Hz are used, as lower frequency currents can result in somewhat
171
uncomfortable polarisation effects in the superficial tissues . Typically a
quadripolar model is adopted where four electrodes are placed over the target area in
such a distribution that their current paths cross directly over the relevant organ(s).
2.2.3 Electroacupuncture
Although the Chinese have been using acupuncture for the around the last 3000
years, it wasn't until the 17th century that it was introduced to Europe. Even then it
failed to gain popularity in Western culture with the majority of people regarding it
as Eastern folklore. It is only in the last 25 years that there has been a dramatic turn
around in the perceived acceptability of acupuncture. This follows the publication of
long-awaited articles that finally reveal causal mechanisms for many of
acupuncture's effects 172.
Ulett et al l73, observed that Chinese surgeons often added electricity via the needles
in cases where they required a higher level of analgesia. They studied
experimentally induced pain toleration in healthy volunteers and found that although
acupuncture with needles alone gave some pain relief, when electricity was added the
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modulation was 100% more effective. Han et al 174 have demonstrated a differential
release of brain neuropeptides by different frequencies of stimulation.
2.2.4 Sacral Nerve Stimulation (SNS)
Sacral nerve stimulation (SNS) was first proposed in 1906 for the treatment of
micturition disorders. Initially therapy took the form of transcutaneous stimulation
before development of devices that employed transvaginal 175 and transrectal routes
176. Unfortunately these devices were prone to infection, migration or fibrous tissue
reaction and so did not gain the popularity that was initially expected. More recently
a new form of stimulation has been created that involves extradural stimulation
within the sacral canal and is primarily utilised in the management of faecal
■j nn i "fQ
incontinence " . Following acute peripheral nerve evaluation to locate the
optimal sacral spinal nerve that will elicit contractions of the striated pelvic floor
muscles (usually S3), patients progress to subchronic peripheral nerve evaluation for
a minimum of 7 days to assess the relative efficacy of SNS. If a clear benefit is
perceived then a permanent implantable device can be inserted. Adoption of this
route of administration of electrical therapy has dramatically reduced the incidence
of complications and this had lead to a more widespread adoption of SNS 177179
2.3 The passage of electrical current through live tissue
Transcutaneous electrical therapy is delivered by means of electrodes that are placed
directly onto the recipient's skin. These are either applied to the area overlying the
target organ or over the root of the affected dermatome or appropriate acupuncture
sites. The electrodes and/or skin are coated in a conductive gel in order to minimise
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contact resistance to the current flow and decrease energy losses in the form of heat
or capacitive effects. In order to lower the current density flowing through the skin,
it is important to maximise the surface area of contact. High current densities result
in localised pain and inflammation 18°. Electrodes must be placed at least a few
centimetres apart in order to prevent short-circuits from forming.
Typically, human tissue is anisotropic, non-linear and inhomogeneous meaning that
it has properties that differ according to the direction of measurement181. Although a
few studies have attempted to ascertain the relative distribution of current when
applied to live tissue 182~185, very little information has been gathered due to the
complex composition of human tissue, the immense variability between subjects and
the technical difficulties in obtaining in vivo measurements. Consequently, scanty
data concerning the precise nature of tissue impedance exist. Lerman et al 182 whilst
investigating the intrathoracic passage of defibrillation current found that only 4% of
transthoracically applied current actually reaches the target organ of the heart.
The mapping of electrical currents and other electromagnetic waves inside the human
body requires the application of complex mathematical models. Most set-ups
incorporate detailed computer-aided design software packages in an attempt to
simulate in vivo conditions, however there is still some doubt as to the accuracy of
their ability to predict live tissue current flow. Currently, the finite element analysis
(FEA) model is most commonly utilised in situations where researchers are
attempting to ascertain the supposed passage of various electrical currents . This
method of analysis converts a continuous solution domain into a finite "mesh" of
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uniform and non-uniform elements that are connected via nodes. This mesh is
programmed to represent the material and structural properties of human tissue
which then defines how it will react to certain loading conditions or the application
of current. The value of particular electrical quantities at a specific node can be
calculated by applying difference equations based on the existing values of adjacent
nodes. In this way the FEA provides the ability to model the complex tissue
properties found in living matter 187.
2.4 The application of electrical stimulation in the treatment of
gastrointestinal disorders
Electrical therapy has been applied in the management of a wide range of
gastrointestinal disorders. By utilising different modes of delivery, electrical
stimulation has been used in the treatment of many gastrointestinal motility disorders
(achalasia, delayed gastric emptying, irritable bowel syndrome, constipation, faecal
incontinence) as well as oesophageal visceral pain and severe functional abdominal
pain.
2.5 The proposed action of TENS on the upper gastrointestinal tract
It is widely appreciated that gastrointestinal motility is controlled by an intrinsic
electrical rhythm that is modulated by the parasympathetic, sympathetic and enteric
nervous systems and gastrointestinal hormones. It is believed that the effect of
TENS on the gastrointestinal tract must involve actions in addition to the gate theory
mechanism l88. It has been hypothesised that TENS could affect gastric motility by
an action on cardiac nerves and the subsequent release of peptides 189. It is thought
63
that the primary peptide involved in this pathway is VIP, however it is possible that
TENS may stimulate the release of other neurotransmitters contained in VIPergic
neurons (peptide histidine isoleucine (PHI), neuropeptide Y (NPY) and galanin) 189.
In some studies aiming to stimulate the upper GI tract, TENS is applied to the hand.
The hand contains recognised gastrointestinal acupuncture points. One electrode
(negative) is placed between the first and second metacarpal bones, and the other
(positive) at the ulnar border of the hand 190. This set-up is designed to stimulate
dermatomes C8-T1 and elicit centrally relaying somatovisceral reflexes. One study
compared the effect of TENS on the upper GI tract when applied to either the hand
or foot 190. It found that there was a measurable effect when TENS was applied to
the hand but no effect when applied to the foot. They concluded that this provided
strong evidence for the existence of a somatovisceral pathway.
Camilleri et al 191 applied TENS to volunteers while simultaneously monitoring their
upper gastrointestinal phasic pressure activity, extraintestinal vasomotor indices, and
plasma levels of accepted humoral mediators of autonomic reflexes. Stimuli were
applied either to the hand (C8-T1) or to the upper abdomen (T5-T10) to determine
whether impulses at these two dermatomes produced different effects. They noted a
significant reduction (p = 0.007) in the antral motility index when TENS was applied
to the hand and abdomen as compared with sham stimulation. They also describes
an associated increase in skin conductance and plasma beta-endorphin levels but no
change in pulse, blood pressure, or circulating catecholamine levels. They
concluded that the similarity of the responses to TENS applied to the hand and
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abdominal dermatomes suggested that the induced somatovisceral responses relay
predominantly at the cerebral level.
2.6 TENS and achalasia
Achalasia is a disorder of the oesophagus in which there is a failure of the lower
oesophageal sphincter (LOS) to relax during swallowing. In addition there is an
abnormality in oesophageal motility and a high resting pressure of the LOS. VIP is
believed to be the inhibitory neurotransmitter responsible for relaxation of the LOS.
In patients with achalasia, the concentration of VIP and the number of VIP-
containing nerve fibres are reduced or absent. The application of TENS as a
treatment modality in patients with achalasia has been assessed in a number of trials
190 192~194. High or low frequency TENS is applied to the subjects' hand until
rhythmic flexion of the fingers is obtained without producing pain.
In one study involving patients with achalasia, the pressure of their LOS, along with
their VIP levels, were measured before and after treatment 193. The authors reported
that there was a statistically significant reduction in the LOS pressure after only 45
minutes of treatment at low-frequency (6.5Hz). This reduction was further increased
after a week of daily treatment. They hypothesised that this response may be
mediated by a nonadrenergic noncholinergic pathway of the autonomic nervous
system and reported a 30% increase in VIP levels following TENS treatment. In
contrast another study, that looked at oesophageal motility and LOS pressure in
patients with achalasia and scleroderma 194, reported that there was no detectable
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changes in oesophageal motility following administration of either low or high
frequency TENS.
2.7 Electrotherapy for delayed gastric emptying
It is generally accepted that gastric electrical activity plays an important role in the
control of gastric motor activity. Gastric myoelectrical activity can be measured by
cutaneous electrogastrography (EGG) and abnormal recordings have been reported in
a number of conditions including diabetic gastroparesis, pregnancy induced nausea
and vomiting, motion sickness, chronic intestinal pseudo-obstruction and anorexia
nervosa 195. Allegedly, all of the above conditions have been successfully treated by
means of acupuncture, electroacupuncture or acupoint TENS with success possibly
resulting from an alteration in gastric electrical activity 196. In order to confirm or
dispute this, Chang et al 196 examined if electrical stimulation over Zusanli points in
healthy volunteers produced any demonstrable changes in myoelectrical EGG
recordings. The Zuslani point (also known as 'stomach-36') is one of the 365
recognised classical acupuncture sites and is one of the most frequently used. It is
located on the anterolateral aspect of the lower leg, approximately 1 finger's breadth
below the tibial tuberosity. The study showed that electrical stimulation appeared to
provoke a significant increase in the percentage of normal frequency gastric
electrical activity with concomitant decreases in the percentages of periods of
tachygastric and bradygastric rhythms 196. These findings lead the authors to the
conclusion that transcutaneous Zusanli electrical stimulation has the ability to
enhance the regularity of gastric myoelectrical activity. These findings supported the
earlier work of Lin et al 197.
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Weinkauf et al 198 describe two case reports of patients with post-lung-transplant
gastroparesis due to a presumed vagus nerve injury during their operations. The first
patient, who was receiving TENS for back pain, was noticed to have a marked
improvement in his gastric emptying following his electrical therapy. The authors
proceeded to apply paraspinal TENS to another patient with persistent gastroparesis
some 8 months post-transplant. After a treatment period of 20-30 days her
symptoms had also completely resolved.
2.8 TENS and severe functional abdominal pain
A small, uncontrolled study in 1986 looked at the effects of TENS on a population of
patients with intractable "functional" abdominal pain l99. This is a condition defined
as abdominal pain for which no structural, biochemical or infective cause can be
determined. Twenty-nine patients were given high frequency TENS stimulation (30-
100Hz) for a treatment period of at least one month. The electrodes were initially
placed over the site of pain; however, if there was no perceived effect, other
electrode positions were tried. This meant that the electrodes were then placed either
paraspinally (over the root of the affected dermatome) or over appropriate
acupuncture sites. 21 of the 29 patients reported some benefit from the TENS after
one month of treatment with the effect being maintained at six months in 15 patients.
Of those who reported an initial response to treatment, 17 responded to placement of
electrodes over the abdomen, 5 to placement paraspinally, and 2 to placement over
acupuncture points (3 patients responded at more than one site). The authors
concluded that TENS may provide pain relief in some patients with functional
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abdominal pain and although the response could have been a placebo effect, the
maintenance of symptom relief made this unlikely.
2.9 TENS and irritable bowel syndrome
Irritable bowel syndrome (IBS) is defined as a condition that is characterised by
lower abdominal pain in association with disturbed defecation in the absence of any
organic abnormality. Those diagnosed with IBS can be further classified as having
either diarrhoea-predominant IBS (IBS-D) or constipation-predominant IBS (IBS-C)
200. Currently the most widely accepted physio-pathological hypothesis to explain
IBS is the presence of dysregulation of the neurobiology of visceral neural afferents
and pain sensitivity control 200. There is evidence that the endogenous analgesia
system is abnormal in IBS patients and it is strongly suspected that levels of
substance P, cholecystokinin (CCK), NPY, and peptide YY may be related to the
pathophysiology of IBS 200.
Patients with IBS often complain of abdominal pain and appear to have a lower
sensory threshold to rectal distension. Recognising the potential application of
electrical therapy in gastrointestinal conditions, Xiao et al 201 evaluated the rectal
sensory thresholds in patients with IBS and to assess whether or not these
measurements were affected by the administration of short- or long-term acupoint
TENS. Their initial data confirmed that patients with IBS-D have a significantly
lower rectal sensory threshold compared to patients with IBS-C or healthy age-
matched controls. Following administration of short- and long-term TENS there was
a significant elevation of rectal sensory thresholds in the participants with IBS-D,
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with patients also reporting a decrease in stool frequency and a decrease in
abdominal pain.
At present the authors are unable to explain their findings, however they hypothesise
that there could be a TENS-mediated release of the endogenous opioid peptides
endorphin and enkephalin. This remains unsubstantiated.
2.10 IFT and treatment-resistant constipation
Interferential stimulation has been used for some time in the treatment of bladder
instability due to detrusor overactivity. It was noted that patients undergoing
treatment for detrusor overactivity reported a high incidence of diarrhoea following
commencement of IFT. This diarrhoea is believed to be as a result of increased
colonic transit due to incidental electrical stimulation of the bowel. Consequently,
researchers have posed the question as to whether or not IFT could be used as a
treatment modality for patients with constipation.
Chase et al 170 initiated a pilot study in 2005 that looked at a group of children with
treatment-resistant slow transit constipation. Children had had chronic constipation
and soiling for a minimum of four years and had had exhaustive medical and
behavioural treatment to no effect (n=8). The study found that following a treatment
period of only one month there was a significant decrease in the reported incidence
of soiling and a significant increase in the incidence of spontaneous defecation. A
subgroup of the children had previously had appendicostomies formed in order to be
able to perform formal bowel washouts (n=3). This group of children reported a
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significantly decreased need for bowel washouts following treatment with IFT, and 2
children were able to stop using their appendicostomy altogether.
2.11 Sacral Nerve Stimulation and Faecal Incontinence
The prevalence of faecal incontinence is estimated to be 3.5% of women and 2.3% of
men 202 however it is thought that the actual incidence is likely to be higher due to
the stigmata associated with a such a diagnosis. Treatment strategies combine
dietary, pharmacology, physiotherapy and surgery in an attempt to minimise
symptoms and maximise quality of life. It is only since the 1990s that sacral nerve
stimulation has been recognised as an excellent treatment option in the management
of this often socially debilitating condition 203.
SNS has been shown to be able to improve faecal incontinence due to physiological
levator ani and external anal sphincter dysfunction 203 where patients have
morphologically intact anatomy. However SNS has also been shown to be of benefit
to patients with neuropathic faecal incontinence, cauda equina syndrome 204 and
internal anal sphincter dysfunction 203 and even patients with limited structural
defects of their internal and external anal sphincters 205. The ability of SNS to
improve faecal incontinence due to such a diverse range of conditions only serves to
highlight how little is understood about its possible mechanism of action.
2.12 Summary
Despite many trials supporting the potential use of electrotherapy in the management
of a wide range of conditions, its routine use has remained limited to a few areas.
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Although TENS is generally accepted by pain specialists as an alternative analgesic
tool in the management of several chronic pain conditions, it has failed to attain
recognition as a prospective treatment modality by other specialities. Several trials
have suggested encouraging results regarding the application of electrotherapy in the
management of achalasia, gastroparesis, IBS, constipation and chronic abdominal
pain however it has never been incorporated into any of their routine management
strategies.
One of the biggest problems regarding the acceptance of electrical therapy is the
overwhelming lack of data concerning its precise mechanism(s) of action. Although
there are many theories as to the potential effects of electric stimulation, they remain
unsubstantiated and thus lack popular support. Many sceptics go so far as to say that
any perceived benefits from recipients of electrotherapy are purely due to a placebo
effect. Trials have attempted to eliminate this argument by blinding participants with
either low-current sham stimulation or by short-circuiting half of the trial machines
so that they do not deliver any current despite the dials/displays/lights functioning
normally. However, both of these methods have obvious limitations. Firstly, since
we are unaware of how electrotherapy works, we cannot be completely sure that
even a low level of current may have some therapeutic action. Secondly,
electrotherapy tends to result in some sort of sensory stimulation under the
electrodes; this is evidently absent when a machine has been short-circuited. As a
result it can be argued as to whether or not participants are truly blinded to their
treatment pathway. Despite this most studies have shown that improvements from
electrostimulation appear to be sustained over a period of time following cessation of
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treatment. This is contrary to what would be expected were the effects due purely to
a placebo response.
Given that we are unable to explain the effects of different types of electrical
stimulation, it may well be that we are currently not utilising the optimal type of
electrotherapy for certain conditions. Similarly, at present, we cannot be certain as to
the best site of electrode placement, the ideal level of stimulation nor indeed the
optimal duration of treatment. If electrotherapy is to become a widely accepted
treatment tool, it is essential that these parameters be defined.
Unfortunately, for as long as we are unable to delineate the exact properties and
optimal delivery of electrical stimulation we will continue be limited in its
application. Until that time, despite having been in use for centuries, electrotherapy
is destined to be regarded by most as an "alternative" treatment.
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3. Quality of Life
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3. Quality of Life
3.1 Definition and general considerations
Quality of life (QoL) can be defined as "an individual's subjective perception of
tt 206overall wellbeing and satisfaction with life " or "physical, social and emotional
f y 207
aspects of a patient's well-being that are important to the individual" . QoL is a
multidimensional concept that incorporates the assessment of recognised core
domains and indicators. It is now widely accepted that in children with chronic
disease, traditional medical indicators of outcome are no longer adequate and a
comprehensive assessment of health status, or health-related QoL (HR-QoL) is also
required 208. HR-QoL can be further defined as "QoL measures that are likely to be
influenced by health interventions " 201.
Although HR-QoL measures have been applied in adult populations for sometime, it
is only since the early 1990's that such tools have been available for use in children.
Most pre-existing adult HR-QoL measures were found to be inappropriate for use in
a paediatric population due to either a lack of content validity or an inability to
accurately ascertain measurements. Although in some instances adjustments could
be made to ensure that the questions conformed to paediatric standards, for the most
part there has been the need for the development of original, specific paediatric HR-
QoL measures.
3.2 QoL domains and indicators
The term "QoL domains" refers to "the set offactors composing personal well-
being" and should be regarded as "the set of elements to which a variable is limited,
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or the range over which the concept of QoL extends" 209. It is generally accepted
that there are 8 core domains: interpersonal relations, social inclusion, personal
development, physical well-being, self-determination, material well-being, emotional
well-being and rights. QoL domains can be further categorised into "QoL
indicators" which are thought of as "QoL domain-specific perceptions, behaviours,
or conditions that give an indication of a person's well-being" 209 (Table 11). QoL
indicators should be (i) functionally related to the respective QoL domain; (ii) able to
measure what is intended (validity); (iii) consistent across people or raters
(reliability); (iv) able to measure change (sensitivity); (v) able to reflect changes only
in the situation concerned (specificity); (vi) affordable; (vii) timely; (viii) person-
referenced; (ix) able to be evaluated longitudinally; and (x) culturally sensitive.
Table 11 - Indicators and descriptors of the core quality of life domains
209
Core QoL Domain Indicators and Descriptors
Emotional well-being Contentment (satisfaction, moods, enjoyment)
Self-concept (identity, self-worth, self-esteem)
Lack of stress (predictability, control)
Interpersonal relations Interactions (social networks, social contacts)
Relationships (family, friends, peers)
Supports (emotional, physical, financial, feedback)
Material well-being Financial status (income, benefits)
Employment (work status, work environment)
Housing (type of residence, ownership)
Personal development Education (achievements, status)
Personal competence (cognitive, social, practical)
Performance (success, achievement, productivity)
Physical well-being Health (functioning, symptoms, fitness, nutrition)
Activities of daily living (self-care skills, mobility)
Leisure (recreation, hobbies)
Self-determination Autonomy/personal control (independence)
Goals and personal values (desires, expectations)
Choices (opportunities, options, preferences)
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Social inclusion Community integration and participation
Community roles (contributor, volunteer)
Social supports (support network, services)
Rights Human (respect, dignity, equality)
Legal (citizenship, access, due process)
3.3 Types of instruments for measuring QoL
QoL measures are generally used for 3 purposes: (i) discriminative; (ii) evaluative; or
(iii) predictive 207. Discriminative measures are those that determine differences
within populations whilst evaluative measures examine changes within an individual
over time and predicative measurements are used for prognostication. Additionally,
QoL tools can be defined as being either generic or disease-specific 207 208. Generic
instruments have the advantage that they can be used to compare different conditions
or patient populations whereas disease-specific instruments have the ability to detect
smaller changes in patients with a particular condition. Generic measures can be
further classified according to the type of score that they produce (i) health profiles;
207 208
or (ii) preference-based index measures . The former consists of multiple items
that are under different domains and can be used to assess almost any population.
They allow for the quantification of the impact of a disease/treatment on different
aspects of a subject's QoL by providing a separate score for each domain. In
contrast, the latter provides a single number (or index) that reflects the net aggregate
impact of the given situation on all areas of QoL. Preference scores have the
advantage that they can be used as an adjustment factor in the calculation of quality-
907 908
adjusted life years for cost-effectiveness analyses
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3.4 QoL assessment administration
There is a wide range of variety concerning the administration of QoL instruments
with regards to assessor, timing, place and subject. Questions can either be
administrated by a trained interviewer or self-administered by the patient.
Additionally, questioning can either take place in person, over the phone or via a
written survey. If tools require self-completed written responses then they can either
be completed in a clinic setting or mailed to the relevant recipients. Each method of
delivery and collection has its advantages 210.
It is generally accepted that although the administration of a QoL tool by a trained
professional requires more resources, there are consistently fewer errors and missing
responses 207. Conversely, although self-completed instruments are much less
expensive to administer, they typically result in missing responses and lower
response rates 21°. One answer is to use a supervised self-administered tool that
eliminates poor response rates and allows for the immediate addition of any missing
data.
Increasingly computers are being utilised both in conjunction with telephone and




Psychometrics refers to the "measurement of psychological constructs" . It
involves two major aspects: (i) the construction of instruments and procedures for
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measurement; and (ii) the development and refinement of theoretical approaches to
measurement 21°. The psychometric properties of any QoL tool are essential when
deciding whether or not it is an aqequate assessment for clinical or research
purposes. When assessing any QoL instrument it is important to consider its
reliability and validity.
Reliability can be defined as "the proportion of variance that is attributable to the
true score of the latent variable" and is directly responsible for the quality of any
measurement. Reliability can be considered in terms of internal consistency and test-
re-testing. Internal consistency assesses the agreement of items in multiple-item
scales within the same administration whereas test-re-testing replicates measures
over time. Internal consistency is defined in terms of Cronbach's a, with a value of >
0.7 being considered acceptable 2I°.
In terms of QoL tools, validity can be divided into content validity, criterion validity
and construct validity 210. Content validity is "the extent to which a specific set of
items reflects a content domain " and asks whether or not an instrument samples all
of the relevant or important domains. Criterion validity is "the correlation ofa scale
with some other measure of the trait or disorder under study " and ideally compares
the tool under question with a 'gold standard' that has already been widely used and
accepted. Criterion validity can be further divided into predictive validity (the ability
to predict something it should theoretically be able to predict) and concurrent
validity (ability to distinguish between groups that it should theoretically be able to
distinguish between). Lastly, construct validity is "the theoretical relationship of a
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variable to other variables " and refers to the comparison of the new QoL instrument
with existing measures 210. This can also be divided into convergent validity
(looking at the degree to which the tool is similar to other tools that it theoretically
should be similar to) and divergent validity (the degree to which the tool is not
similar to other tools that it theoretically should be not be similar to).
3.6 Specific paediatric considerations
In most situations it is inappropriate to apply adult HR-QoL tools to paediatric
populations since they differ substantially in their activities of daily living and
207 211 212
experiences . Adult tools tend to be too long for children, contain
inappropriate language and necessitate sensitivity judgements beyond a child's
capacity. Even within the paediatric population it is important to recognise different
age groups as separate subsets as they often require the inclusion of different
210domains or may even need different types (i.e. words vs. pictures) of instruments
When using written tools it is essential that the reading and comprehension levels
required to complete the instrument are appropriate for the target population. 10-
20% of children can be expected to have learning problems and these problems are
likely to be higher in populations of children who have chronic illness or disability
213. There is a risk that although some children may lack the comprehension required
to complete an assessment, they may answer randomly in order to please the
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examiner
A range of different rating scales are routinely used in paediatric QoL assessment
tools including Likert (bipolar scaling method, measuring either positive or negative
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response to a statement), facial expression, graphic (i.e. graduated circle size) and
visual analogue scales (VAS) 212. A study assessing the relationship between the
type of scale used, the age of the subject and consequent reliability concluded that for
maximum internal reliability, graduated circles should be used for ability items
whilst faces were recommended for social items. In terms of maximum
reproducibility over time, a VAS is suggested for use in children aged 5 to 6 and
faces for children aged 7-9 years 212.
3.7 Use of proxy vs. self-assessment for paediatric QoL evaluation
Until relatively recently, evaluation of a paediatric subject's QoL has relied purely
upon proxy assessment, with children being deemed too unreliable to be able to
accurately quantify their situation 213. It was often assumed that young children are
unable to distinguish between fantasy and reality, however more recent studies
suggest that this is simply due to their limited experience and not a lack of their
ability. This limited experience can also mean that children are unable to appreciate
that life is different for others and adds a further challenge in the development of
reliable assessment tools. It is now generally accepted that although children may
interpret events differently from their adult counterparts, given the correct
circumstances, they are perfectly capable of remembering, reporting and applying
information 213.
Research has shown that children's understanding of self develops sequentially,
relative to their cognitive and language development214. A major change in a child's
sense of self occurs between the age of 18 months and 2 years of age, where they
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begin to develop cognitive representations of themselves and the ability to
distinguish between self and others 2I5. Whilst children below the age of 6 tend to
see themselves in physical terms and have difficulty separating their sense of self
from their actual behaviour, it is strongly believed that they have the ability to
describe their mental state and appreciate that feelings are different from actions 216.
Children at this age have a basic understanding of health focussed around hurts,
aches and eating the right foods 217. As children approach middle childhood (6-12
years) they begin to develop an increasing awareness of their self and a growing
appreciation of their emotions and their understanding of health and illness increase
alongside their perception of bodily functions (a differentiated biological model) 218.
3.8 Reliability of proxy assessment
A proxy's perception of a subject's QoL may not represent an accurate description of
their actual thoughts and feelings. There are mixed opinions as to the reliability of
proxy assessments 219. It appears that the correlation between parent and child
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perception of QoL differs substantially according to domain . In children
with chronic illness, good agreement is generally reported for physical activities
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(functional status), physical symptoms and somatic distress . Conversely, there
appears to be moderate to poor correlation within domains that reflect more social or
emotional QoL issues 219. There is also mixed evidence with regards to the reporting
of the overall level of QoL between children and their parents. Although some
studies suggest that there is no significant difference in global perception, there are
many that propose that parents consistently report a significantly lower QoL than
their child 219.
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There is good reported correlation between a doctor's and a parent's assessment of a
child's QoL 220, however it appears to be poorer between nurses, parents and children
221
. However, although there are studies assessing the difference between medical
staff and parents as proxy raters, there are no studies that address the potential
discrepancy between maternal- and paternal-reported QoL219.
There have been various studies that have looked at the impact of age, gender and
illness on parent-child agreement. One study reports that for children (8-12) there is
maximum correlation for cognitive functioning, however for adolescents the
agreement was greatest for physical functioning 222. There have been no clear
findings with regards to the influence of gender upon concordance of parent-child
reporting 223. When considering disease state, there appears to be a wide variation in
224. 225
correlation between illnesses and also between states of wellness, temporary
223 224
illness and chronic illness
There is no surprise that there appears to be greater parent-child agreement for
questionnaires completed at home compared to those completed in a clinical setting
226. This highlights the importance of consideration and documentation of setting
when administering QoL tools.
3.9 The use of QoL measures in clinical trials
QoL is a central issue when considering the impact of chronic disease and so should
not be ignored by researchers 227 228. with the advent of improved treatment and
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resultant prognosis for many chronic illnesses, there is the reality that more children
are faced with living with long-term ill-health and the effect on their resultant
standard of life must not be forgotten. Although traditionally research has focused
on objective indices including survival rates and reduction in physical symptoms,
investigators are now tending towards the routine inclusion of HR-QoL tools. Indeed
for many families, an improvement in their child's QoL is far more important than
any change in their clinical state. As previously described it is important to consider
whether or not a tool adequately assesses a trial population's disease, what its
psychometric properties are, how long is it and who needs to complete it 2I°.
Specific concerns when using QoL instruments in clinical trials include economics,
maturation and response shift 228.
3.10 Economics
It is the concern of some researchers that adding QoL measures to a trial protocol
may increase the monetary cost of the study. In addition, there are also concerns
about the cost in time associated with the attainment of meaningful data. However, it
is becoming increasingly evident that the omission of such tools reduces the value of
many projects and that their inclusion is entirely justified. It is important to
remember in the context of multicentre trials that a tool must be suitable for use in all





Maturation should be considered in terms of both short- and long-term issues. In the
short-term, if QoL tools are administered too frequently it can result in fatigue and
learning 228. Equally, in the long-term, psychophysical development and both
cultural and environmental changes can affect responses 229. In order to minimise
these effects it is important to try to utilise a versatile measure and administer it as
sensitively as possible 229.
3.12 Response shift
Three types of response shift can be identified: (i) recalibration of scales comprising
the yardsticks respondents use to gauge personal standards; (ii) actual changes in
values as measured by ranking of outcome domains; and (iii) redefinition of the
target construct 230. Response shift was first identified when it became obvious that
there were frequent discrepancies between clinical features of a disease and patients'
self-reports about their quality of life. Over time patients adjust to their condition
and its associated difficulties and may meet with others who are faced even more
restrictions then they are. With this in mind, it is important to recognise and report
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any response shift and to assess its subsequent impact on ratings
One way of recognising any response shift is by using "then" ratings 229. This
method employs the use of pre-, post-testing with the addition of a "then-test" when
the post-test is completed. The "then-test" represents a retrospective pre-test. By
comparing the post- and then-tests, treatment-induced response shift effects can be
eliminated, allowing the detection of unconfounded treatment effects. In addition, by
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comparing the pre- and then-tests, an estimate of the amount and direction of the
response shift can be made 229.
3.13 Specific QoL tools for faecal incontinence/constipation
There exist several HR-QoL tools that have been developed specifically for the
assessment of patients with defecatory disorders. Their use is primarily targeted
towards an adult population as many include sexual activity, work functioning and
length of symptoms (up to > 20 years). The number of tools that are available for the
assessment of faecal incontinence highlights the lack of uniform acceptance of any
one model.
There are 3 types of disease specific measures: (i) a traditional condition-specific
QoL instrument; (ii) a "systemic" QoL tool that assesses the system (i.e.
gastrointestinal, respiratory, cardiac) that the condition affects; and (iii) a population-
specific condition-specific QoL tool that assesses QoL relative to a specific
population (i.e. incontinence in children with Hirchsprungs disease, incontinence
after anorectal malformation repair).
3.14 Traditional condition-specific QoL tools
3.14.1 Fecal Incontinence Questionnaire
This represents a self-reported questionnaire designed to measure the prevalence of
faecal incontinence in a community and the risk factors associated with incontinence
(Appendix 1) 231. It has specific questions designed to: (i) assess general bowel
habits and symptoms; (ii) determine the presence of faecal incontinence and in those
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with an affirmative response, characterise and measure the severity; (iii) measure
associated symptoms related to pelvic floor dysfunction; (iv) assess historic risk
factors that may contribute to the development of faecal incontinence; and (v) help
assess the association between urinary symptoms and faecal incontinence. The
questionnaire has been tested by the authors for feasibility, test administration,
reproducibility, validity and reliability and they report mixed but generally
acceptable results 231. There does not seem to be a scoring method associated with
the tool meaning that it is not suitable for measuring change. It has not been used in
children 23'.
3.14.2 Fecal Incontinence Quality of Life Scale (FIQL)
This QoL instrument is composed of a total of 29 items forming 4 scales: (i)
Lifestyle (10 items); (ii) Coping/Behaviour (9 items); (iii) Depression/Self-
Perception (7 items); and (iv) Embarrassment (3 items) (Appendix 2) 232. The
responses for all items are scored by a five-point Likert scale). The FIQL has been
psychometrically evaluated for reliability (test-retest and internal consistency) and
validity with acceptable results and each of the 4 scales is reported to be capable of
discriminating between patients with faecal incontinence and other gastrointestinal
disorders. It has been endorsed by the American Society of Colon and Rectal
Surgeons (ASCRS) 233. The FIQL is not directly applicable to children as it contains
items with sexual references.
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3.14.3 Patient Assessment of Constipation Quality of Life Questionnaire
(PAC-QOL)
The PAC-QOL was designed to complement the PAC-SYM (patient assessment of
constipation symptoms) and was designed to address the need for a standardised,
patient-reported outcome measure to evaluate constipation over time 234 (Appendix
3). The tool consists of 28 items that form 4 subscales: (i) worries and concerns; (ii)
physical discomfort; (iii) psychosocial discomfort; and (iv) satisfaction. The scores
are combined to give an overall scale. Multicentre/multinational testing revealed
acceptable results for both internal consistency reliability (Cronbach's a > 0.80) and
reproducibility (Test-retest intra-class correlation (ICC)> 0.70). The PAC-QOL was
also shown to be responsive to improvements over time. All of the psychometric
testing has involved an adult population and there is no reported evidence of either
tool being used with children 234.
3.15 "Systemic" QoL tools
3.15.1 Gastrointestinal Quality of Life Index (GIQLI)
This is a bilingual (English and German) questionnaire containing 36 items each with
5 response categories (Appendix 4) 235. The responses to the questions (0-4) are
summed giving a numerical score (0-144). The GIQLI consists of a set of core
questions that are applicable to any patient with any gastrointestinal disease. It is
designed to provide a subjective perception of well-being and is not intended to be
used as a diagnostic tool. The questionnaire has been tested for reliability, validity
and internal consistency (in German) and the authors report levels that are well above
accepted standards (Cronbach's a > 0.90, ICC 0.92). They also claim that the index
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is responsive to changes in the clinical status of patients. There have been no
reported results for testing of the English version and it has not been validated in
children.
3.16 Population-specific, disease-specific QoL tools
3.16.1 Modified Manchester Health Questionnaire (MMHQ)
This QoL tool (Appendix 5) represents a combination of the Faecal Incontinence
Severity Index 236 (FISI) and the Manchester Health Questionnaire (MHQ) 237. It has
been designed, and validated, for telephone administration in an attempt to provide a
measure for use in clinical trials that is cost-effective. It has satisfactory reported
reliability and validity standards (Cronbach's a = 0.79-0.92, ICC = 0.75) for written
and telephone administration. The responsiveness of the MMHQ to changes in
clinical status is yet to be determined in a longitudinal study. Although it was
initially formulated to assess faecal incontinence in females after vaginal delivery, by
the omission of 1 section it is appropriate for use in all adults. It is not suitable for
use in children.
3.16.2 Ditesheim and Templeton QoL scoring system
This represents a simple quantitative five-item QoL tool evaluating the three domains
of personal development (school attendance), social inclusion (social relations) and
physical well-being (physical capabilities) (Appendix 6) . It was initially
developed as a tool to assist in the assessment of short-time vs. long-term QoL in
children following repair of high imperforate anus. It includes questions about
school attendance, social difficulties and physical capabilities. Where questions are
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age specific, if irrelevant, the items are omitted and the score then modified
accordingly.
Unfortunately there is little information available regarding the psychometric
properties of this scoring tool 233 and hence it's ability to accurately assess QoL is
questionable. Even if all questions are answered, the small scoring range (0-3.5)
produces low precision and affects the tool's ability to detect differences. Although
the content of the questions are valuable, there are too few questions for this measure
to truly be able to reflect disease specific QoL. It is however one of the few tools
designed to assess faecal incontinence that is intended for use in children.
3.16.3 Patient Assessment of Constipation Symptoms (PAC-SYM)
The PAC-SYM is a 12 item self-reported tool that is divided into 3 domains (i)
abdominal; (ii) rectal; and (iii) stool 239 240 (Appendix 7). It was initially devised in
an attempt to address the obvious lack of a gold standard for assessment of HR-QoL
of patients with constipation. It is specifically designed to measure symptoms and
their severity and is intended to be used in conjunction with PAC-QOL (Patient
Assessment of Constipation Quality of Life) which is itself is designed to assess
QoL. The authors of the PAC-SYM instrument report high internal consistency and
test-retest reliability (Cronbach's a = 0.89, ICC = 0.75) and they feel it is a valuable
tool for evaluation of chronic constipation. They do however highlight that testing in
multiple clinical settings suggested that additional clinical data were necessary to
perform a complete assessment.
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3.16.4 Quality of Life Score for Children with Fecal Incontinence
A group of researchers following up a cohort of children after surgically corrected
anorectal malformation identified that there was no QoL scale in existence and so
formulated their own tool241. Their instrument consists of 6 items based on somatic,
social and psychological domains and is parent-reported (Appendix 8). The authors
feel that although they have not performed any official reliability or validity testing,
the tool is sensitive enough to reflect changes in QoL. They acknowledge that
further psychometric testing is necessary.
3.16.5 Defecation disorder list (DDL)
This represents a disease specific HRQoL tool for children with constipation or
functional non-retentive faecal soiling 242. It is only relevant for usage in children
who experience soiling as a consequence of their constipation. It consists of 37 items
in 4 domains - constipation related, emotional functioning, social functioning and
treatment/intervention. Its reliability and reproducibility were assessed based upon
its use in only 27 children. The authors describe good reliability for all domains with
Cronbach's a ranging between 0.61 and 0.76. ICCs for all 4 domains ranged
between 0.82 to 0.92. When validity based on comparison to the TACQOL tool was
assessed, the authors reported only moderate results.
3.17 Paediatric generic QoL tools
Generic QoL instruments present several advantages when assessing QoL within a
disease-specific population. Most importantly they allow the comparison of the
target population with other populations in whom a disease specific QoL tool would
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be irrelevant. By using a generic tool, subjects with constipation/faecal incontinence
can be compared with subjects with other chronic disease states as well as healthy
control subjects. Unfortunately generic tools often lack the subtle qualities, or
responsiveness, required to detect "change". Responsiveness is viewed in the
context of 2 central questions: (i) how much change is meaningful (in a particular
area, such as clinical or personal change)?; and (ii) how much change must occur
before the instrument is capable of assessing the change? 243. Generic tools are
usually capable of detecting gross changes but are often poor at picking up small
variations.
There exists no gold standard for the assessment of a child's QoL 2I8. Instead,
several tools are available, providing a combination of self- and proxy-reported
instruments.
3.17.1 The Child Health Questionnaire (CHQ, CHQ-PF50, CHQ-PF28)
Originating from the United States of America (USA) the CHQ represents a self-
report instrument for children aged 10-18 years 244 designed to assess "physical and
psychosocial functioning and well-being". It consists of 87 items addressing 14
different concepts of physical and psychosocial health and associated impairments
(physical ability to function, bodily pain, general health perception, self-esteem,
mental health, behaviour, burden on parents, social impairment and family
activities). Scores can be aggregated into physiological and psychosocial sum
values. In addition, in response to industry demands for instruments of a more
practical length, a 50-item (CHQ-PF50) and a 28-item (CHQ-PF28) parent-
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completed were created. The authors report mixed reliability with Cronbach's a
ranging from 0.62-0.91 across the instruments 244.
More recently the SF-10 (short form -10) has been developed (based on the CHQ
range of instruments) which is a parent-completed QoL assessment tool for children,
aged 5-18 years, consisting of just 10 questions. It addresses eight domains of health
(physical functioning, role limitations due to physical health (role-physical), bodily
pain, general health perceptions, vitality, social functioning, role limitations due to
emotional problems (role-emotional) and mental health) and, like its CHQ
counterparts, is scored to produce physical and psychosocial health summary scores.
3.17.2 The Child Health and Illness Profile (CHIP)
Again developed in the USA, this tool is designed primarily to assess functional
aspects of HR-QoL in adolescents aged 11-17 years 245 246. It is divided into 6 broad
domains (satisfaction, complaints, resilience, health conditions, attainment of social
goals and risk behaviours) which are further subdivided into 20 smaller domains.
The scoring system is designed to produce taxonomy of health profiles owing to its
high psychometric quality. Although the authors report good reliability (Cronbach's
a exceeds 0.7 for all domains), the sample on which the questionnaire was
standardised is not felt to be representative of the 'general population', nor were
large numbers assessed 247. Consisting of 188 items, the instrument is somewhat
lengthy for a paediatric self-assessment tool and the majority of its content was not
designed with input from children and adolescents.
92
3.17.3 The How Are You Questionnaire (HAY)
Originating from the Netherlands, HAY assesses generic and disease-specific aspects
of QoL and is designed for children aged 7-13 years 247. It can either be self- or
proxy-completed. It contains questions from 6 generic domains (physical activities,
cognitive tasks, social activities, social problems, physical complaints and
treatments) as well as 2 chronic illness (concerns and feelings of inferiority) and 2
disease-specific (physical complaints and treatment tasks) domains. Unfortunately, it
is rather lengthy (80 items) and although it is advertised as a generic tool, its
inclusion of chronic illness/disease-specific domains limits its use in healthy control
subjects.
3.17.4 The KIDSCREEN Quality of Life Questionnaire
The KIDSCREEN-52 is a generic questionnaire for children aged between 8 and 18
years of age that was developed simultaneously in 12 European countries 248 249.
Questionnaire development included focus group discussions with children and
adolescents and the result was a 52-item, 10 domain self- or proxy-assessed QoL
instrument. Since its initial creation the KIDSCREEN has been modified, and there
now exist 2 short forms: the KIDSCREEN-27 (27 items, 5 domains) 250 and the
KIDSCREEN-10 (10 items, 1 domain) 251. This QoL tool is the first of its kind to
comprehensively fulfil the standards promoted by the World Health Organisation
(WHO) for a child-suitable measurement of HR-QoL 247. As yet, although its
authors report encouraging psychometric testing results (Cronbach's a 0.77-0.89), it
is not widely available for use and all data relate solely to pilot testing.
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3.17.5 The KINDL Questionnaire for Measuring HR-QOL in Children and
Adolescents
The KINDL QoL measure originates from Germany but has now been translated into
9 S9
14 languages . There are 3 versions that are age appropriate: KINDL-Kiddo (13-
16 years), KINDL-Kid (8-12 years) and KINDL-Kiddy (4-7 years). All measures
come in both self- and parent-reported forms. The KINDL questionnaire is
developed from a conceptual model that includes 4 main components of QoL:
psychological well-being, social relationships, physical functions and everyday-life
activities and consists of 24 items divided into 6 domains (physical health, general
health, family functioning, self-esteem, social functioning and school functioning).
Although the authors have demonstrated good internal consistency (Cronbach's a >
0.75) and test-re-test reliability (ICC = 0.8), current data suggest that the tool is
unable to show a significant difference between healthy and ill children.
3.17.6 TACQOL (The Netherlands Organisation for Applied Scientific
Research-Academic Medical Centre Child QoL Questionnaire)
This tool was developed in the Netherlands for use as a generic instrument in
medical research and clinical trials 253. It consists of 56 items that are divided into 7
domains (physical complaints, mobility, independence, cognitive function, social
function, positive emotions and negative emotions) each with 8 questions. There are
2 versions; a self-reported tool for children aged 8-15 years (Cronbach's a 0.59-0.86)
and a proxy-reported tool for children aged 5-15 years (Cronbach's a 0.71-0.89).
The questions are designed so that the quantity of any impairment can be assessed
and then the subsequent emotion to this impairment evaluated. Although it is a well-
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designed tool for quantifying QoL in children with illness, the questions were not
originally designed for use in healthy subjects.
3.17.7 Pediatric Quality of Life Questionnaire (PedsQL)
The PedsQL range of QoL tools includes several generic and disease-specific
questionnaires 222254 26(). The instruments were developed to assess QoL in paediatric
subjects from 2 to 18 years and exist in self- and parent-report forms that are
designed to be used in parallel, providing a direct comparison between child- and
parent-perceived QoL. The PedsQL 4.0 Generic Core Scales version (Appendix 9)
consists of 23 items from 4 domains (physical, emotional, social and school). The
answers to the questions can be computed to give separate physical and psychosocial
summative scores as well as an overall assessment of QoL. Cronbach's a is reported
as 0.93 for both the child-report and parent-report tools. PedsQL is a short but
reliable tool that is suitable for use in clinical trials, research, clinical practice, school
health settings and community populations 247 261.
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3.17.8 Summary of use of reviewed Quality of Life tools in adults and children
with defecatory disorders and slow transit constipation
Table 12 - Table summarising the use of Quality of Life tools in adults
and children with defecatory disorders and slow transit constipation.






Fecal Incontinence Adults 231 Adults No
Questionnaire
Fecal Quality of Life Scale Adults 232 Adults 233 No
Patient Assessment of Quality Adults 234 Adults 262 No
of Life Questionnaire
Gastrointestinal Quality of Adults 233 Adults 263 264 and Adults 266"26y
Life Index children 265
Modified Manchester Health Adults 237 Adults 2/u No
Questionnaire
Ditesheim and Templeton Children 238 Children 271 No
Patient Assessment of Adults 240 Adults 262 No
Constipation Symptoms
Quality of Life Score for Non-validated Children 241 No
Children with Fecal
Incontinence
Defecation disorder list Children 242 Children 2/2 No
Child Health Questionnaire Children 244 Children 273 No
Child Health and Illness Children 2/4 No No
Profile
The How Are You Children247 No No
Questionnaire
KIDSCREEN Quality of Life Children 24y"23J No No
Questionnaire
The KINDL Questionnaire for Children 232 No No
measuring HR-QOL in
Children and Adolescents
TACQOL Children 233 Children 273 276 No
Pediatric Quality of Life Children 233 236 Children 277 No
Questionnaire
3.18 Summary
Quality of life is now recognised as an important clinical measure that should form
part of routine clinical assessment and follow-up in order to fully evaluate the
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efficacy of any intervention. As such, many generic, population-specific and
disease-specific QoL tools now exist and QoL assessment has almost become
standard practice in adult medicine.
As culture has changed, accepting that children should no longer be 'seen and not
heard', but be allowed to voice their opinions, so trends in paediatric QoL assessment
have changed recognising that parental proxy-assessment should ideally be
complemented by child self-assessment where possible. The PedsQL QoL series of
questionnaires consist of parallel child and parent assessment tools and provide a
valuable insight into differences in QoL perception.
Unfortunately, as yet, there exists no condition-specific, population-specific tool for
children with chronic constipation. Tools are in existence for adults with faecal
incontinence, however, a large part of their questions focus on sexual function and so
their application in children is limited. Similarly, there are many generic tools that
assess QoL in paediatric populations, but none of them seem to address the specific
problems faced by children with intractable constipation. Hopefully, as more studies
highlight potentially serious QoL issues in a diversity of populations and conditions,
then more tools will become available to intimately evaluate QoL in specific disease
states.
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4. Hypothesis and aims
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4. Hypothesis and Aims
This thesis hypothesises that there exists a form of chronic constipation in children
(slow transit constipation (STC)), characterised by abnormal colonic motility, that
not only can be reliably diagnosed by nuclear transit studies or colonic manometry,
but also can be treated by transcutaneous electrical stimulation.
The first aim of this thesis was to establish whether or not living with the daily
stresses of slow transit constipation (STC) adversely affect a child's quality of life
(QoL). This was tested by assessing the QoL of populations of both children with
QoL and healthy controls. QoL was measured by parallel parent proxy-reported and
child self-reported questionnaires. There are no previous studies that have evaluated
the QoL in children with STC.
The second aim was to establish the test-re-test reliability of nuclear transit studies in
the diagnosis of children with slow transit constipation (STC). This was determined
by identifying children with STC who had had transit studies performed on two,
separate occasions and comparing the results of the two studies.
Thirdly, this thesis aimed to evaluate the efficacy of a novel form of therapy in the
treatment of children with STC. It reports the interim analysis of a randomised
placebo-controlled trial assessing the potential application of transcutaneous
interferential electrical therapy in the management of children with chronic
constipation unresponsive to at least 2 years of conventional treatment.
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Finally, the last aim of this thesis was to ascertain whether or not there was any
change in the colonic motility pattern of children with STC following treatment with
IFT. This was ascertained by performing colonic manometric studies both before
and after treatment with IFT and comparing the findings.
In summary, this thesis aimed to assess novel aspects of diagnosis and management
in the evaluation and treatment of chronic childhood constipation.
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5. Quality of life in children with slow transit constipation
5.1 Introduction
Since its first description in 1996 19, slow transit constipation (STC) is gradually
20 146 277 279 281
becoming accepted as a chronic form of constipation in children " . It is
characterised by intractable constipation that is not readily responsive to laxatives,
diet or a change in lifestyle and where there is marked delay in colonic transit time on
transit study 697°.
The aetiology of STC remains unknown with various theories involving neuronal
abnormalities 74 282, genetic linkage 92 280, endocrine dysfunction 283, autonomic
dysfunction 30 and abnormal colonic pacemaking 48 being postulated. Children with
STC suffer from irregular bowel motions, colicky abdominal pain and frequent
uncontrollable soiling. In some children, despite aggressive medical therapy,
spontaneous passage of stools is unachievable. Consequently these children are
managed by the surgical formation of an appendicostomy through which regular
antegrade bowel washouts can be performed to improve continence 126 128. Definitive
treatment remains elusive and consequently families of children with STC are offered
a wide range of management options, many of which are perceived to be
unsuccessful.
There are many studies that have assessed the quality of life in children with chronic
disease, however few studies exist that look at the physical and psychosocial impact
9TR OA 1 "97S 00f\
of gastrointestinal disorders in children , with only a few concentrating on
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those with chronic constipation . Currently no studies exist that have
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examined the quality of life in children with STC. The only studies that have
evaluated QoL in subjects with STC are those that have compared QoL in adults
266 269before and after bowel resection ~ .
The value of any trial is inextricably linked to the quality of the data that is recorded.
Standardisation of recorded outcome measures is being called for as a way to reduce
to risk of inappropriate measurements (especially in children), make it easier to
compare and contrast trials and to minimise any risk of outcome reporting bias 284. It
is being increasingly recognised that the reporting of QoL should form part of any
standard outcome measures in clinical randomised controlled trials (RCT) 285 286.
A review concerning both the frequency and quality of reporting of QoL in RCTs on
the Cochrane Controlled Trials Register (CCTR) from 1980-1997 found that less than
5% of all RCTs during this time period described any evaluation of QoL 287. At the
start of the study period, only 0.63% of registered trials reported assessment of QoL
measures. However a similar trial that reviewed all RCTs registered on the CCTR
from 2002-2008 found the recording of QoL had become a primary outcome measure
in 25.4% of trials with 14% of trials using supplementary reports (separate from the
first publication) to recount their findings 288. This increased rate of inclusion of QoL
as an outcome measure highlights the importance that is now being placed on its
evaluation in clinical trials and further serves to justify the establishment of the
reported study.
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5.2 Hypothesis and aim
The study hypothesises that the clinical features of STC have an impact upon
physical, emotional and social function. This study, using a validated paediatric
questionnaire (PedsQL), aimed to assess physical and psychosocial features of life in
children with STC and compare it with control subjects.
5.3 Subjects and Methods
5.3.1 Study population
Study patients were recruited from the gastrointestinal and surgical clinics in a large
tertiary paediatric hospital (Royal Childrens Hospital, Melbourne, Australia).
Patients were between 8 and 18 years of age and had been treated for constipation for
a minimum of 2 years. Constipation was defined by the Rome II criteria 289 and all
patients had previously had metabolic or hormonal causes excluded. All subjects
were diagnosed with STC by radioisotope nuclear transit study and had retention of
radioactivity in the proximal colon at 48 hours 69. Children with an organic cause for
their constipation, cognitive impairment or anorectal retention/normal transit on their
nuclear transit study were excluded. Control subjects were recruited from: (i) out¬
patient surgical clinics and consisted of children (8-18 years) who were attending for
routine follow-up after uncomplicated appendicectomy or minor surgical procedure
(i.e. scrotal exploration, orchidopexy, herniotomy); and (ii) a scout jamboree that took
place locally during the recruitment period. All control subjects had a "normal"
bowel pattern (between 3 movements a week and 3 movements a day where the stool
is brown or golden brown in colour, formed, has a texture similar to peanut butter,
and a size and shape similar to a sausage). Children who had concurrent co-
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morbidities were excluded along with those who did not describe a "normal" bowel
habit.
5.3.2 Methods
Following the attainment of informed consent, the questionnaire (PedsQL) was
administered by one of two investigators (MC or CC). The PedsQL 4.0 (Pediatric
Quality of Life Inventory) Generic Core Scales consist of parallel child and parent
self-report scales, and have been validated in children and adolescents aged 2-18 254~
256259
questjonnajres consist of 23 items encompassing (i) Physical functioning
(8 items) (ii) Emotional functioning (5 items) (iii) Social functioning (5 items) and
(iv) School functioning (5 items). The categories can then be grouped into Physical
(i) and Psychosocial (ii, iii & iv) functioning. The questions ask how much of a
problem each item has been during the past 1 month. A 5-point response scale is
utilised (0 = never a problem; 1 = almost never a problem; 2 = sometimes a problem;
3 = often a problem; 4 = almost always a problem). Items are reverse scored (0 =100,
1 = 75, 2 = 50, 3 = 25, 4 = 0) and linearly transformed to a 0-100 scale by dividing
the total score (maximum 2300) by the number of questions (23). Higher scores
indicate better quality of life (maximum score = 100).
Parent and child completed the questionnaire independently with impartial assistance
being provided for any child who had difficulty with comprehension.
The local human research ethics committee (HREC) approved the study (23040 B).
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5.3.3 Outcome measures
The primary outcome measures were self- and parent-reported, health-related quality
of life (HR-QoL) in children with STC compared with healthy controls.
5.3.4 Data Analysis
Physical, psychosocial and total quality of life scores were compared using Wilcoxon
matched pairs and Mann Whitney tests. All P values < 0.05 were considered as
statistically significant.
5.4 Results
From March 2006 to March 2007, 51 children (34 Male, 17 Female) with STC and 79
healthy controls (48 Male, 31 Female) were recruited into the study (Table 13). All
children and their parents successfully completed the PedsQL. The data for every
group did not have a Gaussian distribution.
The QoL scores (PedsQL) for all the study participants are summarised in Table 14.




Mean Age (years) 11.5 12.1
Mean duration of symptoms (years) 10.1 N/A
Appendicostomy 14/51 N/A
Soiling 41/51 N/A
Abdominal pain 40/51 N/A
106
Table 14 - Child and parent QoL scores (PedsQL) for control and STC







Mean SD Mean SD Mean SD
Child - control 85.99 9.471 92.14 7.799 83.30 11.15
Child - STC 72.90 16.00 78.79 14.79 69.22 18.32
Parent - control 84.25 8.644 92.77 9.247 79.71 11.10
Parents - STC 64.43 19.57 74.44 20.76 58.55 21.86
Child-reported QoL was significantly lower in children with STC compared to
normal children (mean 72.90 vs. 85.99; p < 0.0001) (Figure 13). Parent-reported QoL
was significantly lower for children with STC compared to the control group (mean
64.43 vs. 84.25; p < 0.0001) (Figure 14). Physical and psychosocial QoL, both child-


















Figure 14 - Parent-reported scores: STC vs. control (Wilcoxon matched
pairs test).
Parents of children with STC reported their child had a significantly lower QoL than
the children themselves reported (64.43 vs. 72.90; p = 0.014) (Figure 15). This was
also apparent in the control group, however to a lesser extent (84.25 vs. 85.99; p =
0.04) (Figure 16). Parents both of children with STC and of controls reported
significantly poorer psychosocial QoL for their child compared to the child's own
report (Figures 15 and 16). There was no statistical difference in the reporting of












Figure 15 - STC: Child- vs. Parent-reported scores (Mann Whitney test).
p= ns
1 oo -| P — 0-04 i 1 p = 0.006
I Child-reported





Figure 16 - Control: Child- vs. Parent-reported scores (Mann Whitney
test).
5.5 Discussion
Quality of life (QoL) can be defined as "an individual's subjective perception of
overall wellbeing and satisfaction with life" 206 or "physical, social and emotional
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aspects of a patient's well being that are important to the individual" . QoL is a
multidimensional concept that incorporates the assessment of recognised core
domains and indicators.
Many studies have looked at the QoL in children with chronic disease, however there
are few studies that have specifically examined the impact of chronic constipation on
physical and psychosocial functioning 277. There are no current publications that
address QoL issues in children with proven STC. This is a population of children
who have in many instances been managed for several years without a definitive
diagnosis and often ineffectual treatment, and for whom social interaction is often
limited due to antisocial symptoms (i.e. soiling).
This study found that there is a significant impairment in QoL of children with STC
compared to healthy controls. This is consistently described by the children and their
parents and affects both physical and psychosocial QoL (Figures 13 and 14).
Parents of children with STC often describe the onset of their child's symptoms as
being at, or shortly after, birth 20; STC represents a lifelong problem. These children
grow up with the daily problem of difficulty with stooling, chronic abdominal pain
and frequent soiling. Their social interactions are often limited due to the lack of
insight of their young peers and consequently they can become withdrawn and
socially isolated.
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Although children with STC have no obvious physical anomalies, both the children
themselves and their parents report a significant deficit in their physical QoL.
Questions included in the physical section of PedsQL ask about participation in sport,
ability to take bath/shower by oneself, having hurts/aches and energy levels. If
children experience involuntary passage of stool, or soiling, then participation in sport
can often seem daunting. Not only do children have to change in a communal area,
where they may inadvertently expose protective clothing or their appendicostomy site
126 127, but they may also experience increased symptoms associated with the increase
in physical exertion. Similarly, if children experience severe soiling then they may
require assistance to adequately clean themselves. As previously mentioned, children
with STC are often affected by chronic abdominal discomfort. This chronic pain can
account for the increased reporting of hurts/aches and also the consistent reporting of
low energy levels. In addition, children affected by the slow passage of stool often
feel full and bloated and complain of a poor appetite. Their resultant decreased
calorific intake will also contribute to their low energy levels.
The psychosocial section of PedsQL is divided into emotional, social and school
functioning. Emotional functioning covers feeling afraid, sad or angry as well as
troubles sleeping and worrying about the future. Feeling strong emotions and
worrying about the future are in many ways features of childhood in general and
cannot always be attributed to chronic disease. Despite this, the subgroup of children
with STC reported significantly poorer emotional QoL and in particular many were
concerned about how their future might be affected by their condition.
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Social functioning enquires about the ability of the child to integrate with others.
Questions focus on ability to get on with other children as well as social acceptability
(other children wanting to be their friend/teasing) and ability to keep up with their
peers. Children are often admired for their honesty and integrity, however it is well
known that they can also be incredibly cruel especially when they lack insight.
Children who are afflicted with chronic soiling are unfortunately easy targets for
social ridicule and bullying. Although the responses of the children with STC suggest
that they feel they have the ability to keep up with their peers, they have poor QoL
scores for social functioning due to their reduced social integration.
The final section of psychosocial QoL concerns school functioning. Subjects are
asked about their ability to pay attention, memory, keeping up with schoolwork and
missing school either because of feeling unwell or because of the need to visit a
medical professional. As previously discussed, some of these questions will score
similar answers when asked to all children, especially those relating to paying
attention and forgetting things. However, the children with STC again score
significantly lower on this section due to poorer school attendance and frequent
medical needs.
This study also showed that although children with STC and their parents both
describe a significantly poorer QoL than healthy children, the parents report a lower
QoL than their own children (Figures 15 and 16). There are several reasons why the
parents may report a poorer QoL. Parents have an objective ability to look at their
children compared to their peers and become distressed by any apparent differences.
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Since children with STC often have a family history of constipation, their parents
may have had similar experiences at school, thus affecting their scoring. As
previously mentioned, STC usually represents a lifelong condition. Children who
suffer with STC grow up with their condition and the lifestyle that it entails and have
no other experiences to which they can relate. Although they have the ability to
appreciate that their life may not be ideal, it is all that they have ever known and so
they make do with things as they are. Parents of children with STC often comment
that their child has only one friend and they do not actively socially interact with their
peers. Whilst a parent may be terribly concerned by this, their child may simply be
happy that at least they have a friend.
Interestingly it was not only in the study group that parents reported a poorer QoL
than their child, with the parents of the control subjects also suggesting that their
child had a worse QoL (Figure 15). Most QoL tools used in children are proxy
reported in the belief than parents are well positioned to accurately judge the thoughts
and feelings of their offspring. This study suggests that this is not the case, especially
when psychosocial functioning is concerned and highlights the need for the use of
self-assessment tools.
As previously mentioned, there are few studies that have sought to evaluate the
Of^S 0*7T 0*7*7
quality of life in children with chronic constipation and none in children with
STC. The only studies concerning subjects with STC have concentrated on the
265 273 277 oaa
effects of bowel resection in adults . Jiang et al 266 describe a retrospective
study comparing two different subtotal colectomy techniques, however they do not
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include any pre-operative measurements of QoL and do not provide any control
population. Similarly Riss et al 267 report solitary post-operative recordings of QoL in
an observational follow-up study of 20 patients who have undergone colectomy at
their institution. Reported post-procedure GLQI scores were diappointingly low,
however of particular concern was the fact that only 6 of the study group (30%)
fulfilled the Rome II criteria for constipation and 3 of their study group (15%) died in
the peri-operative period. The authors do not recommend colectomy as a treatment
for STC. Marchesi et al 268 also report GLQI scores post colectomy for adult subjects
with STC and compare them with mean scores for 'healthy people'. They conclude
that their technique does not appear to be 'inferior to others with regards to the
overall impact on QoU but again fail to comment on any impact that solely having
the condition STC might have on their subjects.
Asipu et al 265 looked at the effects of restorative proctocolectomy in children with
severe childhood constipation. They describe the outcome in 5 children (mean age 12
years) who underwent transanal mucosal proctectomy, total abdominal colectomy
(open (n=3) or laparoscopic (n=2)) and reconstruction with an ileal j-pouch-anal
anastamosis. Prior to this all subjects had failed conventional medical management
and had been left with an end stoma following unsuccessful attempted treatment with
ACE procedures. One subject had an additional rectal resection early in life and one
initially had their stoma unsuccessfully reversed prior to proceeding to restorative
proctocoloectomy. All 5 subjects had transit studies performed with the results only
available for 3 (138-146hrs). These figures suggest that these 3 subjects may have a
diagnosis of STC (Beninga et al 19 use >100hrs to define STC). However, it is not
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clear at what age or stage during their treatment the transit studies were performed
(some subjects had additional surgical procedures that may have affected transit time)
or more importantly the site of colonic delay (STC or FFR). All subjects were
verbally satisfied with their decision to undergo surgery yet still had a mean GIQL
score of 89 (55-127), with the quoted values in healthy volunteers being 126 (SD 13).
Unfortunately due to the small numbers no statistical conclusions can be drawn from
these figures and, as with the adult studies, no pre-operative data were recorded.
Faleiros et al 273 evaluated the health related QoL in children with functional
defecatory disorders categorised according to the Rome II classification criteria 290:
functional constipation, functional faecal retention and non-retentive functional
soiling. The QoL assessment questionnaire was a parent, proxy-reported generic
instrument designed to assess both physical and psychosocial wellbeing 244. The
authors believe that parents' opinions are 'relevant and important' and that they are
'able to estimate global wellbeing and behavioural changes'. The results were
compared to reference QoL scores for healthy controls.
The study found that parents of children with functional defecatory disorders reported
a poorer QoL when compared to parents of healthy controls concerning both physical
(p<0.001) and psychosocial (p<0.001) domains. When comparing the different
subgroups, there was no recorded difference in psychosocial QoL however children
with non-retentive functional soiling were reported as having significantly poorer
physical QoL than those with functional constipation. The authors concluded that
this was perhaps due to the higher incidence of soiling in this group (100% vs. 52%).
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The current study found that physical QoL was affected by STC with scores
significantly lower than controls in both child and parent-reported groups. A high
proportion of the children in the study (41/51 - 80%) experienced soiling. This data
would concur with the theorising of Faleiros et al that soiling adversely affects
physical QoL 273.
The current study, however, found that parents of children, both STC and controls,
reported significantly poorer quality of life than their child (figure 15 and 16). This
perhaps suggests that parents are not as well positioned, as the authors believe, in
estimating their child's QoL and that perhaps a more appropriate QoL tool could have
been utilised.
Youssef et al 277 used the PedsQL QoL tool to investigate the impact of chronic
constipation on QoL and also compared this result to scores they obtained from
healthy control subjects recruited from a community-based general paediatric office
(children who were attending 'for routine physical examination or receiving care for
minor acute medical problems'), children with a new diagnosis of inflammatory
bowel disease (IBD) and gastro-oesophageal reflux disease (GORD). They defined
chronic constipation as 'passing stools for >3 months and passage offewer than 3
stools per week'. They reported that children with chronic constipation described
significantly lower QoL than those with IBD (p<0.05), GORD (/?<0.05) and healthy
controls (p<0.05) (mean scores 70.4 (SD 12.2), 83.8 (SD 13.2), 79.0 (SD 14.0) and
87.7 (SD 14.7) respectively). They also found that parents of children with chronic
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constipation reported a significantly poorer QoL than their child (p<0.05, mean 60.0
(SD 18.4).
The study defines chronic constipation as difficulty passing stools for >3 months
(straining, grunting, stool 'getting stuck') and passage of fewer than 3 stools per week
citing Rasqin et al 290 (Rome II criteria) as their reference. The Rome II criteria
define constipation in terms of Functional constipation (infants and preschool
children), Functional faecal retention (infants to 16yrs, (i) passage of large diameter
stools at intervals <2 times per week and (ii) retentive posturing, avoiding defecation
by purposefully contracting the pelvic floor) and Functional non-retentive faecal
soiling. The study population (5-18yrs) described by Youssef et al do not comply
with the criteria in the reference either in terms of frequency of defecation or retentive
posturing. The study group define the population as having 'chronic' symptoms
presumably in keeping with the somewhat arbitrary definition of >3 months accepted
9Q1
by most investigators " . The QoL score was obtained at the initial gastrointestinal
referral assessment before instigation of treatment. This differs from the population
encountered in the current study who not only have proven delay in their colonic
transit (STC), fulfil the Rome III criteria for functional constipation but who also
have had refractory treatment resistant symptoms for a minimum of 2 years.
Whilst the current study also looks at the differences in reporting by parents in
healthy controls as well as children affected by STC, Youssef et al concentrate solely
on children with constipation. Their results suggest, as in the current study, that some
of the difference seen in the parent-reported scores may be independent of disease
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state (control child mean 87.7 (SD 14.7), control parent mean 80.7 (SD 15.1))
however there has been no formal statistical analysis.
One of the subgroups of children with constipation that the authors concentrate on are
those who experience soiling. Only 29% of their study population experienced any
problems with soiling - perhaps reflecting the differences in overall population in
comparison to the current study. They did not find any difference in overall QoL
when they compared children with constipation who soiled with those who did not.
They did not specifically look at physical QoL in this group.
The authors, however, do concur with the current study that constipation appears to
adversely affect both the physical and psychosocial functioning of children when
compared to healthy controls and that the parents of affected children report poorer
QoL scores in all domains.
There are several other studies that have used the PedsQL to assess HR-QoL in
different populations; overweight/obese children 292, children with differing severity
9Sf\ 9S6
of cardiac disease , children with an acute orthopaedic injury , children with
9/rrv
cerebral palsy, cancer or attention deficit hyperactivity disorder (ADHD) and
healthy children 256 259 260 292. These previous results are summarised in Table 13
along with the results for the current study (in bold).
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Table 15 - Previous results for PedsQL questionnaire in different study
populations.
Mean Child Reported Score Mean Parent Reported
Score




Healthy children 79.6 80.2 79.3 80.9 81.4 80.6
Healthy children 83.9 87.8 81.8 82.3 84.1 81.2
Healthy children 260 84.3 88.0 82.3 79.9 81.8 78.9
Healthy children * 86.0 92.1 833 843 92.8 79.7
Not overweight 80.5 85.7 77.7 83.1 87.8 77.6
Overweight 79.3 83.5 77.0 80.0 82.6 76.1
Obese 292 74.0 77.5 72.1 75.0 76.3 73.9
Orthopaedic (acute)
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78.1 75.3 79.5 73.7 72.7 74.3
Cardiac disease
class la 83.6 82.1 84.5 86.5 89.5 84.6
class lib 75.9 78.7 74.3 80.1 82.8 78.5
- class III, IV 60.9 58.2 62.3 67.9 66.7 69.0
ADHD 2bU 70.2 82.6 63.5 69.5 84.6 61.4
STC* 72.9 78.8 692 64.4 74.4 58.6
Cancer 260 69.0 65.8 70.8 60.7 56.8 63.1
Cerebral Palsy 260 66.3 64.8 67.0 56.3 53.3 57.9
In conclusion, this study shows that QOL is significantly lower in children with STC
compared to normal children with both physical and psychosocial functioning scores
reduced. Parental perception of QOL is worse when their child is affected by chronic
constipation, particularly when estimating their child's psychosocial QOL.
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6. Test-re-test reliability of nuclear transit studies to assess
colonic transit time in children with slow transit constipation
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6. Test-re-test reliability of nuclear transit studies to assess colonic
transit time in children with slow transit constipation
6.1 Introduction
Slow transit constipation (STC) is a condition characterised by global colonic delay
that has been recognised as a cause of constipation in children since the 1990's 19 280
981 98Q • •
. It is characterised by intractable constipation that is not readily responsive to
conventional treatment with patients often requiring surgical management involving
bowel resection or appendicostomy formation 121 123 126-128 279 294"296 Traditionally
gastrointestinal transit time (GITT) has been quantified by radio-opaque marker
studies. Following cessation of laxatives, subjects ingest capsules or food containing
radio-opaque markers at the same time on consecutive days. Abdominal radiographs
are taken at set intervals and the passage of the markers assessed 56-59.
Although marker studies are currently the most widely available tool for the
assessment of GITT, there is significant doubt concerning their reproducibility,
particularly in subjects with colonic inertia 57 61. More recently, another method has
been employed to investigate GITT, namely scintigraphy that is used to perform a
nuclear transit study (NTS). Subjects are required to ingest foodstuffs, a small drink
or capsules containing radiolabeled material (99m-Technetium or 67-Gallium
citrate), then, scintigraphic images are obtained at requisite time intervals - usually 6,
24, 30 and 48hrs post ingestion 62~70. The mean geometric centre (GC) of activity is
calculated at each time point 134 297. The GC is a number that represents the point
where 50% of activity lies on either side. GC analysis has been validated and is
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widely accepted as a means of assessing gastrointestinal transit . One of the clear
advantages of NTS is that they provide more detailed information on segmental
transit. This is especially important if partial colonic resection is being considered.
Although colonic NTS's have been shown to have a satisfactory inter-observer
reproducibility 298, little information exists concerning test-re-test reliability.
Diagnoses, and subsequent surgical management decisions, are most commonly
based on a solitary transit study. It is therefore essential that there be no doubt
concerning the reliability of the information obtained by this single investigation.
Ascertaining whether or not there is any appreciable difference in the results of
nuclear transit studies performed on the same subject over time would aid in
determining whether or not a solitary transit study is suffice.
There are no current studies that have sought to ascertain whether or not the results
of NTS are reliably repeatable, particularly in the context of delayed colonic transit.
Success of management for STC is usually determined subjectively by symptom
severity and individual patient satisfaction. Another way of assessing improvement
would be to repeat a subject's colonic transit study. If the initial diagnosis has been
made by scintigraphic evaluation then, in order to determine whether or not a
difference in transit time is significant, it must first be established whether or not
substantial test-re-test reliability exists.
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6.2 Hypothesis and aim
This study hypothesises that NTS are a reliable means of reassessing colonic transit
over time in children with STC. The aim of this study was to ascertain whether or
not there is a measurable statistical difference in overall or segmental transit time in
two studies performed at different time points in subjects where an initial NTS has
demonstrated global colonic delay.
6.3 Materials and Methods
Children with symptoms of chronic constipation for >2 years who had undergone 2
separate nuclear transit studies to assess their gastrointestinal transit (where the first
study in all cases had demonstrated slow colonic transit) were identified. In all
children, on-going aggressive medical treatment (diet, laxatives, behavioural therapy)
had failed to relieve their symptoms. These children were participating in a
randomised controlled trial at a tertiary paediatric centre to evaluate the application
of interferential electrical therapy (IFT) in the treatment of STC. The trial was
assessing the efficacy of IFT versus placebo therapy. Some children required a
repeat NTS prior to entry into the trial as they were required to have an up-to-date
study (within the previous 2 years) in order to be eligible to participate. Other
children had had 2 studies performed at their clinician's discretion. Subjects were
instructed to keep to their normal diet and to cease their laxative medication for 5
days prior to commencing the study. If they were also having their gastric emptying
assessed then they were instructed to fast for 4 hours on the day of the study.
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Studies performed at RCH used 99m-Technetium colloid prior to 2000, and 67-
Gallium citrate (5-20 MBq) after 2000, suspended in 20ml milk. The study
performed at MMC used 67-Gallium citrate suspended in milk. The dose of tracer
was determined according to each patient's weight and was based on an adult dose of
250 MBq. Anterior and posterior view images were obtained immediately after
ingestion and during the subsequent 2 hours to estimate gastric emptying. Following
this, patients were allowed to eat and drink as normal. Anterior view images were
then collected at 6 +/- 1 (SD), 24 +/- 2, 30 +/- 2 and 48 +/- 2 hours from the time of
ingestion.
The colon was divided into 6 separate regions of interest (ROI): 1 = Small bowel, 2 =
Ascending colon, 3 = Transverse colon, 4 = Descending colon, 5 = Recto-sigmoid
and 6 = Excreted. Each image was reviewed and the GC calculated. For each
image, the fraction of administered activity in each ROI is multiplied by the region
number (n) and then all are added to give the GC (a worked example is contained in
section 1.15.2):
l
GC = X fraction of activity in ROIn x n
n
The GC at each time point for the initial and repeat studies were compared by




In total, 7 children (4 male) had a NTS performed twice. The mean age at first study
was 7.0 yrs (range 5.4-10.8 yrs), the mean age at second study was 11.4 yrs (range
9.7-14.2 yrs). The mean time between studies was 4.4 yrs (range 1-8.5 yrs).
13 of the 14 studies were performed at a single institute (Royal Children's Hospital
(RCH), Melbourne) with the 14th study being performed at a sister hospital (Monash
Medical Centre (MMC), Melbourne). Studies performed at RCH used 99m-
Technetium colloid prior to 2000, and 67-Gallium citrate (5-20 MBq) after 2000.
The study performed at MMC used 99m-Technetium colloid. GC were calculated
for at 6, 24, 30 and 48hrs for the studies performed at RCH and 24 and 48hrs for the
study performed at MMC due to the available raw data.
Qualitative visual assessment was performed on each image at each time interval to
determine whether or not studies had similar overall appearances.
The mean GC and standard deviation (SD) at each time point for the first and second
studies are shown in Table 16.
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Table 16 - Mean geometric centres (GC) of activity for initial and repeat
nuclear transit studies calculated at 6, 24, 30 and 48hrs post ingestion
of radiolabelled material.
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For every child, the GC at each time point for both studies were compared by
parametric statistical analysis using paired t-tests. There was no statistical difference
in GC at 6hrs (mean + SD, 1.78 + 0.26 vs. 1.54 + 0.43; p = 0.161), 24hrs (mean +
SD, 2.30 + 0.41 vs. 2.23 + 0.36; p = 0.780), 30hrs (mean + SD, 2.88 + 0.94 vs. 2.85
+ 0.56; p = 0.947) and 48hrs (mean + SD, 3.20 + 0.98 vs. 3.39 + 0.57; p = 0.615)
(Figure 17).
6.5 Discussion
This is the first study that has assessed the test-re-test reliability of nuclear
scintigraphy in children with slow transit constipation. It has demonstrated that in a
state of colonic inertia, NTS are reliably repeatable and can be relied on both as a
diagnostic tool and perhaps subsequently as a means of assessing response to
treatment. It is important to differentiate sufferers of STC from functional faecal
retention (FFR) since it is now believed that the former represents an organic rather
than a behavioural condition 19 20 280 299. Consequently, treating children diagnosed
with STC with behavioural modification and toileting regimes is for the most part
ineffective and quite demoralising for the patient and family. Conversely, the
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management of children with STC can require surgical intervention in the form of
appendicostomy formation or even colonic resection.
Several studies have assessed the reproducibility of colonic NTS either alone or as
part of other studies; however, those that have used nuclear scintigraphy have tended
to concentrate on healthy individuals with much discrepancy in the time interval
between repeat investigations.
Kamm et al 154 described a technique involving colonic intubation and subsequent
instillation of both 99m-Technetium (in order to monitor colonic transit) and
bisacodyl (to initiate colonic motor activity) in 1988. They evaluated this method on
6 healthy adults with one subject having 2 studies performed 2 days apart. They
found that the second study gave similar results to the first.
McLean et al 142 assessed an oral colonic scintigraphic method in healthy adults
using Ill-Indium. Out of 41 subjects, 19 (10 female) underwent a repeat
investigation, with a mean time between studies of 6 months (range 2-18 months).
They assessed colonic motility in terms of total percent retention of the isotope
(T%R) (expressed as a percentage of the activity in the colon at 6 hrs) and 'mean
activity position' (MAP) (calculated as the GC of activity - where position 0 was at
the caecum and position 99 was excreted activity) at 24, 48, 72 and 96 hrs. For
T%R, the mean difference between the 2 studies at 24 and 48 hrs was less than 20%
with this difference decreasing further with time. The mean difference in MAP was
less than 15 at 24 hrs and decreased rapidly with time. The authors concluded that
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their method demonstrated adequate reproducibility that was similar to that
demonstrated for other nuclear medicine tests of gastrointestinal function.
Cremonini et al 138 also assessed the reproducibility of an oral colonic scintigraphic
method in healthy adults using both Ill-Indium and 99m-Technetium. Out of 37
subjects, 21 underwent a second study 3 weeks after the first. Gastric emptying,
small bowel transit (colonic filling at 6 hrs) and colonic transit (GC calculation) were
evaluated with images taken at 1, 2, 4, 24 and 48 hrs. Gastric emptying at 4 hrs
showed the best reproducibility with only 14% of participants showing differences of
more than 10% on repeat measurements (cf. ±10% difference for 70% of the data at
1 and 2 hrs). Variance in the percentage of colonic filling at 6 hrs was >10% in 45%
of subjects. Colonic measurements varied by more than 1 GC unit in 37% of the
subjects at 24 hrs and 26% of the subjects at 48 hrs. The authors acknowledged that
with this method, gastric emptying showed greater reproducibility than both small
bowel and colonic transit. However, they felt that compared to other studies looking
at variability of gut transit in healthy individuals, the difference for some of the end
points considered in their study was lower. Due to the natural variation in colonic
transit even among healthy individuals, they also highlighted the need for further
validation in relevant disease states.
Stubbs et al 137 investigated a method using non-digestible capsules containing 111-
Indium to assess gastrointestinal transit in 10 healthy adults. Each subject had the
study performed twice. The authors found that although the capsules could not be
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considered as being chymous in nature, the colonic transit was highly reproducible in
each subject and for the group as a whole.
orir>
Another study by Degen et al looked at the variability in colonic transit in healthy
adults but used both scintigraphy and marker studies in tandem. 32 subjects (12
female) had their gastrointestinal transit assessed on 2 occasions. Female subjects
had the studies performed at identical phases in their menstrual cycle, and men had
the studies performed 4 weeks apart. A study protocol using both Ill-Indium and
99m-Technetium was used. Images were taken at 6, 24 and 48 hours and the GC of
activity calculated. Radio-opaque markers were ingested for 3 days with a single
abdominal radiograph taken on day 4. Repeated measurements of colonic transit
showed mean results that were very reproducible with median differences of the GCs
at 6 and 24 hrs very close to zero with narrow associated inter-quartile ranges.
However, outliers were noted and the total ranges of inter-individual differences
were wide with considerable variability in a few persons. The authors felt that as
these differences were seen using both the scintigraphic and radio-opaque marker
methods, they must reflect physiological changes in gut function rather than
methodological artefacts.
Although a few studies have assessed the reproducibility of gastrointestinal transit
studies in subjects with constipation 61 301 and irritable bowel syndrome 57 they have
all used methods employing radio-opaque markers rather than nuclear scintigraphy.
Instead, more studies have concentrated on looking at the reproducibility of studies
comparing differing scintigraphic and radio-opaque marker methods 141 147 302.
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The gold standard for assessing GITT is with radio-opaque marker studies. These
can take the form of either a single 56 57 152 303 or multiple film study 58 131 152 with
ingestion of either single or multiple markers. Although all methods have been
57
shown to produce comparable results when total colonic transit time is evaluated
they each have their own limitations. Single film, single marker studies are unable to
assess segmental transit, which is essential when evaluating colonic transit prior to
potential colonic resection. Multiple film, single marker studies, provide important
information regarding segmental transit time, but involve the subject being exposed
to much larger doses of radiation. A technique has been described where multiple
different markers are ingested for sequential days until a 'steady state' is achieved,
then a solitary film acquired 56 57 149 152 303. In the majority of studies this has been
reported as a reliable technique for assessing segmental transit time in healthy non-
constipated and constipated subjects in both adult 56 152 303 and child 149 populations.
However, in one study analysing this method, although the authors report good
evaluation of segmental and colonic transit time in control subjects, patients with
hindgut dysfunction and patients with outlet obstruction, they estimate that in
patients with colonic inertia subjects would have to ingest markers for 27
consecutive days in order to achieve a 'steady state' and be able adequately assess
transit 57. The authors also highlight that single film studies are unable to assess
retrograde movement of markers which again can be an important physiological
finding.
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NTS have the advantage over radio-opaque marker studies that they allow accurate
assessment of regional colonic transit with multiple images of the colon being easily
obtained with a relatively low radiation dose 147. In addition, in contrast to marker
studies, overlapping regions of the gastrointestinal tract do not pose a problem when
viewing sequential radio-isotope images. Some studies have suggested that there
may be a difference between the passage of radioisotope and radio-opaque markers
with the former possessing the ability to more accurately reflect the passage of
physiological chyme. Stivland et al 304 found that markers were consistently faster in
their transit through the right colon than radio-isotope. It has also been proposed that
indigestible solid particles do not move with a meal, and may not be handled by the
colon in the same manner as stool 61.
This study is hampered both by the small number of subjects (7 children) and the
wide variation in timing between repeat investigations (1-8.5 yrs). Although unlike
repeated x-ray studies NTS involve a low dose of radiation, there is a significant
amount of patient time and cooperation involved and so there are few subjects in
whom two studies have been performed. It could be argued that the fact that there
appears to be good correlation between repeated results in spite of the wide variation
in time between the two studies in fact strengthens the current findings. There will
also discrepancy in the treatment received by each subject in the intervening time
period between studies. It is interesting however, than laxative therapy does not
appear to affect colonic transit time - certainly in these subjects who had experienced
no subjective improvement in their symptoms. Metcalf et al 56, in shorter term
studies assessing colonic total and segmental transit time in healthy adults using a
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multiple marker single film technique, did not find that a small dose of supplemental
fibre altered colonic transit time.
It must also be recognised that there are presently few centres that either have the
ability to or choose to perform NTS and that radio-opaque marker studies remain the
current gold standard for the assessment of colonic transit time.
In conclusion, the current study shows that NTS are a reliable means of reassessing
global colonic transit and segmental colonic transit in children with slow transit
constipation when repeated after a discernable time period.
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7. Evaluation of transcutaneous electrical stimulation in the
treatment of children with slow transit constipation 305 306
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7. Evaluation of transcutaneous electrical stimulation in the treatment
of children with slow transit constipation
7.1 Introduction
Transcutaneous inferential therapy (IFT) is a non-invasive, painless means of
delivering medium-frequency current electrical stimulation. To date its use has been
limited to pain relief 180 and the treatment of urinary incontinence secondary to
detrusor instability 307 308. A pilot study by Chase et al 170 sought to ascertain the
potential benefit of IFT in children with slow transit constipation. The authors noted
that a reported side effect in a previous study was that of diarrhoea 309 and
hypothesised that the diarrhoea might have occurred as a result of increased colonic
motility. This observation lead them to theorise that the application of IFT in
children with STC may either also result in diarrhoea and soiling or might potentially
be able to overcome the slow colonic transit and remove the faecal impaction and its
resultant bypass soiling. The subjects in the study (n=8) were recruited on the basis
of either a nuclear transit study (that showed delayed colonic transit) or seromuscular
biopsies (that showed a reduction in substance P - an excitatory neurotransmitter -
levels). All subjects had experienced symptoms of constipation for a minimum of
four years and had had exhaustive medical therapy (behavioural modification,
laxatives). Three children had required formation of an appendicostomy via which
they were receiving regular antegrade colonic enemas in order to attempt to achieve
continence 17°. Subjects received treatment for twenty to thirty minutes, three times a
week for nine to twelve sessions. The reported outcome measures were frequency of
spontaneous defecation (a stool occurring in response to an urge to defecate), number
of bowel washouts, medication usage and number of incidents of soiling (an
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involuntary loss of faecal material into clothing). The authors reported increased
frequency of defecation in six out of eight subjects and reduced soiling in seven out
of the eight subjects. The improvements in defecation frequency were maintained
for one month in five of the six subjects and up to 3 months in three subjects. In
terms of reduced soiling, the effects were maintained up to three months in the same
three subjects who experienced an increase in their defecation frequency. The
authors concluded that although a placebo response was possible, due to the size and
duration of response, the improvement in symptoms was most likely due to the
application of IFT.
7.2 Hypothesis and aims
This study hypothesises that transcutaneous electrical stimulation (in the form of
interferential therapy (IFT)) can increase bowel motility, and improve symptoms, in
children with STC. The study aims to determine whether or not transcutaneous IFT
can affect the symptoms of STC in children (frequency of defecation, soiling, and
abdominal pain) and their colonic transit time (as measured by nuclear scintigraphy).
It also seeks to measure the quality of life (QoL) of study participants before and
after treatment with IFT.
7.3 Materials and Methods
7.3.1 Study design
The study is a prospective, single blind, randomised (1:1) controlled partial crossover
trial with 7 intervals: (i) 4 weeks baseline, (ii) 4 weeks of real or placebo stimulation,
(iii) 1st 4 weeks post-treatment, (iv) 2nd 4 weeks post-treatment (v) 4 weeks of real
136
stimulation, (vi) 1st 4 weeks post-treatment and (vii) 2nd 4 weeks post treatment.
Further assessments were carried out at 6 and 12 month post-completion of the trial.
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Figure 19 - Timeline showing overview of reported study.
This study reports the interim findings of the trial after a single treatment period the
timeline of which is detailed in Figure 19. For the remainder of the chapter it is this
timeline that should be referred to.
7.3.2 Participants
7.3.2.1 Inclusion criteria
• Children (aged 8-18 years) >2 year history of chronic constipation (consistent
with Rome II criteria), +/- soiling, +/- appendix stoma (utilised for antegrade
continence enemas).
• Blood tests to exclude hormonal, allergic and metabolic causes for their









• Proven slow transit constipation on a recent (within the last 2 years) nuclear
gastrointestinal transit study (scintigraphy).
7.3.2.2 Exclusion criteria
• Children with a normal colonic transit time or functional faecal retention
(FFR) demonstrated on scintigraphy.
• Children with any metabolic or hormonal cause underlying their constipation.
• Children with HD or previous anorectal malformation.
• Children who have undergone any surgical procedure (other than the
formation of an appendix stoma) that has resulted in discontinuity of their
gastrointestinal tract.
• Children who have any contraindication to receiving transcutaneous electrical
therapy (skin sensitivity, pacemaker in situ).
• Children who are unable to respond to the questionnaires due to intellectual
disability or short attention spans.
• Previous transcutaneous electrical therapy for treatment of constipation.
7.3.2.3 Recruitment
Participants were primarily recruited from out-patient surgical and medical clinics at
The Royal Children's Hospital (RCH), Melbourne. All health professionals
(consultant gastroenterologists, consultant surgeons and paediatricians with an
interest in continence) treating children with STC were made aware of the trial and
were provided with recruitment fliers (Appendix 10). An advertisement (identical to
the flyer) was also placed on the Paediatric Continence Association of Australia
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(PCAA) website. If interested in participating in the trial, patients or their parents
were encouraged to contact the trial coordinators and arrange an initial assessment.
There was no unprecedented contacting of potential recruits by the trial coordinators.
7.3.3 Interventions
10 interferential machines (Vectorsurge 5 VS470, Metron Medical, Carrum Downs,
Victoria, Australia) were purchased. 5 were returned to the manufacturer for
modification. The machines were adapted so that although the dials read as though
current was being delivered (i.e. lights came on and figures appeared in the digital
panels) no actual stimulation was received by the patient. These machines were
marked 'B' in a discrete place on their underside. The remaining 5 machines were
marked 'A'.
The strategies employed to ensure effective blinding of both the trial coordinators
and participants are discussed later.
7.3.3.1 Physiotherapist recruitment and instruction
Physiotherapists (n=26) located in the vicinity of each participant were recruited by
the trial physiotherapist ( Ms Janet Chase). Either the participant themselves, or the
trial physiotherapist, identified potential practices which were then contacted and
informed about the trial. If the physiotherapist was willing to participate in the trial
then they were sent an information pack (Appendix 13). Each enrolled
physiotherapist was visited by the trial physiotherapist prior to commencing any
treatments. They were provided with 2 interferential machines (and appropriate
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electrodes) and instructed on how to deliver therapy consistent with the trial protocol.
At the end of each treatment period, the physiotherapist sent the invoice for the
treatments to JC for appropriate reimbursement ($35 AU per treatment).
7.3.3.2 Stimulation regime/parameters
12 (20 minute) treatment sessions were performed over a 28 day period. In order for
their data to be included in the final analysis, participants had to receive a minimum
of 10 treatments in a 28 day period. They must have had no more than 4 treatments
in any 7 day period (This is also detailed in appendix 13)
Machines were set to deliver 4 electrode interferential current with a carrier
frequency of 4kHz and a beat frequency range of 80-150Hz at an intensity of <40
mA for a duration of 20 minutes. The vector rotation and surge options were
switched off. Current was delivered via 4 self-adhesive conducting electrodes
(40mm x 40mm, Verity Medical Ltd., Hampshire, England). 2 electrodes were
placed paraspinally (T9-T12) with the paired electrode positioned diagonally
opposite on the anterior abdominal wall below the costal margin.
7.3.4 Outcome measures
7.3.4.1 Primary outcome measure
Episodes of 'spontaneous' defecation (i.e. the stool was passed with an associated
positive need to defecate).
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7.3.4.2 Secondary outcome measures
Episodes of 'sit' defecation (i.e. the stool was passed whilst the child was
participating in a timed sit on the toilet - often in association with a toilet training
program).
Total episodes of defecation (i.e. both 'spontaneous' and 'sit' defecation episodes).
Episodes of'stain' soiling (i.e. just a mark on the underpants).
Episodes of 'scrape' soiling (i.e. faecal matter had to be removed from the
underpants before they could be washed).
Episodes of abdominal pain.
Quality of life (assessed by the PedsQL, Holschneider and Templeton QoL
assessment tools).
Colonic transit time (assessed by nuclear transit study).
7.3.4.3 Measurements
7.3.4.3.1 Baseline data collection
Having expressed an interest in participating in the trial, and having contacted the
trial coordinators, potential recruits were invited to attend an initial assessment. This
took place at the Royal Children's Hospital and was conducted by our Paediatrician
(Dr Susie Gibb [SG]), Physiotherapist (Ms Janet Chase [JC]) and Associate
investigator (Miss Melanie Clarke [MC]).
The trial was explained to the family and they were provided with written and verbal
information outlining the study (Patient and Parent Information Statements -
Appendix 14 and 15). Eligibility to enrol in the trial was assessed (see
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inclusion/exclusion criteria) and scintigraphic, blood and pathological results were
reviewed. If the child was considered appropriate to enrol, and both child and family
were willing, then they were asked to complete a consent form (included in the
parent and participant information statements). Children over 12 years of age were
given their own consent forms with competence to give consent being determined on
an individual basis by the assessing team, all of whom were experienced
practitioners. Consent forms were signed by the participant or their parent (mother
or father) and witnessed by a trial coordinator (SG or MC). If a family were keen to
enlist but required an additional investigation (i.e. missing blood test) then they were
still enrolled in the trial and the investigation was performed during the baseline
period before their child received their first treatment. Once they were enrolled in
the trial, each participant was allocated a unique identifying trial number.
SG or MC, using a questionnaire developed as the Medical Assessment Data Sheet
(Appendix 16), assessed each child's bowel function and performed a clinical
examination. The examination consisted of height, weight, blood pressure (BP) and
pulse rate (PR) measurements (the latter 2 were performed with the child both supine
and erect due to a possible correlation between SCT and autonomic dysfunction)
along with an abdominal examination, lower limb neurological examination and anal
inspection (See Medical Assessment Data Sheet (Appendix 16) for further details).
At the same visit JC assessed the child's muscular defecatory control by asking the
child to demonstrate how they sat on the toilet and strained to empty 6. If any
correctable issues were highlighted (i.e. abnormal posturing, incorrect muscle
contraction/relaxation, incorrect feet placement) then they were addressed
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accordingly. In addition JC assessed rectal perception by asking the child to
complete a visual analogue scale (Appendix 17). The visual analogue scale (VAS)
consisted of a horizontal line, 100 mm in length, anchored by word descriptors (in
this case describing rectal perception) at each end. The child placed a mark on the
line at the point that they felt represented their perception of their current state. The
VAS score was then determined by measuring in millimetres from the left hand end
of the line to the point that the patient marked (score 0-100).
7.3.4.3.2 Bowel diary
Each child was provided with a Bowel Diary (Appendix 18). This was a daily record
of bowel function, symptomatology and medication usage. Each participant, or their
parent, was required to complete their bowel diary, every day, for the entire duration
of the trial. Participants, and their family, were instructed at this initial consultation
about how to fill in their diary and the importance of doing so. They documented the
passage of any stool and whether or not it was passed 'spontaneously' (i.e. with an
associated positive need to defecate) or was a 'sit' (i.e. the stool was passed whilst
the child was sitting on the toilet often in association with a sitting toilet training
program). The stool type, according to the Bristol Stool Scale (Appendix 19), was
also recorded. In addition, any involuntary passage of stool, or 'soiling', was noted.
Participants were asked to detail any episode of soiling and whether or not was a
'stain' (just a mark on the underpants) or a 'scrape' (faecal matter had to be removed
from the underpants before they could be washed). In addition, any medicines or
therapies received each day were recorded (both name and dosage). Finally,
participants were asked to document whether or not they had any IFT treatment, or
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'physio', and whether or not they experienced any abdominal discomfort or 'tummy
pain'. There was an extra column where any additional information could be written
(intercurrent illness, travel away from home etc...). The diary pages were colour
coordinated dependent upon treatment period (blue for pre-treatment, red for the
First Treatment Period, yellow for the following 8 weeks, purple for the Second
Treatment Period and green for the final 8 weeks) and were provided to each
participant in a waterproof folder. This folder also contained contact details for the
trial coordinators.
The child was asked to create themselves a 'code name'. This was used on all of
their documentation, along with their trial number, in order to maintain complete
anonymity.
7.3.4.3.3 Quality of life
Quality of life was assessed by obtaining Holschneider (clinical evaluation of faecal
incontinence) and Templeton (quantitative assessment of QOL) scores, and by
completion of Pediatric Quality of Life Inventory 4.0 Generic Core Scale QOL
questionnaires (PedsQL - Appendix 9, Holschneider and Templeton - Appendix 20).
The PedsQL questionnaires consist of parallel child and parent self-report scales, and
have been validated in children and adolescents aged 2-18. This study utilised the
child (8-12yrs) and the teen (13-18yrs) questionnaires. Each questionnaire consists
of 23 items encompassing (i) Physical functioning (8 items) (ii) Emotional
functioning (5 items) (iii) Social functioning (5 items) and (iv) School functioning (5
items). The categories can then be grouped into Physical (i) and Psychosocial (ii, iii
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& iv) functioning. The questions ask how much of a problem each item has been
during the past 1 month. A 5-point response scale is utilised (0 = never a problem; 1
= almost never a problem; 2 = sometimes a problem; 3 = often a problem; 4 = almost
always a problem). Items are reverse scored (0 =100, 1 = 75, 2 = 50, 3 = 25, 4 = 0)
and linearly transformed to a 0-100 scale (by adding all the scores together and
dividing by the number of questions). Higher scores indicate better quality of life.
Parent and child completed the questionnaires independently with impartial
assistance being provided by the trial coordinators for any child who had difficulty
with comprehension.
Quality of life was assessed prior to entering into the trial and subsequently after
completion of each treatment period.
7.3.4.3.4 Colonic transit time
Colonic transit time was measured using nuclear transit studies (see chapter 2 and
chapter 6). Subjects were instructed to keep to their normal diet and to cease their
laxative medication for 5 days prior to commencing the study. If they were also
having their gastric emptying assessed then they were instructed to fast for 4 hours
on the day of the study.
Studies performed prior to 2000 used 99m-Technetium colloid, and those after 2000
67-Gallium citrate (5-20 MBq), suspended in 20ml milk. The dose of tracer was
determined according to each patient's weight and was based on an adult dose of 250
MBq. Anterior and posterior view images were obtained immediately after ingestion
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and during the subsequent 2 hours to estimate gastric emptying. Following this,
patients were allowed to eat and drink as normal. Anterior view images were then
collected at 6 +/- 1 (SD), 24 +/- 2, 30 +/- 2 and 48 +/- 2 hours from the time of
ingestion.
The colon was divided into 6 separate regions of interest (ROI): 1 = Small bowel, 2 =
Ascending colon, 3 = Transverse colon, 4 = Descending colon, 5 = Recto-sigmoid
and 6 = Excreted. Each image was reviewed and the GC calculated. For each
image, the fraction of administered activity in each ROI is multiplied by the region
number (n) and then all are added to give the GC (a worked example is contained in
section 1.15.2):
l
GC = X fraction of activity in ROIn x n
n
Colonic transit was assessed prior to entry into the trial after subjects were invited to
attend for reassessment following completion of each treatment period.
7.3.5 Sample size
7.3.5.1 Sample size estimation
Sample size was calculated using the outcome measure that changed the least in the
pilot study 170 - defecation. During the study, 5/8 (63%) children increased
defecation frequency from <3 into the normal range. It was expected that the
placebo effect would be between 30-40%.
(i) Comparing proportions - change in full treatment vs. placebo
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Given that the placebo effect is normally ~30%, and in the pilot study the treatment
produced a change in 30% more children than the placebo, one can reasonably
expected a greater than 10% change.
Using data from the pilot study where 5/8 (63%) children showed increased
defecation: p = 0.63, n = 8
Where SE2 = p(l-p)/n (SE = standard error)
= 0.63 (1-0.63)/8
= 0.029
and SD2 = SE2 x n
= 0.00084 x 8
= 0.0067
SD = 0.082
In order to see a change of >10% (5 = 0.1) with a statistical significance ofp< 0.5:
n = 16 (SD2 / 82) (S =difference)
= 16(0.0067/0.01)
= 10.72
sample size = 2n = 22
22 patients are required to conclude a statistical difference (p<0.05) if the
treatment produced changes in 10% more patients than the placebo.
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7.3.5.2 Interim analysis
To ensure that excess participants are not studied, once >75% of participants have
been recruited and completed their treatment it is the intent of the investigators to
perform interim analysis in order to determine whether or not it is ethically
appropriate to continue recruiting subjects into the trial.
7.3.6 Randomisation
Participants were randomised to either receive treatment A (real stimulation) or
treatment B (placebo stimulation) for their First Treatment Period. Randomisation
was in blocks of 6 according to age (8-12 and 13-18) in order to ensure even
distribution of the 2 groups. Randomisation was performed by independent
investigators (CP & AH). 6 cards, 3 labelled A and 3 labelled B, were shuffled and
then the order recorded (i.e. 1=A, 2=A, 3=B, 4=B, 5=A, 6=B). This was repeated for
each block of 6 until 60 numbers had letters assigned. Letters addressed to the
treating physiotherapist stating to which treatment arm the participant had been
randomised (Appendix 11) were placed in sealed, numbered envelopes. The
envelopes were numbered sequentially from 1 to 60 with the contents of each
envelope (treatment A or B) corresponding to the previously generated
randomisation sequence. The list recording the number and contents of each
envelope was not be seen by the trial coordinators and was stored in a separate
locked office.
On entry into the trial each participant was given a trial number by the trial
coordinators. The child's name and trial number were written on the outside of the
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next envelope, and the envelope sent to the appropriate treating physiotherapist.
Both the unique identifying trial number and envelope number were recorded in
duplicate.
7.3.7 Blinding
The participants were informed that they would be receiving one of 2 levels of
treatment. They were not told in which order they were to receive the treatment and
so were blinded to their treatment. The trial coordinators were also blinded as to the
treatment received by each participant. Only the treating physiotherapist was aware
whether or not the child was receiving real or placebo treatment due to the legalities
of applying a machine with/without live electric current to a patient. The
physiotherapist was asked not to divulge the treatment information to any of the trial
coordinators or the participants. In addition each physiotherapist recorded which
machine (A or B) they used for each session on each participant and returned the
recording sheets to an independent person (SD'C) for locked storage following the
completion of each treatment period (Appendix 12).
Interferential stimulation is performed utilising cutaneous electrodes. Whilst the
current is being delivered, a tingling sensation is felt in the skin underlying the
electrode. In order to attempt to effectively blind the participants, physiotherapists
delivering the treatment used a set dialogue independent of whether machine A (real)
or machine B (placebo) was used. Participants were informed that as the machine
was turned up they may or may not feel something and to let the treating
physiotherapist know if they did. As all of the participants had never had any
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electrical stimulation prior to entering into the trial, it was our hope that they would
not have any preconceived idea about what they should be feeling. Physiotherapists
were instructed to avoid discussing with the participant and their family how the
treatment was affecting their symptoms.
7.3.8 Statistical analysis
7.3.8.1 Bowel symptom diary data
Data were separated into four 4 week (28 day) periods - (i) 4 weeks baseline, (ii) 4
weeks of real or placebo stimulation, (iii) 1st 4 weeks post-treatment, (iv) 2nd 4 weeks
post-treatment. Events of defecation (spontaneous, sit and total), soiling (stain,
scrape and total) and abdominal pain occurring per 4 week (28 day) period were
divided by 4 to give number of events per week (7 days). These resultant figures
were utilised for data analysis. Events/week occurring in the different data periods
were compared between the two groups (real and placebo) and in a linear manner
within each group for the study period. All data were tested for normality.
Independent sample and paired t tests (two-tailed) were performed using Graphpad
Prism Version 3.02. All p values < 0.05 were considered as statistically significant.
7.3.8.1.2 Missing data
In some cases data periods were incomplete due to a variety of reasons (lost diary
pages, forgetting to complete diary, starting treatment period too early, dropping out
of trial). In these cases, the number of known events in the treatment period were
divided by the number of days of available data and then multiplied by 28 to give the
expected number of events. This figure was then divided by 4 to provide the
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expected number of events per week and this final figure was entered into the
analysis. Where there was no available data for a treatment period, no data analysis
could be performed.
7.3.8.2 Quality of life questionnaires
7.3.8.2.1 Peds QL scores
Parent-reported and child-reported physical, psychosocial and total quality of life
scores pre- and post-intervention were compared between the two treatment groups
before and after intervention and for each treatment group in a linear manner. All
data were tested for normality. Independent sample and paired t tests (two-tailed)
were performed using Graphpad Prism Version 3.02. All p values < 0.05 were
considered as statistically significant.
7.3.8.2.2 Holschneider Templeton scores
Holschneider 310 incontinence and Templeton 271 quality of life scores were
calculated for each participant pre- and post-intervention. Again, scores were
compared between the two treatment groups before and after intervention and for
each treatment group in a linear manner. All data were tested for normality.
Independent sample and paired t tests (two-tailed) were performed using Graphpad
Prism Version 3.02. Where the data were not normally distributed either Mann
Whitney or Wilcoxon matched pairs testing was performed. All p values < 0.05
were considered as statistically significant.
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7.3.8.3 Nuclear transit studies
Geometric centres (GC) of activity were calculated at 6, 24 and 48 hours for each
study. Post intervention GC were compared between the placebo and real treatment
groups. Pre- and post-intervention studies were also compared for each treatment
group. All data were tested for normality. Independent sample and paired t tests (2-
tailed) were performed using Graphpad Prism Version 3.02. All p values < 0.05
were considered as statistically significant.
7.4 Results
Between February 2006 and February 2008, 47 participants were recruited and
randomised (see CONSORT 2010 Flow Diagram). Six potential participants
volunteered to have colonic manometry performed and so were unable to be
recruited (see Chapter 7). Another family declined to participate. 24 participants
t were randomised to receive real stimulation and 23 to receive placebo stimulation.
Of these 47 subjects, 35 had usable bowel diary data for analysis. Of the remaining
12, 3 were found to ineligible (1 due to undisclosed previous surgery, 1 did not have
slow colonic transit on further review of their nuclear transit study, 1 had an
underlying undiagnosed condition), 2 dropped out (1 due to pre-existing
psychological problems that required in-patient treatment in a psychiatric unit, 1 due
< to family issues resulting in a move away from the treating physiotherapist), 1
participant lost their bowel diary and 6 participants had incomplete data sets.
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2010 Flow Diagram
Figure 20 - CONSORT 2010 Flow Diagram.
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Eight of the 35 data sets that were used for the interim results had 1 -2 days missing
from the 2nd post-First Treatment Period data. As previously stated, in these cases,
the number of known events in the treatment period were divided by the number of
days of available data and then multiplied by 28 to give the expected number of
events. This figure was then divided by 4 to provide the expected number of events
per week and this figure was entered into the analysis.
Table 17 - Demographics of study population.
Placebo Real
Number of children 18 17
Male:Female 1:1 1.8:1
Average age (yrs) 11.6 12.0
Male/Female (yrs) 11.1/12.0 12.1/11.8
Age range (yrs) 7.8-16.5 7.4-17.7
Average duration of symptoms (yrs) 8.6 10.5
Range of duration of symptoms (yrs) 2.7-14.4 4.4-13.9
Symptoms since birth 4/18 6/17
Abdominal pain 13/18 13/17
Average score /10 5.5 4.3
Soiling 16/18 13/17
Severe (daily/constant) soiling 12/16 10/13
Appendicostomy 2/18 3/17
Weight
Underweight (BMI <5th centile) 0/18 1/17
Healthy (BMI 5-85th centile) 14/18 12/17
Overweight (BMI 85-95th centile) 4/18 2/17
Obese (BMI >95th centile) 0/18 2/17
Medication 16/18 12/17
Thirty-five children (20 male), mean age 11.8 years (range 7.4-17.7 years) with STC
were analysed. Seventeen children received real IFT. There were no statistical
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differences between the 2 groups concerning sex, age, onset/duration of symptoms,
soiling and abdominal pain (Table 17).
7.4.1 Primary outcome measure
7.4.1.1 Frequency of 'spontaneous' defecation
The mean number of 'spontaneous' defecation episodes per week for each 28 day
treatment period for both the real and placebo groups are shown in Table 18. All
data sets demonstrated normal Gaussian distribution.
Table 18 - Table showing episodes of 'spontaneous' defecation (mean +
SD) for both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 3.00 3.14
Treatment (4 weeks) 3.67 4.01
1st post treatment (4 weeks) 3.54 3.96
2nd post treatment (4 weeks) 2.97 3.12
PLACEBO (n=18)
Pre-treatment (4 weeks) 2.67 2.41
Treatment (4 weeks) 3.35 2.52
1st post treatment (4 weeks) 3.43 2.74
2nd post treatment (4 weeks) 3.51 2.95
When comparing the real and placebo treatment groups, there was no difference in
number of 'spontaneous' defecation episodes in the pre-treatment period (mean 3.00
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vs. 2.67; p = 0.73). Following intervention, there remained no significant difference
in the number of 'spontaneous' defecation episodes between the 2 groups during the
treatment period (mean 3.67 vs. 3.35; p = 0.77) and during both the first post-
treatment period (mean 3.54 vs. 3.43; p = 0.92) and second post-treatment periods
(mean 2.97 vs. 3.51; p = 0.60).
Linear analysis was also performed for both treatment groups. In the real treatment
group, there was no significant difference in episodes of 'spontaneous' defecation
when comparing the pre-treatment period with treatment (mean 3.00 vs. 3.67; p =
0.29), first post-treatment (mean 3.00 vs. 3.54; p = 0.33) and second post-treatment
(mean 3.00 vs. 2.97; p = 0.96) periods. In the placebo group there was no difference
in episodes of 'spontaneous' defecation when comparing the pre-treatment and
treatment (mean 2.67 vs. 3.35; p = 0.14) or first post-treatment (mean 2.67 vs. 3.43; p
= 0.13) periods. There was, however, a significant difference when comparing the
pre-treatment and second post-treatment periods (mean 2.67 vs. 3.51; p = 0.03).
7.4.2 Secondary outcome measures
7.4.2.1 Frequency of 'sit' defecation
The mean number of 'sit' defecation episodes per week for each 28 day treatment
period for both the real and placebo groups are shown in table 19. All data sets
demonstrated normal Gaussian distribution.
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Table 19 - Table showing episodes of 'sit' defecation (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 3.26 4.24
Treatment (4 weeks) 2.90 4.10
1st post treatment (4 weeks) 2.54 3.89
2nd post treatment (4 weeks) 2.80 3.95
PLACEBO (n=18)
Pre-treatment (4 weeks) 2.83 3.31
Treatment (4 weeks) 2.74 3.79
1st post treatment (4 weeks) 2.40 3.60
2nd post treatment (4 weeks) 2.11 2.64
When comparing the real and placebo treatment groups, there was no difference in
number of 'sit' defecation episodes in the pre-treatment period (mean 3.26 vs. 2.83; p
= 0.74). Following intervention, there remained no significant difference in the
number of 'sit' defecation episodes between the 2 groups during the treatment period
(mean 2.90 vs. 2.74; p - 0.90) and during both the first post-treatment period (mean
2.54 vs. 2.40; p = 0.91) and second post-treatment periods (mean 2.80 vs. 2.11; p =
0.54).
As with the primary outcome measure, linear analysis was also performed for both
treatment groups. In the real treatment group, there was no significant difference in
episodes of 'sit' defecation when comparing the pre-treatment period with the
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treatment (mean 3.26 vs. 2.90; p = 0.08) and second post-treatment (mean 3.26 vs.
2.80; p = 0.18). There was a decrease in episodes of 'sit' defecation when comparing
the pre-treatment and first post-treatment periods (mean 3.00 vs. 2.54; p = 0.0004).
In the placebo group there was no difference in episodes of 'spontaneous' defecation
when comparing the pre-treatment and treatment (mean 2.83 vs. 2.74; p = 0.68) or
first post-treatment (mean 2.83 vs. 2.40; p = 0.12) periods. There was, however, a
significant decrease in episodes of'sit' defecation when comparing the pre-treatment
and second post-treatment periods (mean 2.83 vs. 2.11; p = 0.04).
7.4.2.2 Frequency of 'total' defecation
The mean number of 'total' defecation episodes per week for each 28 day treatment
period for both the real and placebo groups are shown in table 20. All data sets
demonstrated normal Gaussian distribution.
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Table 20 - Table showing episodes of 'total' defecation (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 6.26 4.96
Treatment (4 weeks) 6.57 4.39
1st post treatment (4 weeks) 6.09 4.69
2nd post treatment (4 weeks) 5.78 3.45
PLACEBO (n=18)
Pre-treatment (4 weeks) 5.50 3.66
Treatment (4 weeks) 6.08 3.87
1st post treatment (4 weeks) 5.83 3.81
2nd post treatment (4 weeks) 5.63 3.94
When comparing the real and placebo treatment groups, there was no difference in
number of 'total' defecation episodes in the pre-treatment period (mean 6.26 vs.
5.50; p = 0.61). Following intervention, there remained no significant difference in
the number of 'total' defecation episodes between the 2 groups during the treatment
period (mean 6.57 vs. 6.08; p = 0.73) and during both the first post-treatment period
(mean 6.09 vs. 5.83; p = 0.86) and second post-treatment periods (mean 5.78 vs.
5.63; p = 0.83).
When looking at the linear analysis for both treatment arms, there was no difference
in 'total' number of episodes of defecation when comparing the pre-treatment period
to any of the treatment/post-treatment periods.
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7,4.2.3 Frequency of 'stain' soiling
The mean number of 'stain' soiling episodes per week for each 28 day treatment
period for both the real and placebo groups are shown in table 21. All data sets
demonstrated normal Gaussian distribution.
Table 21 - Table showing episodes of 'stain' soiling (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 1.78 1.78
Treatment (4 weeks) 1.57 1.66
1st post treatment (4 weeks) 1.31 1.90
2nd post treatment (4 weeks) 1.28 1.62
PLACEBO (n=18)
Pre-treatment (4 weeks) 2.10 1.90
Treatment (4 weeks) 1.86 2.15
1st post treatment (4 weeks) 1.67 1.88
2nd post treatment (4 weeks) 1.57 1.90
When comparing the real and placebo treatment groups, there was no difference in
number of'stain' soiling episodes in the pre-treatment period (mean 1.78 vs. 2.10; p
= 0.61). Following intervention, there remained no significant difference in the
number of 'scrape' soiling episodes between the 2 groups during the treatment period
(mean 1.86 vs. 1.57; /? = 0.66) and during both the first post-treatment period (mean
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1.31 vs. 1.67; p = 0.58) and second post-treatment periods (mean 1.28 vs. 1.57; p =
0.63).
As with the primary outcome measure, linear analysis was also performed for both
treatment groups. In the real treatment group, there was no significant difference in
episodes of 'stain' soiling when comparing the pre-treatment period with the
treatment (mean 1.78 vs. 1.57; p = 0.20) and second post-treatment (mean 1.78 vs.
1.28; p = 0.14). There was a decrease in episodes of 'stain' soiling when comparing
the pre-treatment and first post-treatment periods (mean 1.78 vs. 1.31; p = 0.003). In
the placebo group there was no difference in episodes of 'stain' soiling when
comparing the pre-treatment period with treatment (mean 2.10 vs. 1.86; p = 0.63),
first post-treatment (mean 2.10 vs. 1.67; p = 0.39) and second post-treatment (mean
2.10 vs. 1.57; p - 0.14) periods.
7.4.2.4 Frequency of 'scrape' soiling
The mean number of 'scrape' soiling episodes per week for each 28 day treatment
period for both the real and placebo groups are shown in table 22. All data sets
demonstrated normal Gaussian distribution.
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Table 22 - Table showing episodes of 'scrape' soiling (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 1.88 2.28
Treatment (4 weeks) 1.38 1.54
1st post treatment (4 weeks) 1.44 1.93
2nd post treatment (4 weeks) 1.04 1.42
PLACEBO (n=18)
Pre-treatment (4 weeks) 0.83 1.10
Treatment (4 weeks) 0.94 1.57
1st post treatment (4 weeks) 1.44 2.19
2nd post treatment (4 weeks) 1.24 2.17
When comparing the real and placebo treatment groups, there was no difference in
number of 'scrape' soiling episodes in the pre-treatment period (mean 1.88 vs. 0.83;
p = 0.09). Following intervention, there remained no significant difference in the
number of 'scrape' soiling episodes between the 2 groups during the treatment period
(mean 1.38 vs. 0.94; p = 0.41) and during both the first post-treatment period (mean
1.44 vs. 1.44; p = 0.76) and second post-treatment periods (mean 1.04 vs. 1.24; p =
0.82).
When looking at the linear analysis, in the real treatment group, there was a
significant difference in episodes of 'scrape' soiling when comparing the pre-
treatment period with the treatment (mean 1.88 vs. 1.38; p = 0.05) and second post-
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treatment (mean 1.88 vs. 1.04; p = 0.03). There was no difference in episodes of
'scrape' soiling when comparing the pre-treatment and first post-treatment periods
(mean 1.88 vs. 1.44; p = 0.15). In the placebo group there was no difference in
episodes of 'scrape' soiling when comparing the pre-treatment period with treatment
(mean 0.83 vs. 0.94; p = 0.64), first post-treatment (mean 0.83 vs. 1.44; p = 0.10) and
second post-treatment (mean 0.83 vs. 1.24; p = 0.21) periods.
7.4.2.5 Frequency of 'total' soiling
The mean number of 'total' soiling episodes per week for each 28 day treatment
period for both the real and placebo groups are shown in table 23.
Table 23 - Table showing episodes of 'total' soiling (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 3.66 3.34
Treatment (4 weeks) 2.96 2.75
1st post treatment (4 weeks) 2.75 3.13
2nd post treatment (4 weeks) 2.32 2.41
PLACEBO (n=l 8)
Pre-treatment (4 weeks) 2.93 2.18
Treatment (4 weeks) 2.81 2.51
1st post treatment (4 weeks) 3.11 2.96
2nd post treatment (4 weeks) 2.81 2.96
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All data sets demonstrated normal Gaussian distribution.
When comparing the real and placebo treatment groups, there was no difference in
number of 'total' soiling episodes in the pre-treatment period (mean 3.66 vs. 2.93; p
= 0.45). Following intervention, there remained no significant difference in the
number of 'total' soiling episodes between the 2 groups during the treatment period
(mean 2.96 vs. 2.81; p = 0.87) and during both the first post-treatment period (mean
2.75 vs. 3.11; p = 0.73) and second post-treatment periods (mean 2.32 vs. 2.81; p =
0.60).
When looking at the linear analysis, in the real treatment group, there was a
significant difference in episodes of 'total' soiling when comparing the pre-treatment
period with the treatment (mean 3.66 vs. 2.96; p = 0.003), first post-treatment (mean
3.66 vs. 2.75; p = 0.03) and second post-treatment periods (mean 3.66 vs. 2.32; p =
0.02). In the placebo group there was no difference in episodes of 'total' soiling
when comparing the pre-treatment period with treatment (mean 2.93 vs. 2.81; p =
0.83), first post-treatment (mean 2.93 vs. 3.11; p = 0.76) and second post-treatment
(mean 2.93 vs. 2.81; p = 0.79) periods.
7.4.2.6 Frequency of abdominal pain
The mean number of episodes of abdominal pain per week for each 28 day treatment
period for both the real and placebo groups are shown in table 24. All data sets
demonstrated normal Gaussian distribution.
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Table 24 - Table showing episodes of abdominal pain (mean + SD) for
both treatment arms pre- and post- intervention.




Pre-treatment (4 weeks) 2.12 1.76
Treatment (4 weeks) 1.37 1.44
1st post treatment (4 weeks) 1.06 1.25
2nd post treatment (4 weeks) 0.60 0.73
PLACEBO (n=18)
Pre-treatment (4 weeks) 2.14 2.12
Treatment (4 weeks) 1.89 2.22
1st post treatment (4 weeks) 1.51 2.06
2nd post treatment (4 weeks) 1.81 2.37
When comparing the real and placebo treatment groups, there was no difference in
number of episodes of abdominal pain in the pre-treatment period (mean 2.12 vs.
2.14; p = 0.97). Following intervention, there remained no significant difference in
the number of episodes of abdominal pain between the 2 groups during the treatment
period (mean 1.37 vs. 1.89; p = 0.42) and during the first post-treatment period
(mean 1.06 vs. 1.51; p = 0.44). There was however a trend towards significance in
episodes of abdominal pain when comparing the second post-treatment periods
(mean 0.60 vs. 1.81; p = 0.05).
When looking at the linear analysis, in the real treatment group, there was a
significant difference in episodes of abdominal pain when comparing the pre-
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treatment period with the treatment (mean 2.12 vs. 1.37; p = 0.007), first post-
treatment (mean 2.12 vs. 1.06; p = 0.0006) and second post-treatment periods (mean
2.12 vs. 0.60; p = 0.0007). In the placebo group there was no difference in episodes
of abdominal pain when comparing the pre-treatment period with treatment (mean
2.14 vs. 1.89; p = 0.30) and second post-treatment (mean 2.14 vs. 1.81; p = 0.33)
periods. There was a difference when comparing the pre-treatment and first post-
treatment (mean 2.93 vs. 1.51;/? = 0.05) periods.
7.4.2.7 Quality of life scores
Table 25 - Demographics of study population.
Placebo Real
Number of children 17 16
Male:Female 1.4:1 2.2:1
Average age (yrs) 11.4 12.1
Male/Female (yrs) 10.6/12.6 12.1/12.2
Age range (yrs) 7.8-16.5 7.4-17.7
Average duration of symptoms (yrs) 8.5 10.6
Range of duration of symptoms (yrs) 2.7-14.4 4.4-15.1
Symptoms since birth 4/17 6/16
Abdominal pain 14/17 12/16
Average score /10 5.5 4.1
Soiling 15/17 12/16
Severe (daily/constant) soiling 10 10
Appendicostomy 2/17 3/16
Weight
Underweight (BMI <5th centile) 0/17 1/16
Healthy (BMI 5-85th centile) 11/17 11/16
Overweight (BMI 85-95th centile) 5/17 2/16
Obese (BMI >95th centile) 1/17 2/16
Medication 15/17 11/16
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Quality of life data are available for thirty-three children (21 male), mean age 11.8
years (range 7.4-16.5 years). Sixteen received real IFT. There were no statistical
differences between the 2 groups concerning sex, age, onset/duration of symptoms,
soiling and abdominal pain (Table 25).
7.4.2.7.1 Peds QL quality of life scores
The parent and child reported mean QoL scores for both the real and placebo groups
before and after intervention are shown in tables 26 and 27. All data sets
demonstrated normal Gaussian distribution.
Table 26 - Parent reported PedsQL scores (mean + SD) for both











Mean SD Mean SD Mean SD
REAL Pre-treatment 70.3 20.13 81.3 14.30 64.5 24.97
Post-treatment 70.0 14.00 79.3 15.44 65.1 18.60
PLACEBO Pre-treatment 69.8 13.84 79.6 13.37 63.8 18.90
Post treatment 70.2 14.69 79.6 14.91 65.2 18.12
Parent reported scores - when comparing the real and placebo groups, there was no
difference in pre-treatment total (mean 70.3 vs. 69.8; p = 0.93), physical (mean 81.3
vs. 79.6; p = 0.73) and psychosocial (mean 64.5 vs. 63.8; p = 0.93) QoL scores.
Following intervention, there remained no difference in total (mean 70.0 vs. 70.2; p =
0.97), physical (mean 79.3 vs. 79.6; p = 0.96) and psychosocial (mean 65.1 vs. 65.2;
p = 0.99) QoL scores.
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Table 27 - Child reported PedsQL scores (mean + SD) for both











Mean SD Mean SD Mean SD
REAL Pre-treatment 72.9 16.86 76.4 14.93 71.0 19.18
Post-treatment 81.1 14.17 86.3 11.35 78.3 16.66
PLACEBO Pre-treatment 74.9 8.24 85.3 8.17 69.0 10.45
Post treatment 78.1 11.35 85.1 8.16 74.4 16.17
When performing linear analysis, there was no difference in parent reported QoL in
the real treatment group after intervention for total (mean 70.3 vs. 70.0; p = 0.93),
physical (mean 81.3 vs. 79.3; p = 0.63) and psychosocial (mean 64.5 vs. 65.1; p =
0.86) scores. This was also true for the placebo pre-and post-treatment total (mean
69.8 vs. 70.2; p = 0.90), physical (mean 79.6 vs. 79.6; p = 0.99) and psychosocial
(mean 63.8 vs. 65.2; p = 0.70) scores.
Child reported scores - when comparing the real and placebo groups, there was no
difference in pre-treatment total (mean 72.9 vs. 74.9; p = 0.67) and psychosocial
(mean 71.0vs. 69.0; p = 0.71) QoL scores. There was however a difference in
reported physical QoL scores (mean 76.4 vs. 85.3; p = 0.04). Following
intervention, there remained no difference in total (mean 81.1 vs. 78.1; p = 0.51) and
psychosocial (mean 78.3 vs. 74.4; p = 0.50) QoL scores. There was no difference in
post-treatment child-reported physical QoL scores (mean 86.3 vs. 85.1; p = 0.72).
When performing linear analysis, there was a difference in child reported QoL in the
real treatment group after intervention for total (mean 72.9 vs. 81.1; p = 0.005),
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physical (mean 76.4 vs. 86.3; p = 0.003) and psychosocial (mean 71.0 vs. 78.3; p =
0.02) scores. There was no difference in child-reported placebo pre-and post-
treatment total (mean 74.9 vs. 78.1; p = 0.12), physical (mean 85.3 vs. 85.1; p =
0.93) and psychosocial (mean 69.0 vs. 74.4; p = 0.06) scores.
7.4.2.7.2 Holschneider and Templeton quality of life scores
The mean Holschneider and Templeton QoL scores for both the real and placebo
groups before and after intervention are shown in table 28. All data sets (apart from
Templeton scores post intervention in the real treatment group) demonstrated normal
Gaussian distribution.
Table 28 - Holschneider and Templeton scores (mean + SD) for both









Mean SD Mean SD
REAL Pre-treatment 8 2.37 2.5 0.56
Post-treatment 10 1.45 2.5 0.40
PLACEBO Pre-treatment 7 2.76 2.5 0.50
Post treatment 9 2.42 2.5 0.39
When comparing the real and placebo groups, there was no difference in pre-
treatment Holschneider (mean 8 vs. 7; p = 0.56) or Templeton (mean 2.5 vs. 2.5; p =
0.63) QoL scores. Following intervention, there remained no difference in
Holschneider (mean 10 vs. 9; p = 0.15) or Templeton (mean 2.5 vs. 2.5; p = 0.74)
QoL scores.
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When performing linear analysis, there was a difference in Holschneider QoL scores
following both real (mean 8 vs. 10; p = 0.01) and placebo (mean 7 vs. 9; p = 0.02)
intervention. There was no difference in Templeton QoL scores following either real
(mean 2.5 vs. 2.5; p = 0.30) or placebo (mean 2.5 vs. 2.5; p = 0.11) intervention.
7.4.2.7 Nuclear transit studies
Nuclear transit study data are available for twenty four children (14 male), mean age
12.0 years (range 7.4-17.7 years). Fifteen received real IFT.
Table 29 - Demographics of study population.
Placebo Real
Number of children 9 15
Male:Female 1.25:1 1.5:1
Average age (yrs) 11.7 12.2
Male/Female (yrs) 11.3/12.2 12.4/11.8
Age range (yrs) 7.8-16.5 7.4-17.7
Average duration of symptoms (yrs) 9.1 10.1
Range of duration of symptoms (yrs) 5.2-14.4 4.4-15.1
Symptoms since birth 3/9 3/15
Abdominal pain 6/9 11/15
Average score /10 5 4
Soiling 7/9 10/15
Severe (daily/constant) soiling 5/7 8/10
Appendicostomy 1/9 2/15
Weight
Underweight (BMI <5th centile) 0/9 1/15
Healthy (BMI 5-85th centile) 7/9 10/15
Overweight (BMI 85-95th centile) 2/9 2/15
Obese (BMI >95th centile) 0/9 2/15
Medication 8/9 12/15
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There were no statistical differences between the 2 groups concerning sex, age,
onset/duration of symptoms, soiling and abdominal pain (Table 29).
Twenty eight studies were identified (2 subjects in each group had 2 pre-treatment
studies performed). The mean GC at 6, 24, 30 and 48 hours with 95% confidence
intervals for pre-treatment studies and pot-treatment studies in both treatment arms
are shown in table 30. All data sets demonstrated normal Gaussian distribution.
Table 30 - Mean geometric centres (GC) of activity for pre- and post-
intervention nuclear transit studies calculated at 6, 24, 30 and 48hrs
post ingestion of radiolabelled material.
6hrs 24 irs 30 irs 48 irs





































Post treatment GC at 6, 24, 30 and 48 hours were compared between the placebo and
real intervention groups. There was no difference between the GC for the post-
treatment placebo and real studies at 6 hours (mean +/- SEM - 1.64 +/- 0.12 vs. 1.81
+/- 0.10; p = 0.28). There was a significant difference in the post-intervention GC
between the 2 treatment arms at 24 (mean +/- SEM - 2.52 +/- 0.09 vs. 3.05 +/- 0.12;
p = 0.004), 30 (mean +/- SEM - 2.71 +/- 0.17 vs. 3.47 +/- 0.20; p = 0.02) and 48
(mean +/- SEM - 3.10 +/- 0.23 vs. 4.24 +/- 0.23; p = 0.002) hours.
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When comparing the pre- and post-intervention studies, for the group who received
real therapy, there was a significant difference in GC at 24 (mean +/- SEM - 2.53 +/-
0.12 vs. 3.05 +/- 0.11; p = 0.001), 30 (mean +/- SEM - 2.92 +/- 0.13 vs. 3.47 +/-
0.20; p = 0.04) and 48 (mean +/- SEM - 3.48 +/- 0.17 vs. 4.28 +/- 0.21; p = 0.004)
hours. This was not so for the placebo group where statistical significance was not
reached at any time point.
7.5 Discussion
Slow transit constipation in children represents a chronic medical condition that is
refractory to current medical treatment. Interferential therapy is a non-invasive,
transcutaneous form of electrical stimulation that is commonly used by
physiotherapists for the treatment of bladder instability. Since electrical therapy is
not widely used in current medical practice, and it's mechanism of action is poorly
understood, placebo-intervention trials are recommended to confirm the validity of
any perceived improvement. This chapter reports the interim results of a randomised
controlled blinded placebo-partial crossover trial assessing the application of IFT in
the treatment of children with STC.
Analysis of the results comparing the placebo and real treatment groups post
intervention show that treatment of subjects with STC with IFT does not affect the
defecation frequency ('spontaneous' and 'sit' defecation) or soiling frequency
('stain' and 'scrape' soiling). However, there was a reduction in the episodes of
abdominal pain in the group who received real therapy in the second post-treatment
period {p = 0.05). When directly comparing the real and placebo groups, there was
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no measurable effect on quality of life when evaluated by PedsQL (parent and child
reported), Holschneider or Templeton QoL tools. There does appear to be a decrease
in colonic transit time quantified by nuclear scintigraphy following treatment with
real IFT (24hrs p = 0.004,30hrs p = 0.02,48hrs p = 0.002).
When comparing data in a linear manner in each treatment arm, there is again no
difference in defecation frequency in either group. There does appear to be a
reduction in soiling (total soiling in all post treatment periods p = 0.003, 0.03 and
0.02) in the group that received real therapy. This is not so for the placebo group.
The data also shows that there is an improvement in episodes of abdominal pain (all
post treatment periods p = 0.007,0.0006 and 0.0007) in the participants that received
real treatment. When looking at the QoL data, there was no difference in parent-
reported PedsQL scores in either treatment group. There was however a significant
improvement in child-reported total (p = 0.005), physical (p = 0.003) and
psychosocial (p = 0.02) scores in the real intervention group. There was an
improvement in the colonic transit in participants who had received real treatment
(24hrs p = 0.001, 30hrs p = 0.04, 48hrs p = 0.004) but not in those who had been
given placebo therapy.
The current study sought to ascertain whether or not IFT was able to increase the
defecation frequency in children with STC and as such was unable to demonstrate
any improvement. It is, however, strikingly apparent that some children with STC
do not display the defecation pattern normally associated with constipation of
infrequent passage of stools 10. Some of the subjects in the study reported pre-
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intervention stool frequency of >2 or more defecations in the toilet per week.
Children with STC often pass soft, putty like stool that is both difficult to pass and
subsequently to wipe away. What is unknown, and difficult to quantify, is the
volume of stool that is being passed on each occasion. Along with a record of each
time they defecated, participants were also asked to record the consistency of their
stool in accordance with the Bristol stool scale. Anecdotal analysis of this data
suggested that there was an improvement in stool consistency despite there being no
difference in frequency of defecation.
One of the most distressing symptoms associated with STC is the uncontrollable
passage of stool. This can result either in a small mark on the underpants, a 'stain',
or an amount of stool in the underwear that needs to be physically removed, a
'scrape'. It is thought that the soiling associated with STC is a major contributing
• 978
factor to sufferer's poor quality of life . Comparison of the placebo and real
treatment groups did not demonstrate any improvement in soiling post-intervention.
When looking at the linearly analysed data, following treatment with real IFT, there
was a decrease in total episodes of soiling in all post treatment periods. The episodes
of 'scrapes' were reduced during the treatment and second post-treatment periods
with the 'stains' reduced in the first post-treatment period. There was no difference
in either episodes of stains or scrapes in the placebo group.
The current study found that there was improvement in episodes of abdominal pain
following treatment with real IFT. This was apparent in the second post-treatment
period when directly comparing the real and placebo groups, and in all treatment
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periods when looking at the linear analysis for the real intervention group. For some
children abdominal pain is the most debilitating symptom associated with their
constipation and results in many days off school. It was these children that seemed
to have the most significant decrease in their pain. Interestingly, there were a few
children for whom the episodes of abdominal pain appeared to increase. On further
questioning, it became apparent that it was actually a need to defecate that these
children were experiencing however, since it was a novel sensation, it was perceived
as a painful stimulus. The meaning of this sensation was explained to subjects and
they were encouraged to attempt to defecate when they felt they were experiencing
'pain'.
The study found that although there was no difference in child reported PedsQL QoL
scores when comparing the post intervention real and placebo groups, there was a
significant improvement in child self-perceived QoL when looking at the group who
received real interferential therapy (p = 0.005). This was not so after placebo
therapy. This improvement was apparent when examining both the physical (p =
0.003) and psychosocial (p = 0.02) aspects of their QoL.
Questions in the psychosocial domain mainly concentrate on getting along with other
children, being teased and keeping up with peers. Children who experience faecal
soiling are often shunned by their classmates, and so any improvement in this will
undoubtedly improve their social acceptance and minimise any taunting.
Interestingly, although children in the study for the most part have no outward
physical disability, their QoL answers suggest that they feel that they are unable to
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keep up with, and perform to the same standards, as their peers. This perceived gap
appears to narrow following treatment with real IFT with significant improvement in
physical QoL scores.
There was no improvement in parent-reported QoL following treatment with either
real or placebo IFT when looking at the data comparing the treatment arms or within
each intervention group. It is common for children with STC to have had defecatory
problems from birth. When a parent has been living with a child with a chronic
condition for so long, it may take longer than a few weeks of improvement for them
to experience a change in mindset when considering the QoL of their child. Whereas
a child has the ability to take an improvement in their condition at face value, an
adult is more likely to be sceptical and need longer to accept that things have indeed
changed.
In terms of clinical significance, when looking at the real IFT group, in the second
post-treatment period the number of episodes of soiling decreased from a mean of
3.66/wk to 2.32/wk and the episodes of abdominal pain from a mean on 2.12/wk to
0.60/wk. This means that in a 28 day period, children experienced an average of 6
fewer days with soiling episodes (15/28 vs. 9/28) and 6 fewer days with abdominal
pain (8/28 vs. 2/28). Although children are still clearly symptomatic, this small
improvement, when considered in association with the chronicity of their symptoms,
may feel like there's 'light at the end of the tunnel' and account for the improvement
in child-reported QoL in the real intervention group. These findings, over a
177
relatively short period of time, certainly suggest that further evaluation of IFT as a
treatment modality is warranted.
This study demonstrates that transcutaneous electrical treatment with IFT is effective
in reducing colonic transit time, as measured by nuclear scintigraphy at 6-8 weeks
after treatment, in children with STC. Their colonic transit times at 24, 30 and 48
hours were significantly decreased. This was not so when placebo IFT was
administered and the transit study repeated. This is an objective measure and
suggests that interferential therapy may have the ability to alter colonic motility.
There were, however, a limited number of studies available with only 18 of the 35
participants attending for a repeat transit study following intervention. In terms of
clinical significance, the results suggest that at 48hrs, in the real treatment group, the
mean centre of radioactivity moves from the transverse colon to the lower descending
colon (3.48 vs. 4.28).
It is a widely held belief that constipation and soiling are associated with obesity 31
However, in the current study, 27 of the 35 children (77%) were either healthy or
underweight. In 1995, the proportion of overweight or obese children and
in
adolescents aged 2-17 years was 21% for boys and 23% for girls and it is believed
that in the last 10 years these figures have further increased. This shows that our
study population is entirely representative of the Australian population as a whole
and that STC is not associated with obesity.
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Many of the children in the trial reported an increase in rectal sensation, following
treatment with IFT, in association with an increase in their ability to hold back
defecation and discriminate between formed, loose or gaseous stools. The anal canal
is innervated both by free nerve ending and sensory organs with the maximum
density of nerve endings being in the region of the anal crypts and the adjacent
proximal mucosa (the 'transition zone')313. Distal to this region the anal mucosa is
sensitive to pain, temperature and touch whilst the proximal rectal mucosa is not
sensitive to pain but instead is sensitive to pressure changes due to the existence of
numerous Golgi-Mazzoni bodies and pacinian corpuscles 3I4. Since the rectum is not
sensitive to pain, but is sensitive to distension of its lumen, it has been hypothesised
that the sensation of rectal fullness is not a result of mucosal stimulation but instead
arises from stimulation of the pelvic floor muscles and receptors in surrounding
structures 313. However, the precise role of anorectal sensation in the maintenance of
continence is unclear.
The 'anal sampling reflex' consists of opening of the upper anal canal following
rectal filling so that the rectal contents can come into contact with the sensate anal
mucosa. It is seen in normal subjects up to 7 times an hour and is thought to aid in
distinction between flatus and liquid or solid stool 314. Despite its perceived
importance, its frequent loss following ileoanal or coloanal anastomosis does not, for
O 1 c
the most part, appear to result in faecal incontinence . in addition, replication of
loss of the sampling reflex, by applying lignocaine gel into the rectum of healthy
subjects, does not result in incontinence of instilled liquid 316.
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A study in 1984 in which Loening-Bauke assessed anorectal function (by means of
anorectal manometry) in healthy children and in children with constipation (both
with and without soiling), revealed that children with constipation (regardless of
soiling state) had a lower anal resting tone and pull through pressure than the healthy
controls. This abnormal rectal function was still apparent when the investigation was
repeated up to 4 years after apparently successful treatment 317. However, despite
these findings, the subjects in the current study appear to have an improvement in
their rectal perception and function.
The concept of applying electrical stimulation to improve faecal continence is not a
new one however to date most techniques have employed trans-anal application, or
direct implantation, of devices. There have been mixed reports regarding the
efficacy of anal sphincteric electrical stimulation by means of an anal canal electrode
•5 i o
. It is thought that application of a tetanising stimulus to the anal sphincter and
pelvic floor, resulting in contraction of the anal musculature, over time builds up and
improves sphincter tone and contractility.
Greater success has been reported with sacral nerve stimulation (SNS). Like
interferential therapy, the primary application of SNS was for the treatment of
urinary incontinence 32'~323. Since this time, several studies have been performed that
have assessed its efficacy in subjects with constipation and/or faecal incontinence;
the use of SNS is advocated in subjects who have an intact anal sphincter and
nervous system but who have a functional mechanical deficit " " . Although,
as with all electrotherapy, the precise mechanism of action of SNS remains
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unknown, it is believed to work via neuromodulation. In general, peripherally
applied electric current is thought to exert an influence centrally by altering the
balance between excitation and inhibitory neural control resulting in a change in the
neural drive 171. It is likely that these changes are mediated by supraspinal as well as
spinal pathways 327. A number of physiological changes have been noted following
electrical stimulation including an increase in afferent C fibre activity, an increase in
the release of neurotransmitter substances (in the bladder), an increase in beta
adrenergic activity, a reduction in cholinergic activity and changes in VIP and
serotonin (smooth muscle relaxants) concentration 328. Electric current has also been
shown to stimulate the release of endorphins and encephalins in cerebral spinal fluid
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SNS involves applying a low amplitude electrical stimulation directly to a sacral
nerve via an electrode inserted through the corresponding sacral foramen. Most
benefit appears to be gained through stimulation of the third sacral nerve root (S3), a
mixed nerve containing voluntary somatic, afferent sensory and efferent autonomic
motor nerves 329. Although the means by which sub-sensory stimulation produces
the clinical results is unknown, direct stimulation of S3 produces elevation of the
pelvic floor through external sphincter and levator contraction along with plantar
flexion of the great toe 3I4. SNS is achieved through the implantation of either
temporary or permanent stimulating devices; permanent electrodes are now able to
be inserted using a minimally invasive percutaneous technique with the stimulator
placed in a pocket below the superficial fascia in the buttock 329_
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Several studies have evaluated the efficacy of SNS either for the treatment of faecal
incontinence 179 330 0r constipation 324 326. The studies concluded that SNS can lead
to significant improvement in selected patients with faecal incontinence characterised
by a reduction in episodes of faecal incontinence along with an improvement in
ability to defer defecation. Although a period of temporary stimulation is able to
determine in most instances those who will benefit from SNS, the studies found that
despite having met the criteria for permanent device insertion, not all patients then go
on to experience an improvement in their symptoms. In terms of treating patients
with constipation, the studies found that SNS had the ability to increase their number
of bowel movements and, as with the current study, reduce their abdominal pain and
bloating. Dinning et al showed that although SNS had the capacity to induce pan-
colonic propagating sequences as recorded by intraluminal colonic manometry, the
stimulation parameters necessary to optimise colonic response remain unclear 324.
Stimulation of the S3 nerve root significantly enhanced antegrade colonic activity
however stimulation of the S2 nerve root increased retrograde activity. They also
experimented with different stimulus frequency and found that depending on the
precise application of stimulators and pacing devices the optimum frequency could
vary widely. They concluded that additional formal evaluation of frequencies and
pulse width is required in order to determine the best possible treatment parameters.
The most apparent advantage of IFT over SNS is its non-invasive nature that
subsequently makes it an attractive treatment option in children. As previously
discussed, investigation into the application of SNS has been progressing for many
years with investigators still experimenting to determine optimum stimulus
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parameters. The current study used IFT treatment parameters based on a pilot study
that in turn was based upon current settings used in adult subjects to promote bladder
stability 170. IFT employs 4 electrodes (2 abdominal, 2 paraspinal) and the paraspinal
electrodes are currently placed at a level midway between T9 and L2 vertebrae.
Since SNS studies have demonstrated that S3 stimulation produces an increase in
colonic antegrade propagating activity, it may well be that results can be further
improved by changing the electrode placement. There is also some anecdotal
evidence that abdominal stimulation may have a slowing effect on gastrointestinal
motility, hence the traditional cure of massaging the abdomen to ease a stomach
ache. It may be that paraspinal stimulation alone is suffice to produce the desired
clinical effects. In the same way, it might well be that the form of electrical
stimulation currently being employed is not optimal. Further research needs to be
performed to clarify optimal electrode placement, current frequency and intensity
and the type of electrical stimulation.
As previously stated, IFT is a painless well tolerated treatment modality. None of
the subjects participating in the trial experienced any adverse effects related to their
IFT nor did they request to leave the trial at any point due to dislike of treatment.
Since the commencement of the trial, new IFT machines have been released onto the
open market that are battery operated (cf. mains electricity) and are of a portable
nature. Rather than having to visit a physiotherapist for treatment and having to
remain completely stationary for the duration of the treatment period, subjects can
now partake in quiet activities and walk around whilst receiving their treatment.
This means that IFT is now much more accessible and will appeal to a wider group
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of patients. The investigators who carried out the pilot study in 2003 investigating
the use of IFT in children with STC arbitrarily chose 3 x 20 minute treatment
sessions per week. Since an improvement in symptoms was demonstrated with this
regimen, it was carried forward to this larger trial. As with the current parameters, it
remains unclear as to whether or not this represents the optimal treatment frequency.
With the advent of portable machines it may be easier to trial different, including
more frequent, treatment regimes.
This study suffers from its relatively short time scale and small numbers. It will
therefore be important to determine the long-term effects of stimulation and whether
or not the small decrease in soiling and abdominal pain are maintained or deteriorate
over time. This is especially important as previous studies suggest that placebo
effects are usually short-lived rather than producing long-standing results. Similarly,
it is unclear whether or not the decrease in colonic transit time suggested by the
repeat nuclear transit studies will be sustained over time. This may be a harder
question to answer owing to the considerable time required for each transit study and
the poor compliance in attendance of study participants. Whether or not a different
response would be evident with increased participant numbers also remains
unknown. Slow transit constipation represents a specific form of chronic
constipation and as such there is a relatively small available patient pool from which
to recruit subjects. Although all participants have demonstrable colonic delay on
nuclear transit studies they are likely to represent a heterogeneous group of
pathologies and as such grouping them together to assess response is not ideal.
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In conclusion, this study is the first to attempt to evaluate transcutaneous electrical
stimulation compared to placebo stimulation in the management of children with
chronic slow transit constipation. Although the results are disappointing, with only
small perceivable clinical benefits, objective evidence suggest that there is a decrease
in colonic transit time following treatment with interferential therapy. Much still
remains unknown regarding optimal treatment regimens and clearly further research
is required in order to ascertain its potential clinical effectiveness.
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8. Evaluation of colonic function in children with slow transit
constipation and appendix stomas following the application
of transcutaneous electrical stimulation
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8. Evaluation of colonic function in children with slow transit
constipation and appendix stomas following the application of
transcutaneous electrical stimulation
8.1 Introduction
A small proportion of children with chronic slow transit constipation are unable to
maintain a sociably acceptable level of continence by the usage of laxatives alone
and require the formation of an appendix stoma. It is via this appendiceal conduit
that regular antegrade enemas can be performed in order to keep the colon empty of
faecal matter in an attempt to avoid faecal leakage and soiling 125.
This subset of children with STC also underwent therapy with interferential
electrical stimulation as described in the previous chapter, however, in addition to
the aforementioned measurements, the subjects also had 24 hour colonic manometry
performed via their appendicostomy 76 both before and after intervention.
Colonic manometry is a means of examining pan-colonic motility. A pressure
recording catheter is placed in the colon by either a retrograde (via colonoscopy) or
antegrade (via oral ingestion or an appendicostomy) route 76. This catheter is able to
determine changes in intraluminal pressure which result from colonic motor activity.
Eight-sixteen recording sites are spaced at 7.5-10 cm intervals along the catheter,
beginning at 7.5cm from the catheter tip. The pressure signals from each site are
then amplified and digitised to produce an interpretable readout on a computer
screen.
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Previous studies have shown that colonic activity occurs in propagating waves or
sequences and that these can be in either an antegrade (antegrade propagating
sequence - APS) or retrograde (retrograde propagating sequence - RPS) direction 155.
Pressure waves are defined as a predominantly monophasic pressure elevations of
>5mmHg that have a discernable onset, peak and offset and that do not have features
of strain artefact (strain is discernable as it produces simultaneous, often identical,
pressure elevations at all recording sites). Propagating sequences are in turn defined
as a collection of 3 or more pressure waves occurring at adjacent recording sites and
having a conduction velocity of 0.2-12cm/sec l55. High amplitude colonic
propagating sequences have also been demonstrated and are associated with mass
colonic movements such as defecation or the post-prandial gastro-colic reflex. In
order for a propagating sequence to be described as high amplitude, the pressure at
(at least) one of the recording sites must be equal to or greater than 116mmHg 155.
High pressure waves can also occur in an antegrade (high amplitude antegrade
propagating sequence - HAAPS) or retrograde (high amplitude retrograde
propagating sequence - HARPS) direction 76.
Although colonic motor patterns in children are poorly described, previous
investigators have demonstrated that children with STC appear to have decreased
antegrade propagating motor activity with an altered ratio between antegrade and
retrograde pressure waves. They also lack normal colonic motor responses to
waking and meal ingestion 76.
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8.2 Hypothesis and aims
This study hypothesises that transcutaneous electrical stimulation (in the form of
interferential therapy (IFT)) can increase bowel activity, and improve symptoms.
The study aims to determine whether or not transcutaneous IFT can affect the
symptoms of STC in children (frequency of defecation, soiling, and abdominal pain)
and their colonic activity (as measured by colonic manometry).
8.3 Subjects and methods
8.3.1 Participants
The participant inclusion and exclusion criteria were the same as those described in
chapter 7 with the following additional points:
• Participant had to have an existing appendix stoma that was placed at least 6
months previously and had not recently been revised or had recurrent
problems with infection/severe over-granulation.
• The stoma did not have to currently be in use for the provision of antegrade
continence enemas.
• Participant must have been willing, with no parental coercion, to participate
in 2 rounds of colonic manometry and fully understand what the
investigation entailed.
• Any subject who had previously had colonic manometry and was unable to
tolerate the procedure was excluded.
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8.3.2 Recruitment and intervention
Complete recruitment strategies and intervention are described in full in chapter 7.
8.3.3 Outcome measures
8.3.3.1 Primary outcome measure
The primary outcome measure is colonic activity as measured by colonic
manometry. This includes frequency, amplitude, velocity and distance of
propagation, site of origin and regional linkage of propagating sequences (antegrade
and retrograde). Waking and postprandial responses are also assessed. The methods
are described later in the chapter.
8.3.3.2 Secondary outcome measures
The secondary outcome measures are the bowel diary measurements outlined in
Chapter 7 (including the primary outcome measure - this time recorded as a
secondary outcome measure).
8.3.4 Timing of manometry
Children willing to participate were required to have 2 separate manometric
recordings - one before and one after receiving IFT. The baseline recording had to
have been performed any time before their first treatment, with no minimum time
period specified. Some children had undergone colonic manometry as part of a
previous study and this information was utilised to determine their baseline colonic
motor function. Other children had both their studies performed as part of this study.
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The second study was performed 8 weeks after completing a course of treatment
with IFT.
8.3.5 Colonic manometry methods
Children participating were required to attend the Royal Children's Hospital for 3
consecutive days (Wednesday, Thursday and Friday). If they lived locally then they
were given the option of returning home for the night on Wednesday, however if
they lived a long way away, or were reluctant to go home, then they either spent the
Wednesday night in the hospital's Medihotel or were admitted a day early as an
inpatient to a ward. All participants spent the Thursday and Friday as inpatients.
Participants were able to have a family member stay with them at all times. Prior to
attending they were sent a letter (Appendix 21) outlining their admission details and
containing instructions about how they should alter their washouts in the days
leading up to the manometry. They were asked to cease all use of stimulant washout
media (i.e. Bisacodyl, Phosphate/Dulcolax enemas) for the 5 days before coming in
and to perform washout with water only on the Sunday and Tuesday.
The manometry catheter utilised was a custom-designed, 3.5mm (external diameter)
balloon tipped 9-lumen (8-channel) extruded silicone catheter (Dentsleeve, Adelaide,
South Australia, Australia) (Figure 21). The 8 recording side holes are spaced at
7.5cm intervals beginning 7.5cm from the tip of the catheter. The total length of the
catheter is 180cm. The central lumen inflates a 5ml Foley-type balloon situated 2cm
proximally from the tip of the catheter. The centre of the catheter is coated with










Figure 21 - Colonic manometric recording catheter.
The recording lumen were continuously perfused with degassed distilled water
(Figure 53). The water is driven by a low compliance pneumohydraulic perfusion
pump at a rate of 0.25ml/minute (Neomedix Systems Pty Ltd., Warriewood, New
South Wales, Australia). The 8 lumens are connected to 8 external pressure
transducers. The signals are amplified and digitised at 16Hz by preamplifiers using







Figure 22 - Manometry recording equipment.
Day 1 (Wednesday) - Catheter insertion
Children and their parent(s) were asked to attend the Royal Children's Hospital at
9AM. They were met by MC and the specialist gastrointestinal nurse (DS) and
taken to a treatment room in the gastrointestinal department. The procedure was
explained once more and if the participant was happy to proceed they were asked to
lie on an examination couch.
Having examined the appendicostomy site for any infection it was cleaned with
alcohol (70%) swabs and both the stoma and peristomal skin were liberally coated
with 1% lignocaine gel. After waiting an appropriate time for the lignocaine to
become effective, any existing device within the appendicostomy was removed (i.e.
chait button 128 or foley catheter). A lOFr cut-off feeding tube was then passed into
the appendicostomy and up to 5mg (5ml) of Bisacodyl (5mg/10ml pre-made
solution, Rhone-Poulenc, Baulkham Hills, New South Wales, Australia) was
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instilled. Bisacodyl has been shown to stimulate colonic contraction, by an unknown
mechanism, and is used to aid propulsion of the manometry catheter around the
colon (recording was commenced approximately 24hrs after the use of Bisacodyl to
minimise any possible residual effects) 107. The catheter was then lubricated and
inserted into the appendicostomy (Figure 23). The balloon was inflated with 3ml
water (to further aid antegrade propulsion) and the catheter was slowly advanced.
Once all 8 side holes had been inserted, with the final hole within the caecum, the
catheter was temporarily taped into position and the child was taken to fluoroscopy.
Figure 23 - Appendicostomy with manometry catheter in place.
In fluoroscopy, the child's abdomen was briefly screened and the exact position of
the catheter determined. If the catheter was seen to be looped back on itself (Figure
24) it was withdrawn and readvanced, then the screening was repeated. Once a
satisfactory position was obtained (Figure 25), the catheter was firmly secured with
Hyperfix hypoallergenic tape, the balloon was deflated, and the child was free for
the rest of the day. If the catheter was unable to be advanced without curling, then
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the appropriate length of catheter was again inserted and the catheter was secured.
The child was encouraged to walk around and eat normally for the next few hours, in
an attempt to encourage the colon to advance the catheter, before returning to
fluoroscopy for repeat screening. As previously stated, once the catheter was in a
satisfactory position it was taped and the child was free for the remainder of the day.
If an acceptable position was unattainable then further screening was performed on
the Thursday morning before commencing manometric recording.
Figure 24 - Fluoroscopy screening demonstrating looping of tip of
manometry catheter in descending colon.
Day 2 - Commencement of manometric recording
The child was either asked to attend the fluoroscopy suite at 8AM for repeat
screening, or, if the catheter position had already been deemed satisfactory, they
were asked to report to the surgical ward after breakfast (approx 9AM). The skin
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Figure 25 - Fluoroscopy screening demonstrating correct positioning of
manometry catheter (side hole 1 in rectum, side hole 8 in caecum).
integrity around the appendicostomy site was checked and the child settled into their
bed. As they had to remain recumbent or semi-recumbent for the next 24hrs they
were reminded that they would have to use a bedpan or bottle for toileting and it was
ensured that they had plenty of activities to occupy their time.
As calorie intake, along with the protein:carbohydrate:fat ratios in a meal, has been
shown to affect colonic motility, participants were provided with a special menu
(Appendix 22) with each menu choice consisting of 17% protein, 34% carbohydrate
and 45% fat. The calorific content of each meal was also standardised: breakfast
300kCal (1255kJ), lunch lOOOkCal (4184kJ) and dinner lOOOkCal (4184kJ). The
participants were discouraged from ingesting any other food or drink during the
recording period apart from water if absolutely necessary.
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Having attached the catheter to the perfusion channels and having ensured that each
recording site is active, recording was commenced and continued for an
uninterrupted 24hr period. During the study, participants were asked to complete an
event diary documenting all their activities such as eating, postural changes,
sleeping/waking, micturition/defecation, abdominal sensations and passage of flatus
(Appendix 23). Diary events were subsequently correlated with manometric data
during analysis of the recordings.
Regular checks were made throughout the 24hr period to ensure that the machine
was recording correctly and that the participant was not experiencing any
discomfort.
Day 3 - IFT session and catheter removal
After 24hrs the recording was complete. The final position of the manometry
catheter was checked with a plain abdominal film (this was also used to calculate the
relative positions of the recording side holes within the colon) (Appendix 24). The
appendicostomy site and catheter were once again lubricated with 1 % lignocaine gel
and the catheter was slowly withdrawn until it was removed. If the child had an




Analysis of the recordings was performed visually with propagating sequences
(antegrade and retrograde) and high amplitude propagating sequences (antegrade and
retrograde) identified using the criteria previously defined (see Introduction) 155.
Analysis was performed in a manner identical to that formerly described by
Bampton et al 155. Regional baselines were established, meaningful activity
identified visually, then the amplitude and velocity calculated with computer
assistance. Data were then entered into Excel and further analysis performed. For
antegrade and retrograde activity, the frequency, amplitude and distance of
propagation were compared before and after IFT using paired t tests. Data were also
examined to determine whether or not the propagating sequences were linked to each
other. Propagating sequences were defined as linked if they were in the same
direction with different originating side holes but overlapping side hole activity. The
frequency of events was expressed in terms of 24 separate hourly periods. All data
are expressed as mean (± SEM) unless otherwise indicated. Recordings were also
examined for possible waking and post-prandial responses, defined as an increase in
activity for the hour following the event (recorded in the patient diary). All p values
< 0.05 were considered as statistically significant.
Bowel diary and QoL data were analysed as previously described in Chapter 7.
8.4 Results
Six children underwent colonic manometry pre- and post-treatment with IFT (12
studies). Their demographics are shown below. Complete data were available for
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analysis on 5 of the subjects due to a technical error that resulted in 8 hours of
irretrievable post-IFT data for one subject (subject 6). This meant that paired
analysis (pre- and post-IFT) could not be performed for this subject.
Table 31 - Demographics of study population.
Number of children 6
Male:Female 5:1
Average age (yrs) 13.4
Male/Female (yrs) 13.8/11.8
Age range (yrs) 9.2-19
Average duration of symptoms (yrs) 12.6
Range of duration of symptoms (yrs) 6.2-19.0
Symptoms since birth 4/6
Abdominal pain 2/6
Average score /10 4.5
Soiling 5/6
Severe (daily/constant) soiling 2/5
Appendicostomy 6/6
Weight
Underweight (BMI <5th centile) 0/6
Healthy (BMI 5-85th centile) 3/6
Overweight (BMI 85-95th centile) 0/6
Obese (BMI >95th centile) 3/6
Medication 6/6
The catheter tip was located in the lower descending colon or sigmoid colon in 9 of
the 12 studies. In two subjects, despite having all side holes present within the colon,
the catheter only reached the splenic flexure. All subjects tolerated the procedure
well and did not request the catheter to be removed.
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8.4.1 Colonic activity
The colonic activity for each subject (antegrade and retrograde activity and high
amplitude activity) is shown in tables 32-35. Data for subject 6 are incomplete as
they lack 8hours of recorded material.
Table 32 - Frequency and properties of antegrade colonic activity.
Subject Pre/Post
IFT


















Subject 1 Pre 26 2 4 40 0.83
Post 93 4 3 15.4 2.15
Subject 2 Pre 1 1 8 11 4.77
Post 128 6 3 15.2 2.01
Subject 3 Pre 31 5 3 26.4 1.70
Post 57 1 3 25.8 1.18
Subject 4 Pre 61 6 3 16 1.66
Post 155 6 3 23.2 1.41
Subject 5 Pre 128 5 3 13.6 2.35 .
Post 140 1 3 21.7 1.67
Subject 6 Pre 60 1 3 17.9 1.82
Post * 24 1 3 27.1 1.40
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Subject 1 Pre 13 5 4 33.9 0.96
Post 18 6 3 35.7 1.05
Subject 2 Pre 0
Post 14 1 5 26.4 2.68
Subject 3 Pre 10 1 7 45.8 0.60
Post 15 1 4 39.8 0.89
Subject 4 Pre 1 3 6 32.0 1.17
Post 7 1 8 49.6 1.27
Subject 5 Pre 0
Post 0
Subject 6 Pre 7 5 4 34.0 0.77
Post * 4 5 3 34.0 0.73
Table 34 - Frequency and properties of retrograde colonic activity.




















Subject 1 Pre 0
Post 20 8 3 6.7 2.81
Subject 2 Pre 4 6 6 25.3 2.08
Post 37 8 3 16.9 1.31
Subject 3 Pre 7 8 3 11.1 2.40
Post 14 8 3 12.6 1.66
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Subject 4 Pre 53 4 3 12.8 1.98
Post 78 8 3 17.2 1.53
Subject 5 Pre 134 3 3 14.9 1.57
Post 384 5 3 11.9 1.97
Subject 6 Pre 77 8 3 7.6 2.85
Post * 17 8 3 6.6 3.25






















Subject 1 Pre 0
Post 0
Subject 2 Pre 3 6 6 30.0 1.18
Post 0
Subject 3 Pre 0
Post 1 8 4 36.0 0.63
Subject 4 Pre 1 3 3 17.0 0.88
Post 1 8 3 22.0 0.68
Subject 5 Pre 0
Post 0
Subject 6 Pre 0
Post * 0
8.4.1.1 Frequency of propagating sequences (PS)
Following treatment with IFT there was an increase in total colonic activity (mean 89
± 47 vs. 221 ± 80; p = 0.03) (Figure 26). There was an increase in both antegrade
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(mean 49 ± 22 vs. 115 ± 18;/? = 0.03) and retrograde (mean 40 ± 25 vs. 107 ± 70; p

















Figure 26 - Total number PS, antegrade and retrograde, in each 24hr
study, before and after treatment with IFT (paired t-test).
mean (SEM)
Pre-IFT Post-IFT
Figure 27 - Number of antegrade propagating sequences (APS), in each
24hr study, before and after treatment with IFT (paired t-test).
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Figure 28 - Total number of retrograde propagating sequences (RPS), in
each 24hr study, before and after treatment with IFT (paired t-test).
Although there was an increase in antegrade high amplitude propagating sequences
(HAPS) (mean 5±3vs. 11 ±3 p = 0.06), there was a decrease in high amplitude
retrograde propagating activity (HARPS) (mean 0.8 ± 0.6 vs. 0.4 ± 0.2; p = 0.59).
8.4.1.2 Amplitude of propagating sequences
The mean amplitude of antegrade PS was 52 ± 10 mm Hg pre-treatment compared to
36 ± 4 mm Hg post-treatment (p = 0.09) and the mean amplitude of retrograde PS
was 34 ± 9 mm Hg pre-treatment compared to 22 ± 1 mm Hg post-treatment (p =
0.24). With regards to HAPS, the mean amplitude prior to IFT was 98 ± 7 mm Hg
compared to 90 ± 14 mm Hg after IFT (p = 0.61).
8.4.1.3 Velocity and propagation distance
There was no significant change in average velocity of either antegrade or retrograde
propagating sequences following treatment with IFT (antegrade - 1.7 ± 0.2 cm/sec
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vs. 1.6 ± 0.2 cm/sec; p = 0.78 and retrograde - 2.2 ± 0.2 cm/sec vs. 1.9 ± 0.3 cm/sec;
p = 0.43). There was also no significant difference in HAPS velocity pre- and post-
intervention (0.9 ± 0.1 cm/sec vs. 1.0 ± 0.1 cm/sec; p = 0.20).
There was no significant difference in the propagation distance when the average
number of side holes travelled by each propagating sequence was compared pre- and
post-intervention. This was so for antegrade (4.2 ± 0.2 vs. 4.5 ± 0.1; p = 0.43),
retrograde (3.9 ± 0.6 vs. 3.4± 0.1; p = 0.53) and high amplitude antegrade (5.0 ±0.3
vs. 5.8 ±0.8;/? = 0.19).
8.4.1.4 Site of origin of propagating sequences
Pre-treatment with IFT, the most common site of origin of antegrade PS was the
caecum (Rl) (mean ± SD of total activity = 35% ± 37%). The most common site of
retrograde PS origin was the splenic flexure/descending colon (mean ± SD of total
activity = 26% ± 20%) (Figure 29).
Post-treatment with IFT, the most common site of origin of antegrade PS was still the
caecum (Rl) (mean ± SD of total activity = 25% ± 13%). However, the most
common site of retrograde PS origin had become the rectosigmoid (mean ± SD of
total activity = 58% ± 30%) (Figure 30).
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Figure 29 - Distribution of site of origin (% total activity) for both
antegrade and retrograde propagating sequences pre-treatment with
IFT.
Figure 30 - Distribution of site of origin (% total activity) for both




As previously stated, sequential propagating sequences were defined as being
regionally linked if they started at different side holes, were in the same direction and
had overlapping side hole activity. In addition, if 3 or more regionally linked PS
occurred sequentially, this was defined as a colonic complex. Pre treatment with
IFT, 65% ± 13% (mean ± SD) of antegrade propagating sequences and 61% ± 10%












Figure 31 - % of total colonic activity, antegrade and retrograde, that
could be defined as being regionally linked pre-treatment with IFT.
Post treatment with IFT, only 56% ± 10% (mean ± SD) of antegrade propagating
sequences and 33% ± 23% (mean ± SD) of retrograde propagating sequences could





Figure 32 - % of total colonic activity, antegrade and retrograde, that
could be defined as being regionally linked post-treatment with IFT.
When looking at the antegrade-linked activity, pre-treatment 4 of the 5 subjects had
activity that formed colonic complexes whereas post-treatment all 5 subjects had
colonic complexes (36% ± 8.5% vs. 44.5% ± 6.0% of total antegrade linked activity;
p = 0.18). With regards to the retrograde linked activity, only 2 of the 5 subjects
formed retrograde colonic complexes prior to intervention compared to 3 subjects
following IFT (15.9% ± 12.5% vs. 26.4% ± 11.0% of total antegrade linked activity;
p = 0.35).
8.4.1.6 Waking and postprandial responses
Recordings were examined for waking or postprandial responses identified by a high
amplitude activity following waking or ingestion of foodstuffs (Figure 33). Times of
meals obtained from the patient diary (Appendix 33) were correlated with
manometric events.
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Data were available for 4 subjects both pre and post intervention with interferential
therapy. The results are shown in Table 36.
Figure 33 - Manometric recording illustrating a post-prandial response.
There are multiple high amplitude propagating sequences (HAPS) one
originating from the splenic flexure (channel 5) and another in the caecum
(channel 1).
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Table 36 - Number of subjects with waking and post-prandial responses
before and after intervention with IFT.
Post-prandial Response
Waking Response Breakfast Lunch Dinner
Pre IFT 0/4 0/4 1/4 2/4
Post IFT 3/4 2/4 1/4 3/4
8.4.2 Bowel diary data
8.4.2.1 Defecation
8.4.2.1.1 Spontaneous defecation
The mean number of 'spont' defecation episodes per week for each 28 day treatment
period for the manometry group are shown in table 37. All data sets demonstrated
normal Gaussian distribution.
Table 37 - Table showing episodes of 'spontaneous' defecation (mean +
SD) pre- and post- intervention.




Pre-treatment (4 weeks) 1.60 1.10
Treatment (4 weeks) 0.95 1.24
1st post treatment (4 weeks) 2.30 0.89
2nd post treatment (4 weeks) 1.45 0.87
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There was no statistical difference in the number of episodes of 'spont' defecation
when comparing the pre-treatment with the treatment (mean 1.60 vs. 0.95; p = 0.38),
first post-treatment (mean 1.60 vs. 2.30; p = 0.35) or second post-treatment (mean
1.60 vs. 1.45; p = 0.82) periods.
8.4.2.1.2 Sit defecation
The mean number of 'sit' defecation episodes per week for each 28 day treatment
period for the manometry group are shown in table 38. All data sets demonstrated
normal Gaussian distribution.
Table 38 - Table showing episodes of 'sit' defecation (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 2.00 1.36
Treatment (4 weeks) 2.15 1.26
1st post treatment (4 weeks) 2.25 1.57
2nd post treatment (4 weeks) 1.85 1.61
There was no statistical difference in the number of episodes of'sit' defecation when
comparing the pre-treatment with the treatment (mean 2.00 vs. 2.15; p = 0.70), first
post-treatment (mean 2.00 vs. 2.25; p = 0.62) or second post-treatment (mean 2.00
vs. 1.85; p = 0.79) periods.
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8.4.2.1.3 Total defecation
The mean number of 'total' defecation episodes per week for each 28 day treatment
period for the manometry group are shown in table 39. All data sets demonstrated
normal Gaussian distribution.
Table 39 - Table showing episodes of 'total' defecation (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 3.60 1.51
Treatment (4 weeks) 3.10 0.14
1st post treatment (4 weeks) 4.55 1.20
2nd post treatment (4 weeks) 3.30 1.55
There was no statistical difference in the number of episodes of total defecation when
comparing the pre-treatment with the treatment (mean 3.60 vs. 3.10; p = 0.53), first
post-treatment (mean 3.60 vs. 4.55; p = 0.28) or second post-treatment (mean 3.60
vs. 3.30; p = 0.74) periods.
8.4.2.2 Soiling
9.3.2.2.1 Stain soiling
The mean number of 'stain' soiling episodes per week for each 28 day treatment
period for the manometry group are shown in table 40. All data sets demonstrated
normal Gaussian distribution.
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Table 40 - Table showing episodes of 'stain' soiling (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 1.30 2.91
Treatment (4 weeks) 0.50 0.87
1st post treatment (4 weeks) 0.30 0.67
2nd post treatment (4 weeks) 0.30 0.54
There was no statistical difference in the number of episodes of 'stain' soiling when
comparing the pre-treatment with the treatment (mean 1.30 vs. 0.50; p = 0.44), first
post-treatment (mean 1.30 vs. 0.30; p = 0.37) or second post-treatment (mean 1.30
vs. 0.30; p = 0.40) periods.
8.4.2.2.2 Scrape soiling
The mean number of 'scrape' soiling episodes per week for each 28 day treatment
period for the manometry group are shown in table 41. All data sets demonstrated
normal Gaussian distribution.
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Table 41 - Table showing episodes of 'scrape' soiling (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 0.75 1.68
Treatment (4 weeks) 0.40 0.76
1st post treatment (4 weeks) 0.85 1.76
2nd post treatment (4 weeks) 0.60 1.34
There was no statistical difference in the number of episodes of 'scrape' soiling when
comparing the pre-treatment with the treatment (mean 0.75 vs. 0.40; p = 0.45), first
post-treatment (mean 0.75 vs. 0.85; p = 0.18) or second post-treatment (mean 0.75
vs. 0.60; p = 0.37) periods.
8.4.2.2.3 Total soiling
. The mean number of 'total' soiling episodes per week for each 28 day treatment
period for the manometry group are shown in table 42. All data sets demonstrated
normal Gaussian distribution.
There was no statistical difference in the number of episodes of 'total' soiling when
comparing the pre-treatment with the treatment (mean 1.40 vs. 0.85; p = 0.50), first
post-treatment (mean 1.40 vs. 1.10; p = 0.46) or second post-treatment (mean 1.40
vs. 0.85; p = 0.42) periods.
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Table 42 - Table showing episodes of 'total' soiling (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 1.40 3.13
Treatment (4 weeks) 0.85 1.51
1st post treatment (4 weeks) 1.10 2.32
2nd post treatment (4 weeks) 0.85 1.76
8.4.2.3 Abdominal pain
The mean number of episodes of abdominal pain per week for each 28 day treatment
period for the manometry group are shown in table 43. All data sets demonstrated
normal Gaussian distribution.
Table 43 - Table showing episodes of abdominal pain (mean + SD) pre-
and post- intervention.




Pre-treatment (4 weeks) 0.60 0.84
Treatment (4 weeks) 0.15 0.13
1st post treatment (4 weeks) 0.45 0.67
2nd post treatment (4 weeks) 0.45 0.67
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There was no statistical difference in the number of episodes of abdominal pain when
comparing the pre-treatment with the treatment (mean 0.60 vs. 0.15; p = 0.26), first
post-treatment (mean 0.60 vs. 0.45; p = 0.21) or second post-treatment (mean 0.60
vs. 0.45; p = 0.77) periods.
8.5 Discussion
Colonic manometry is slowly becoming recognised not only as a research tool but
also as a clinical diagnostic measure for assessing colonic motor function. However,
most centres still only perform short, 4 hour, recordings with colonoscopically placed
recording catheters 5 77 158. It is only recently that the technique of antegrade catheter
placing via an appendicostomy has been described in children that requires no
sedation and enables longer recording times 76. By employing this technique, this
study was able to compare 24 hour colonic manometric activity before and after
intervention with interferential therapy. One of the advantages of 24-hour recording
is that it allows satisfactory assessment of waking and post-prandial responses as
well as providing sufficient length of recording in order to adequately ascertain the
presence or absence of high amplitude activity. Unfortunately, in order to obtain the
manometric recordings the subjects have to remain in bed for 24 hours, in a
recumbent or semi-recumbent position, which may decrease the amount of observed
colonic activity. However, since in this study both recordings were obtained using
an identical protocol, the results and subsequent conclusions should not be affected.
Other advantages of this method of insertion compared to colonoscopic placement is
that it does not require a prepared colon and that it provides recording from the
whole colon rather than just the distal portion 76.
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This study found that total colonic activity increased following intervention with IFT
(p = 0.03). This was, however, only so for antegrade activity (p = 0.03) and not so
for retrograde activity (p = 0.22). Although, there was an increase in high amplitude
antegrade propagating sequences following electrical it did not reach statistical
significance (p = 0.06). Although the mechanism by which transcutaneous electrical
stimulation could perhaps influence colonic motor activity remains unclear, the
reactivity of the colon appears to increase with a small but consistent increase in
antegrade colonic activity. Potential theories include increased activity of the
colonic pacemaker interstitial cells of Cajal (ICC) or changes in the balance of
excitatory and inhibitory neuronal transmission 20. The latter possibly occurring
secondary to alterations in neurotransmitter release, or augmented nerve fibre
activity, or by an as yet completely unidentified mechanism.
Although some centres diagnose subjects with STC based on the apparent absence of
high amplitude activity 77 158, previous 24-hour studies have shown that our cohort
with proven STC on nuclear scintigraphy do in fact have the capacity to generate
high amplitude activity although there is a reduction in the frequency of such events
76. The current study showed that there was a small, and nearly significant (p =
0.06), increase in the number of HAPS observed in each 24-hour study period
following intervention with IFT. Normal data from controls predict that there should
be 8.5-11.5 HAPS per 24-hour period l55; the mean number of events per 24-hours
increased from 5 pre-IFT to 11 following IFT showing that the majority of children
are experiencing, or at least approaching, normality in terms of expected HAPS
frequency. HAPS are often the result of colonic physiological reactions such as
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waking or post-prandial responses. Following electrical stimulation there appeared
to be an increase in these physiological responses - both following waking and
eating. Early morning increases in activity can be difficult to differentiate between
post-waking and post-breakfast responses; however 3 of the 4 subjects also
experienced an increase in HAPS following their evening meal suggesting that they
did have the ability to generate a true post-prandial response.
Despite having a small increase in antegrade colonic motor activity after IFT, there
was no change in amplitude, velocity or propagating distance. If anything, there was
a trend towards a decrease in amplitude with regard to both antegrade and retrograde
activity. Although it would be reasonable to assume that a decrease in amplitude of
antegrade activity would affect the efficacy of forward propulsive movement of
faecal matter, it may well be that any effect is in part counteracted by the increase in
total number of antegrade propagating sequences. It has previously been
demonstrated that low amplitude sequences are in fact able to produce propulsive
movement of intestinal contents 324. Little is known about the function of retrograde
propagating sequences but they are present in healthy control subjects with an
approximate ratio of antegrade:retrograde activity of 3:1 155. As such, nothing can
be concluded from a decrease in the amplitude of retrograde activity since it is
unclear whether or not this is deleterious or in fact advantageous.
There was no significant change in velocity of antegrade, retrograde or high
amplitude propagating sequences when comparing pre- and post- intervention values
(see section 8.4.1.3). Previous studies have highlighted that the mean velocity of
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HAPS in normal subjects is considerably slower than the mean conduction velocity
of non-high amplitude antegrade activity 155. Pre-electrical therapy recordings in the
current study population supported these findings (0.9 ± 0.1 cm/sec vs. 1.7 ± 0.2
cm/sec; p = 0.03) and the difference was unaffected by IFT.
There was no alteration in the mean propagating distance of antegrade, retrograde or
high amplitude antegrade propagating sequences after electrical therapy (see section
8.4.1.3). It has been well documented that in healthy controls high amplitude
propagating sequences propagate further than lower amplitude sequences 155. Again,
pre-intervention data for the study subjects supported these findings (5.0 ± 0.3 vs. 4.2
± 0.2; p - 0.06) and this difference remained unaltered following electrical
stimulation.
Prior to treatment with IFT, the majority (34.9%) of antegrade propagating sequences
originated in the caecum. Although following intervention the commonest site of
origin remained the caecum (24.9%), the distribution was more evenly spread along
the colon. Previous studies in normal subjects have shown that antegrade
propagating sequences arise more frequently in the caecum than in any other region
155. It has recently been proposed that it may be favourable to exhibit local regional
variation in the site of propagation due to the concept that this might produce a more
effective propulsive action. In addition, colonic motor activity is now being defined
as exhibiting regional linkage if sequential propagating sequences start at different
sites but are in the same direction with overlapping side hole activity. It is believed
that the amount of colonic activity that is regionally linked is directly related to the
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efficacy of motor function and that increasing the percentage of linked propagating
sequences should improve colonic performance. Following intervention with
electrical therapy there was no increase in colonic regional linkage with an actual
decrease seen with regards to retrograde activity (61% ± 10% vs. 33% ± 23% (mean
± SD)). There was however an increase in the proportion of regionally linked
activity that in turn formed colonic complexes (a sequence of 3 or more regionally
linked PS) following IFT. This was so for both antegrade and retrograde activity.
This suggests that to a certain extent the increase in colonic propagating sequences is
represented by disorganised activity; however, some subjects that did not exhibit any
ability to form colonic complexes prior to intervention but did do so following
therapy with electrical stimulation. It may be that more time is required for the colon
to organise the increased activity which would correlate with the fact that some
subjects seemed to experience a lag time between receiving IFT and experiencing
clinical improvement.
None of the subjects reported any problems either during the insertion of the
recording catheter or over the subsequent 24-hour recording period. The study
confirms that following careful explanation and adequate preparation, recording
catheters can be inserted straightforwardly and repositioned via an existing
appendicostomy without the need for sedation or analgesia 76.
With regards to the bowel diary data, there was no significant change in frequency of
defecation, soiling or abdominal pain after treatment with IFT. These results are
similar to those found in chapter 6. Since patients are managed with
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appendicostomies they have relatively few episodes of stooling and soiling and so
data analysis is subsequently difficult. The subjects also reported relatively few
episodes of abdominal pain pre-treatment.
All aspects of the current study were significantly hampered by the number of
participants. With data only available for 5 subjects, it is hard to make meaningful
statistical comparisons. With such small numbers, even the addition of an additional
subject can lead to very different conclusions - had the full set of data been available
for the 6th subject, then the same results (including the small increase in antegrade
activity) may not have been evident.
In conclusion, this study shows that following treatment with transcutaneous
interferential electrical therapy, subjects with STC have an increase in the total
number of propagating sequences as measured by 24-hour continuous manometry,
however, it is only a small increase and only with regards to antegrade propagating
sequences. There is no change with regards to the site of origin, distance travelled or
average amplitude for both antegrade and retrograde activity. There does, however,
seem to be an increase in the amount of high amplitude propagating sequences in
response to eating and waking. There was no effect on frequency of defecation,
soiling or abdominal pain. The current study represents novel data that has not been
previously reported in any study. Although findings are minimal, further
investigation and participant recruitment is warranted in order to ascertain whether or
not there is a potential clinical application for IFT in the management of children




Chronic childhood constipation is a common and debilitating condition. Although
the majority of children with constipation respond to simple measures, some
unfortunately fail to gain any benefit from laxatives, behavioural therapy or intensive
toileting programs. These children are faced with a life of infrequent defecation,
intractable soiling and abdominal pain 1920279299
This thesis aimed to ascertain the affect on quality of life of longstanding chronic
slow transit constipation and found that children described a significant impairment
in their physical and psychosocial functioning when compared to age matched
controls. It then sought to determine whether or not nuclear scintigraphy can be
regarded as a reliable means of assessing colonic transit in children with STC and
concluded that appropriate test-re-test reliability does appear to exist. The thesis then
proposed to evaluate the potential application of transcutaneous electrical stimulation
in the form of interferential therapy in the management of children with STC by
means of a prospective, single blind, randomised controlled trial. It found that there
was no effect on stool frequency or soiling but there was a small improvement in
abdominal pain. Although there did not appear to be any improvement in QoL when
comparing the two treatment arms, when looking solely at the group that received
real therapy, there was significant improvement in both their physical and
psychosocial QoL. When looking at colonic transit before and after intervention,
there was a small, but consistent, decrease in colonic transit time after treatment with
real IFT. Finally, the thesis considered the potential effect of IFT upon colonic
activity as measured by colonic manometric catheters sited in an antegrade manner
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through appendicostomies in children with pre-existing appendix stomas. This study
showed that there was an increase in antegrade manometric activity, but no effect on
all other recording parameters.
It is not only the child who is affected but also their parents and siblings as often the
whole family schedule has to be based around ease of access to toilets and changing
facilities. Any excursion, or overnight stay, that is out of the ordinary has to be
carefully planned in advance in order to avoid potentially embarrassing situations.
With this in mind it is perhaps unsurprising that in the study reported in chapter five,
children with STC describe a significant deficit in their quality of life with both their
physical and emotional functioning clearly affected 278. What is also maybe
unexpected, is that the level of quality of life that children with slow transit
constipation and their parents depict is similar to that reported by children, and
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parents of children, with malignancy . This highlights that although it is often
perceived as a relatively benign condition, constipation is in fact extremely
deleterious to both physical and mental health 260. In association with the recognition
of the importance of QoL evaluation in clinical research, there have been other recent
studies that have sought to evaluate the effect of QoL in children with chronic
constipation and soiling. A study by Grootenhuis et al. similarly reported that
children with a higher frequency of soiling episodes described poorer emotional and
979
social functioning . Two recent reviews of the impact of constipation in children
and adults (that both included the study reported in this thesis) concluded the impact
of constipation on QoL is significant and comparable with other common chronic
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conditions, both gastrointestinal and non-gastrointestinal " . They also
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highlighted the fact that most existing QoL tools are not able to accurately assess the
impact of constipation and soiling on QoL in children and that few studies have
looked at the effect of treatment in the paediatric population. Further research in this
area is evidently required and justified based on evidence to date.
There are currently a number of criteria that are utilised to diagnose subjects with
slow transit constipation; clinical symptoms of constipation need to be associated
with specific radiographic, and in some instances manometric, findings. It is
important to be able to reliably diagnose and identify those who experience
constipation secondary to slow colonic transit as it becoming more evident that they,
unlike others, will not respond to conventional management. Children with chronic,
treatment-resistant constipation therefore require to be separated into those with
delayed global colonic transit and those with anorectal holdup. Colonic transit time
has traditionally been assessed by radio-opaque marker studies, however their
consistency in subjects with colonic inertia has been questioned 57 61. In addition,
there needs to be a dependable, objective, means of assessing response to treatment.
More recently, gastrointestinal transit time has been evaluated using nuclear
scintigraphy 62-70. This method has both been validated 138 and found to have
satisfactory inter-observer reliability 298. Nuclear transit studies (NTS) allow
accurate assessment of regional colonic transit with multiple images of the colon
being easily obtained with a relatively low radiation dose 147. In addition, in contrast
to marker studies, overlapping regions of the gastrointestinal tract do not pose a
problem when viewing sequential radio-isotope images. Some studies have
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suggested that there may be a difference between the passage of radioisotope and
radio-opaque markers with the former possessing the ability to more accurately
reflect the passage of physiological chyme 304. It has also been proposed that
indigestible solid particles do not move with a meal, and may not be handled by the
colon in the same manner as stool 61.
There are, however, no studies that have evaluated the test-re-test reliability of
nuclear scintigraphy over time. If indeed GITT is to be used as a consistent means of
objective assessment following changes in therapy, then it important that any
changes can reliably be attributed to the treatment and not to chance. The study
described in chapter six, the first of its kind, demonstrates that in a state of colonic
inertia, NTS are indeed reproducible and can therefore perhaps be relied upon as
both a diagnostic tool and a means of assessing response to treatment. It must
however be remembered that, despite their potential shortfalls in subjects with
colonic inertia, the gold standard for assessing colonic transit time still remains
radio-opaque marker studies and presently there are few centres that either have the
ability, or choose, to use nuclear scintigraphy to evaluate colonic transit.
Currently, the treatment options for children with chronic constipation in whom
conventional measures have failed are limited. In some the only remaining choice is
surgical intervention in the form of either colonic resection of redundant, or dilated,
121 333bowel " or appendicostomy formation with subsequent instigation of antegrade
l * 196 128
colonic enemas in an attempt to achieve continence . Both of these procedures
are invasive and unfortunately, resultant clinical responses are variable. A recent
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review of surgical options for treatment of constipation in children and adults
highlighted the importance of patient selection and that surgery should be thought of
as a last resort following exhaustion of all dietary, pharmacological and behavioural
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options
Electrical therapy is a longstanding treatment modality that has been utilised, with
varying success, for a multitude of complaints and ailments 165~167. Transcutaneous
electrical therapy is a well recognised treatment modality in children as it is painless,
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well-tolerated and can be administered in an out-patient, or even home, setting
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IFT is a form of electrical stimulation that involves the transcutaneous application,
via electrodes, of two crossed, slightly out of phase, medium-frequency currents
which produces an amplitude-modulated current effect within the tissues. The
frequency, amplitude and pulse width of the output waveforms can all be regulated.
Conventionally, currents within the range of 3,900 to 4,100Hz are used, as lower
frequency currents can result in uncomfortable polarisation effects in the superficial
tissues. Typically a quadripolar model is adopted where four electrodes are placed
over the target area in such a distribution that their current paths cross directly over
the relevant organ(s). IFT has been utilised, with significant success, in the
management of both adults and children with detrusor instability 328. As yet, its
mechanism of action remains unknown however it is thought to act via means of
neuromodulation.
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Chapter 7 reports a randomised controlled trial assessing the potential use of IFT in
the treatment of children with STC. The study found that subjects who received real
IFT experienced no alteration in either the frequency of their stooling or soiling when
compared to subjects who received placebo stimulation. Linear analysis however,
showed a small decrease in soiling in those subjects who were randomised to receive
real intervention. Both intergroup and linear analysis suggested a small
improvement in abdominal pain in subjects in the real treatment arm.
Given that there appeared to be no effect on the frequency of either spontaneous
stooling or timed 'sit' stooling, it might be fair to assume that IFT has no prospective
role in the treatment of children with STC. Alternatively, in this highly selected
group of subjects for whom treatment options, apart from surgical intervention, are
becoming limited, if there is any potential benefit from a non-invasive therapy than
full evaluation should be performed. The current study had small numbers and many
of the outcome measures were difficult to objectively assess. Children with STC,
unlike the majority of children with chronic constipation, do not always display
infrequent defecation. Instead, they often have frequent passage of pasty, poor
quality stools. In an individual subject, a decrease in stool frequency, perhaps
associated with an improvement in stool consistency, may represent a better clinical
outcome than an increase in stooling.
Since electrical therapy is a recognised treatment modality for pain, and has indeed
be utilised with reported success in subjects with functional abdominal pain it is
unclear whether or not this outcome was due to an improvement in the underlying
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gastrointestinal pathology or simply due to electrically induced neuromodulation of
painful stimuli.
Children who received real IFT reported an improvement in their quality of life when
paired analysis before and after treatment was performed in each treatment arm.
This was reflected by an increase in both self-perceived physical and psychosocial
scores. Several studies have now highlighted the deleterious effect of abdominal
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pain and soiling associated with constipation in children . The change in
QoL seen in the real intervention group could potentially be linked to the small
improvement in these subjects in association with these symptoms. It must again be
remembered, however, that the study contained small numbers of participants in each
treatment arm. If, however, the post-intervention data are compared to the control
values obtained in chapter 5, the real treatment group no longer display significantly
poorer QoL than the control subjects (mean 86.0 vs. 81.1; p = 0.09) whereas the
placebo group still do (mean 86.0 vs. 78.1; p = 0.003).
Although it is essential for any successful therapy to produce an improvement in
clinical symptoms, it is also important that it evokes some kind of objective,
quantifiable response. Children with STC have characteristic, reproducible patterns
in their colonic motility with regards to nuclear transit studies (NTS). Those subjects
in the real treatment arm of the study had a small significant decrease in their colonic
transit time, as measured by nuclear scintigraphy suggesting that IFT might have
some effect upon colonic motility. Unfortunately, the numbers of studies available
for analysis are small and so the significance of the findings should be interpreted
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with caution. The clinical significance of the small increase in colonic transit is also
questionable, however, the studies were performed after only 12 treatment sessions
with IFT. It remains unknown as to whether or not a prolonged course of treatment
might further decrease colonic transit time or the inclusion or more data might negate
any positive findings. As with the other studies described, there is the need for
further investigation to be executed.
The final study investigated the effects of IFT on colonic activity as measured by
colonic manometry. This, again, is an objective means of assessing any effect of IFT
upon colonic function. However unfortunately, the number of subjects available for
recruitment was even smaller than those in the previous studies. The only consistent
effect of IFT appeared to be an increase in antegrade colonic activity. However,
some subjects post intervention also appeared to have developed 'normal'
physiological responses to waking and/or eating along with an overall increase in
their high amplitude activity. As with the previous studies, although the results are,
at best, inconclusive any positive findings warrant the instigation of additional
investigation of IFT as an adjunctive treatment modality.
The mechanisms by which IFT may have any potential effect remain unclear.
Possible means of action include alteration of activity of the colonic pacemaker
interstitial cells of Cajal (ICC) or changes in the balance of excitatory and inhibitory
neuronal transmission, either due to alterations in neurotransmitter release or due to
augmented nerve fibre activity. A recent review by Ward of transcutaneous
electrical stimulation using alternating current sought to offer some insight into its
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mechanism of action . He suggests that claims that cross-modulated current
delivered via quadripolar stimulation (rather than bipolar stimulation) produces
stimulation at greater depth are unsubstantiated and that 'current spreading' means
that there will not be a region at the centre of intersection of the currents where
maximum stimulation occurs. This is due to current flow between adjacent
electrodes occurring because of shorter-distance, lower-resistance pathways. The
author also highlights that with alternating current, the biphasic waveform can be
sinusoidal or rectangular and the current can be delivered continuously, in bursts or
in sinusoidally modulated bursts; in total there are 5 different parameters that need to
be specified in order to describe an IFT waveform. As a consequence, the greater
number of current parameters that exist, the greater the number of possible treatment
permutations and combinations that exist. In addition, it remains unknown what the
optimum treatment regimen entails with regards to treatment frequency, duration of
treatment and electrode placement.
In the current study, electrodes were placed paraspinally at the level of T9-L2 and on
the abdominal wall at the level of the umbilicus. In this position, current could
potentially be exerting influence upon local sensory and motor nerves in the skin,
spinal nerves, sympathetic and parasympathetic nerves, enteric nerves or cells (ICC
or smooth muscles) within the bowel wall. The lack of immediate response (i.e.




Interferential therapy represents a painless, well-tolerated, non-invasive and
relatively inexpensive form of therapy that may have a potential clinical application
in this sub-group of children with chronic constipation. Further studies are required
to attempt to quantify its mode of action and to delineate optimum treatment
parameters. If these can be more accurately determined then electrical therapy may
once again become a widely accepted and applied therapeutic modality.
9.1.1 Animal studies
IFT utilises the transcutaneous application of current and as yet the degree of tissue
penetration is unknown; this knowledge could provide a vital key as to its means of
action. Animal studies involving the use of implantable electrodes have been
suggested in order to attempt to ascertain both the depth of attainable dissemination
of current and also any changes in actual electrical conduction within tissues. If, in
the context of transcutaneously applied current, implanted electrodes were able to
demonstrate a direct change in colonic electrical activity then neuromodulation
would seem a less likely mechanism of action. Animal studies are not without their
own problems with one obvious discrepancy being that they currently involve
disease free models. In addition, in order to implant electrodes in the bowel wall, not
only is general anaesthesia required but the bowel has to be both exposed and
handled; factors that have a well-documented association with intestinal stasis.
Therefore, in order to adequately determine whether or not colonic electrical activity
is affected, studies need to be designed to ensure that animals are appropriately
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recovered following electrode placement, before transcutaneous stimulation and
subsequent recording is commenced.
9.1.2 Different modes of current delivery
Although IFT is relatively inexpensive, it is not available in all centres and usually
requires to be administered by a qualified practitioner - most often a physiotherapist.
There exists a much more widely available, cheaper and 'home friendly' form of
electrical therapy, namely TENS. In addition to determining the optimum treatment
parameters of IFT, it is important to determine whether or not similar results can be
achieved following the administration of TENS.
In addition, since the completion of this thesis, there has become available a portable,
battery-operated, home treatment amenable form of IFT. A pilot study assessing 11
children having daily stimulation delivered at home via a portable IFT unit found that
defecation increased in 9 of the 11 subjects 339.
9.1.3 Other clinical applications
This study concentrated only on children with intestinal dysmotility secondary to
slow transit constipation. There are many other conditions resulting in delayed
passage of intestinal contents that may also benefit from electrical therapy. In
particular, although for some children with Hirschsprung's disease surgical resection
of the aganglionic bowel is curative, there are many in whom refractory constipation
is an ongoing challenge. These children would make excellent subjects for ongoing
research since treatment options are limited and often ineffectual.
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If a clear benefit can be demonstrated by the clinical application of electrical therapy
then not only could it be applied in cases of chronic intestinal dysmotility, but
perhaps also in the acute setting where a prolonged ileus is the result of either an
underlying condition (i.e. sepsis, burns, drugs) or a post-operative complication.
Improvement in intestinal function in many of these patients could result in an
increase in their nutritional state and immune function along with decreasing their
time to recovery and subsequent discharge from hospital.
In conclusion, this study describes a novel approach to the evaluation and subsequent
treatment strategies for children with slow transit constipation. It presents evidence
that routine assessment of children with constipation should involve appraisal of QoL
and that nuclear scintigraphy is an alternative, reliable means of assessing colonic
transit. It also provides data that support the further assessment of an entirely novel
treatment mode - transcutaneous electrical stimulation with interferential therapy.
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Appendix 1 - Fecal Incontinence Questionnaire 231
Have you had problems with leakage of stool (accidents or soiling because of the
inability to control the passage of stool) until you reached a toilet? (Check answer.)
[] No
[] Yes
IN THE LAST YEAR, did you have to take medication (like antidiarrheals, Lomotil,
Imodium AD, etc.) to prevent leakage of stool? (Check one answer.)
[] No
[] Yes, sometimes (less than 25% of the time)
[] Yes, often (more than 25% of the time)
[] Yes, usually (more than 75% of the time)
If YES, what did you take?
When in your life did this problem with leakage of stool FIRST begin as close as you
can recall? (Check one answer.)
[] in the last 6 months
[] 7 months to 1 year ago
[] more than 1 year to 2 years ago
[] more than 2 years to 5 years ago
[] more than 5 years to 10 years ago
[] more than 10 years to 20 years ago
[] more than 20 years ago
IN THE LAST YEAR, did you ever wear a pad to protect your underclothes from
soilage or leakage of stool? (Check one answer.)
[] never
[] sometimes (less than 25% of the time)
[] often (more than 25% of the time)
[] usually (more than 75% of the time)
If you have to wear a pad to protect your underwear from stool leakage, when do you
wear it? (Check one answer.)
[] while awake
[] while asleep
[] both while awake and asleep
[] I do not wear a pad




[] there was no difference in leakage while asleep or awake
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IN THE LAST YEAR, have you felt the need to always know where the nearest
toilet is? (Check one answer.)
[] No
[] Yes
When leakage of stool has occurred IN THE LAST YEAR, did you have problems
with leakage of LIQUID or RUNNY stool? (Check one answer.)
[] never
[] sometimes (less than 25% of the time that leakage occurred)
[] often (more than 25% of the time that leakage occurred)
[] usually (more than 75% of the time that leakage occurred)
When leakage of stool has occurred IN THE LAST YEAR, did you have problems
with leakage of SOLID, or formed stool? (Check one answer.)
[] never
[] sometimes (less than 25% of the time that leakage occurred)
[] often (more than 25% of the time that leakage occurred)
[] usually (more than 75% of the time that leakage occurred)
When these "accidents" with leakage of stool occurred IN THE LAST YEAR, how
much stool TYPICALLY leaked out? (Check one answer.)
[] a small amount, with a stain about the size of a quarter
[] moderate amounts (often requiring a change of pad or underwear)
[] large bowel movements (often requiring a complete change of clothes)
[] solid or formed stool
IN THE LAST YEAR, have you been able to tell when this leakage of stool was
about to occur? (Check one answer.)
[] never
[] sometimes (less than 25% of the time)
[] often (more than 25% of the time)
[] usually (more than 75% of the time)
When these "accidents" with leakage of stool occurred, were you aware when the
leakage was actually happening? (Check one answer.)
[] never
[] sometimes (less than 25% of the time)
[] often (more than 25% of the time)
[] usually (more than 75% of the time)
Have you had difficulty telling the difference between the need to pass gas and the
need to pass stool IN THE LAST YEAR? (Check one answer.)
[] never
[] sometimes (less than 25% of the time)
[] often (more than 25% of the time)
[] usually (more than 75% of the time)
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Appendix 2 - Fecal Incontinence Quality of Life Scale232
Q 1: In general, would you say your health is:
1 [] Excellent




Q2: For each of the items, please indicate how much of the time the issue is a
concern for you due to accidental bowel leakage. (If it is a concern for you for
reasons other than accidental bowel leakage then check the box under Not Apply,
(N/A).)
1 = Most of the time
2 = Some of the time
3 = A little of the time
4 = None of the time
Due to accidental bowel leakage:
a. I am afraid to go out
1 2 3 4 N/A
b. I avoid visiting friends
1 2 3 4 N/A
c I avoid staying overnight away from home
1 2 3 4 N/A
d. It is difficult for me to get out and do things like going to a movie or to church
1 2 3 4 N/A
e. I cut down on how much I eat before I go out
1 2 3 4 N/A
f. Whenever I am away from home, I try to stay near a restroom as much as possible
1 2 3 4 N/A
g It is important to plan my schedule (daily activities) around my bowel pattern
1 2 3 4 N/A
h. I avoid traveling
1 2 3 4 N/A
i I worry about not being able to get to the toilet in time
1 2 3 4 N/A
j. I feel I have no control over my bowels
1 2 3 4 N/A
k. I can't hold my bowel movement long enough to get to the bathroom
1 2 3 4 N/A
1.1 leak stool without even knowing it
1 2 3 4 N/A
m. I try to prevent bowel accidents by staying very near a bathroom
1 2 3 4 N/A
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Q3: Due to accidental bowel leakage, indicate the extent to which you AGREE or
DISAGREE with each of the following items. (If it is a concern for you for reasons
other than accidental bowel leakage then check the box under Not Apply, N/A).
1 = Strongly agree
2 = Somewhat agree
3 = Somewhat disagree
4 = Strongly disagree
Due to accidental bowel leakage:
a. I feel ashamed
1 2 3 4 N/A
b. I can not do many of things I want to do
1 2 3 4 N/A
c. I worry about bowel accidents
1 2 3 4 N/A
d. I feel depressed
1 2 3 4 N/A
e. I worry about others smelling stool on me
1 2 3 4 N/A
f. I feel like I am not a healthy person
1 2 3 4 N/A
g. I enjoy life less
12 3 4 N/A
h. I have sex less often than I would like to
1 2 3 4 N/A
i. I feel different from other people
1 2 3 4 N/A
j. The possibility of bowel accidents is always on my mind
1 2 3 4 N/A
k. I am afraid to have sex
1 2 3 4 N/A
1.1 avoid traveling by plane or train
1 2 3 4 N/A
m. I avoid going out to eat
*12 3 4 N/A
n. Whenever I go someplace new, I specifically locate where
1 2 3 4 N/A
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Q 4: During the past month, have you felt so sad, discouraged, hopeless, or had so
many problems that you wondered if anything was worthwhile?
1 [] Extremely So - To the point that I have just about given up
2 [] Very Much So
3 [] Quite a Bit
4 [] Some - Enough to bother me
5 [] A Little Bit
6 [] Not At All
Scale Scoring
Scales range from 1 to 5, with a 1 indicating a lower functional status of quality of
life. Scale scores are the average (mean) response to all items in the scale (e.g., add
the responses to all questions in a scale together and then divide by the number of
items in the scale. Not Apply is coded as a missing value in the analysis for all
questions.)
Scale 1. Lifestyle, ten items: Q2a Q2b Q2c Q2d Q2e Q2g Q2h Q3b Q31 Q3m
Scale 2. Coping/Behavior, nine items: Q2f Q2i Q2j Q2k Q2m Q3d Q3h Q3j Q3n
Scale 3. Depression/Self Perception, seven items: Q1 Q3d Q3f Q3g Q3i Q3k Q4,
(Question 1 is reverse coded.)
Scale 4. Embarrassment, three items: Q21 Q3a Q3e
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Appendix 3 - Patient Assessment of Constipation Quality of Life
Questionnaire (PAC-QOL)234
The following questions are designed to measure the impact constipation has had on
your daily life over the past 2 weeks. For each question, please check one box.
The following questions ask about vour symptoms related to constipation.
During the past 2 weeks, to what extent or intensity have you ...
1 = Not at all
2 = A little bit
3 = Moderately
4 = Quite a bit
5 = Extremely
1. Felt bloated to the point of bursting?
1 2 3 4 5
2. Felt heavy because of your constipation?
1 2 3 4 5
The next few questions ask about how constipation affects vour daily life.
During the past 2 weeks, how much of the time have you ...
1 = None of the time
2 = A little of the time
3 = Some of the time
4 = Most of the time
5 = All of the time
3. Felt any physical discomfort?
1 2 3 4 5
4. Felt the need to have a bowel movement but not been able to?
1 2 3 4 5
5. Been embarrassed to be with other people?
1 2 3 4 5
6. Been eating less and less because of not being able to have bowel movements?
1 2 3 4 5
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The next few questions ask about how constipation affects your daily life.
During the past 2 weeks, to what extent or intensity have you ...
1 = Not at all
2 = A little bit
3 = Moderately
4 = Quite a bit
5 = Extremely
7. Had to be careful about what you eat?
1 2 3 4 5
8. Had a decreased appetite?
1 2 3 4 5
9. Been worried about not being able to choose what you eat (for example, at a
friend's house)?
1 2 3 4 5
10. Been embarrassed about staying in the bathroom for so long when you were
away from home?
1 2 3 4 5
11. Been embarrassed about having to go to the bathroom so often when you were
away from home?
1 2 3 4 5
12. Been worried about having to change your daily routine (for example, traveling,
being away from home)?
1 2 3 4 5
The next few questions ask about your feelings related to constipation.
During the past 2 weeks, how much of the time have you ...
1 = None of the time
2 = A little of the time
3 = Some of the time
4 = Most of the time
5 = All of the time
13. Felt irritable because of your condition?
1 2 3
14. Been upset by your condition?
1 2 3
15. Felt obsessed by your condition?
1 2 3











17. Felt less self-confident because of your condition?
12 3 4 5
18. Felt in control of your situation?
1 2 3 4 5
The next questions ask about your feelings related to constipation.
During the past 2 weeks, to what extent or intensity have you ...
1 = Not at all
2 = A little bit
3 = Moderately
4 = Quite a bit
5 = Extremely
19. Been worried about not knowing when you are going to be able to have a bowel
movement?
1 2 3 4 5
20. Been worried about not being able to have a bowel movement?
1 2 3 4 5
21. Been increasingly bothered by not being able to have a bowel movement?
1 2 3 4 5
The next questions ask about your life with constipation.
During the past 2 weeks, how much of the time have you ...
1 = None of the time
2 = A little of the time
3 = Some of the time
4 = Most of the time
5 = All of the time
22. Been worried that your condition will get worse?
1 2 3 4 5
23. Felt that your body was not working properly?
1 2 3 4 5
24. Had fewer bowel movements than you would like?
1 2 3 4 5
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The next questions ask about your degree of satisfaction related to constipation.
During the past 2 weeks, to what extent or intensity have you been ...
1 = Not at all
2 = A little bit
3 = Moderately
4 = Quite a bit
5 = Extremely
25. Satisfied with how often you have a bowel movement?
1 2 3 4 5
26. Satisfied with the regularity of your bowel movements?
1 2 3 4 5
27. Satisfied with the time it takes for food to pass through the intestines?
1 2 3 4 5
28. Satisfied with your treatment?
1 2 3 4 5
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Appendix 4 - The Gastrointestinal Quality of Life Index (GIQLI)235
1. How often during the past 2 weeks have you had pain in the abdomen?
all of the time, most of the time, some of the time, a little of the time, never
2. How often during the past 2 weeks have you had a feeling of fullness in the upper
abdomen?
all of the time, most of the time, some of the time, a little of the time, never
3. How often during the past 2 weeks have you had bloating (sensation of too much
gas in the abdomen)?
all of the time, most of the time, some of the time, a little of the time, never
4. How often during the past 2 weeks have you been troubled by excessive passage
of gas through the anus?
all of the time, most of the time, some of the time, a little of the time, never
5. How often during the past 2 weeks have you been troubled by strong burping or
belching?
all of the time, most of the time, some of the time, a little of the time, never
6. How often during the past 2 weeks have you been troubled by gurgling noises
from the abdomen?
all of the time, most of the time, some of the time, a little of the time, never
7. How often during the past 2 weeks have you been troubled by frequent bowel
movements?
all of the time, most of the time, some of the time, a little of the time, never
8. How often during the past 2 weeks have you found eating to be a pleasure?
all of the time, most of the time, some of the time, a little of the time, never
9. Because of your illness, to what extent have you restricted the kinds of food you
eat?
very much, much, somewhat, a little, not at all
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10. During the past 2 weeks, how well have you been able to cope with everyday
stresses?
extremely poorly, poorly, moderately, well, extremely well
11. How often during the past 2 weeks have you been sad about being ill?
all of the time, most of the time, some of the time, a little of the time, never
12. How often during the past 2 weeks have you been nervous or anxious about
your illness?
all of the time, most of the time, some of the time, a little of the time, never
13. How often during the past 2 weeks have you been happy with life in general?
never, a little of the time, some of the time, most of the time, all of the time
14. How often during the past 2 weeks have you been frustrated about your illness?
all of the time, most of the time, some of the time, a little of the time, never
15. How often during the past 12 weeks have you been tired or fatigued?
all of the time, most of the time, some of the time, a little of the time, never
16. How often during the past 2 weeks have you felt unwell?
all of the time, most of the time, some of the time, a little of the time, never
17. Over the past week, have you woken up in the night?
every night, 5-6 nights, 3-4 nights, 1-2 nights, never
18. Since becoming ill, have you been troubled by changes in your appearance?
a great deal, a moderate amount, somewhat, a little bit, not at all
19. Because of your illness, how much physical strength have you lost?
a great deal, a moderate amount, some, a little bit, none
20. Because of your illness, to what extent have you lost your endurance?
a great deal, a moderate amount, somewhat, a little bit, not at all
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21. Because of your illness, to what extent do you feel unfit?
extremely unfit, moderately unfit, somewhat unfit, a little unfit, fit
22. During the past 2 weeks, how often have you been able to complete your normal
daily activities (school, work, household)?
all of the time, most of the time, some of the time, a little of the time, never
23. During the past 2 weeks, how often have you been able to take part in your usual
patterns of leisure or recreational activities?
all of the time, most of the time, some of the time, a little of the time, never
24. During the past 2 weeks, how much have you been troubled by the medical
treatment of your illness?
very much, much, somewhat, a little, not at all
25. To what extent have your personal relations with people close to you (family or
friends) worsened because of your illness?
very much, much, somewhat, a little, not at all
26. To what extent has your sexual life been impaired (harmed) because of your
illness?
very much, much, somewhat, a little, not at all
27. How often during the past 2 weeks, have you been troubled by fluid or food
coming up into your mouth (regurgitation)?
all of the time, most of the time, some of the time, a little of the time, never
28. How often during the past 2 weeks have you felt uncomfortable because of your
slow speed of eating?
all of the time, most of the time, some of the time, a little of the time, never
29. How often during the past 2 weeks have you had trouble swallowing your food?
all of the time, most of the time, some of the time, a little of the time, never
30. How often during the past 2 weeks have you been troubled by urgent bowel
movements?
all of the time, most of the time, some of the time, a little of the time, never
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31. How often during the past 2 weeks have you been troubled by diarrhoea?
all of the time, most of the time, some of the time, a little of the time, never
32. How often during the past 2 weeks have you been troubled by constipation?
all of the time, most of the time, some of the time, a little of the time, never
33. How often during the past 2 weeks have you been troubled by nausea?
all of the time, most of the time, some of the time, a little of the time, never
34. How often during the past 2 weeks have you been troubled by blood in the
stool?
all of the time, most of the time, some of the time, a little of the time, never
35. How often during the past 2 weeks have you been troubled by heartburn?
all of the time, most of the time, some of the time, a little of the time, never
36. How often during the past 2 weeks have you been troubled by uncontrolled
stools?
all of the time, most of the time, some of the time, a little of the time, never
Calculation of the score:
most desirable option: 4 points
least desirable option: 0 points
GIQLI score: sum of the points
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Appendix 5 - Modified Manchester Health Questionnaire 237
SECTION A&B
1 = Never a = Never
2 = Rarely b = 1 to 3 times a month
3 = Sometimes c = Once a week
4 = Often d = 2 or more times a week
5 = Always e = Once a day
f = 2 or more times a day
A1. How often do you have a strong desire to move your bowels which makes you
rush to the toilet?
1 2 3 4 5
A2. How often in the past month have you experienced any amount of accidental
bowel leakage that consisted of solid stool?
b e f
B1. Do you lose any solid stool when coughing or sneezing?
1 2 3 4 5
B2. Do you lose any solid stool when walking?
1 2 3 4 5
B3. Besides coughing, sneezing, and walking, do you lose any solid stool during the
rest of the day or night?
1 2 3 4 5
A3. How often in the past month have you experienced any amount of accidental
bowel leakage that consisted of liquid stool?
b e f
B4. When you leak stool, how often is it liquid or watery?
1 2 3 4 5
B5. Do you lose any liquid stool when coughing or sneezing?
1 2 3 4 5
B6. Do you lose any liquid stool when walking?
1 2 3 4 5
B7. Besides coughing, sneezing, and walking, do you lose any liquid stool during the
rest of the day or night?
1 2 3 4 5
A4. How often in the past month have you experienced any amount of accidental
bowel leakage that consisted of mucus?
b d e f
A5. How often in the past month have you experienced any amount of accidental
bowel leakage that consisted of gas?
b d e f
B8. Do you lose any gas when coughing or sneezing?
1 2 3 4 5
B9. Do you lose any gas when walking?
1 2 3 4 5
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BIO. Besides coughing, sneezing, and walking, do you lose any gas during the rest of
the day or night?
1 2 3 4 5
B11. Do you have difficulty controlling gas?
1 2 3 4 5
SECTION C: If the answers to A1, A2, A3, A4, and A5 are all "Never," skip this
section.
A = 1-2 times a day 6 = 0
B = 3-4 times a day 7 = 25%
C = 5-6 times a day 8 = 50%
D = 7 or more times a day 9 = 75%
E = every other day 10 = 100%
F = less than every other day
CI. How much do you think your bowel problem affects your life?
1 2 3 4 5
C2. How often do you move your bowels each day?
A B C D E F
C3. Do you have difficulty wiping clean after you have moved your bowels?
1 2 3 4 5
C4. What percent of your bowel movements are hard or little balls?
6 7 8 9 10
C5. What percent of your bowel movements are loose or watery?
6 7 8 9 10
Role limitations:
C6. Do you have a problem with your bowels that affects doing jobs within the
home?
1 2 3 4 5 •
C6a. If so, how often does it affect you?
1 2 3 4 5
C7. Do you have a problem with your bowels that affects your job, or your normal
daily activities outside the home?
1 2 3 4 5
C7a. If so, how often does it affect you?
1 2 3 4 5
Physical/social limitations:
C8. Do you have a problem with your bowels that affects your ability to travel?
1 2 3 4 5
C8a. If so, how often does it affect you?
12 3 4 5
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C9. Do you have a problem with your bowels that affects your physical activities
(such as going for a walk, running, sport, gym, etc.)?
1 2 3 4 5
C9a. If so, how often does it affect you?
1 2 3 4 5
CIO. Do you have a problem with your bowels that limits your social life?
1 2 3 4 5
ClOa. If so, how often, does it affect you?
1 2 3 4 5
C11. Do you have a problem with your bowels that limits your ability to see and visit
friends?
1 2 3 4 5
CI la. If so, how often does it affect you?
1 2 3 4 5
Personal relationships:
CI2. Do you have a problem with your bowels that affects your relationship with
your partner?
1 2 3 4 5
CI2a. If yes, how often does it affect your relationship?
1 2 3 4 5
C13. Do you have a problem with your bowels that affects your family life?
1 2 3 4 5
CI3a. If so, how often does it affect your family life?
1 2 3 4 5
Emotions:
C14. Do you have a problem with your bowels that makes you feel depressed?
1 2 3 4 5
C14a. If yes, how often does it affect you?
1 2 3 4 5
CI5. Do you have a problem with your bowels that makes you feel anxious or
nervous?
1 2 3 4 5
CI5a. If yes, how often does it affect you?
1 2 3 4 5
C16. Do you have a problem with your bowels that makes you feel bad about
yourself?
12 3 4 5
CI6a. If yes, how often does it affect you?
1 2 3 4 5
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Sleep/energy:
CI7. Do you have a problem with your bowels that affects your sleep?
1 2 3 4 5
CI7a. If so, how often does it affect your sleep?
1 2 3 4 5
CI8. Do you have a problem with your bowels that makes you feel worn out and
tired?
1 2 3 4 5
CI 8a. If yes, how often does it affect you?
1 2 3 4 5
Sexual Activity: (For general audience, skip questions C19a to C19c.)
CI9. Have you resumed sexual activity since delivery?
CI 9a. If "Yes," when did you resume sexual activity? weeks after
delivery
CI9b. If "No," why have you not resumed sexual activity? (and skip to C24)
1 = not allowed by clinician yet
2 = too tired
3 = too painful
8 = other; specify
C20. Do you have a problem with your bowels that affects your sex life?
1 2 3 4 5
C20a. If so, how often does it affect your sex life?
1 2 3 4 5
C21. Do you lose any gas during or after sexual activity?
1 2 3 4 5
C22. Do you lose any stool during or after sexual activity?
1 2 3 4 5
C23. Do you lose any urine during or after sexual activity?
1 2 3 4 5
Lifestyle Adaptation:
C24. Do you wear pads to keep clean because of a problem with your bowels?
1 2 3 4 5
C24a. If yes, how often do you wear pads?
1 2 3 4 5
C25. Are you careful about how much food you eat because of a problem with your
bowels?
1 2 3 4 5
C25a. If yes, how often are you careful about how much food you eat?
12 3 4 5
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C26. Do you change your underclothes because they get dirty due to a problem with
your bowels?
1 2 3 4 5
C26a. If yes, how often do you change your underclothes for this reason?
1 2 3 4 5
C27. Do you worry about odor because of a problem with your bowels?
1 2 3 4 5
C27a. If yes, how often do you worry about it?
1 2 3 4 5
C28. Do you get embarrassed because of a problem with your bowels?
1 2 3 4 5
C28a. If yes, how often do you get embarrassed?
1 2 3 4 5
Medical:
C29. Did you bring any of your bowel symptoms to the attention of your clinician?
1 2 3 4 5
C30. Have you received treatment for your bowel symptoms?
C30a. If "Yes," please specify:
a = medical
b = behavioral
c = pelvic muscle exercise
d = surgical (specify)
e = other (specify)
C31. Do you have any comments that are important to you which have not been
covered?
A2, A3, A4, and A5 compose the FISI component of the questionnaire.
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Appendix 6 - Ditesheim and Templeton QoL scoring system 271
Regular school attendance Full time 1.0
Part time 0.5
Never 0
Social relations No limitations 1.0
Some self-imposed or parental restrictions 0.5
(eg, no overnights, no camping)
Very limited or restricted (eg, no parties, no 0
dating, very little contact with peers)
Physical capabilities Toilet free (able to be at least one hour 0.5
away from a toilet, as on a long-distance
car ride)
Participates in any sport; no limits on 0.5
swimming (age dependent)
No job limitations (age dependent) 0.5
Total score (range) 0-3.5
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Appendix 7 - Patient Assessment of Constipation Symptoms (PAC-
SYM)240
"How severe have each of these symptoms been in the last two weeks?"
1. Discomfort in your stomach.
2. Pain in your stomach.
3. Bloating in your stomach.
4. Stomach cramps.
5. Painful bowel movements.
6. Rectal burning during or after a bowel movement.
7. Rectal bleeding or tearing during or after a bowel movement.
8. Incomplete bowel movement, like you did not "finish".
9. Bowel movements that were too hard.
10. Bowel movements that were too small.
11. Straining or squeezing to try to pass bowel movements.
12. Feeling like you had to pass a bowel movement but you could not ("false
alarm").
Items are rated on a 5-point (0-4) Likert scale.
Responses are scored as 0 = absence ofsymptom, 1 = mild, 2 = moderate,
3 = severe and 4 = very severe.
The ABD, REC and STO domain scores are the mean scores ofeach domain.
The global score is the mean ofall 12 items.








School absence Never 2
Accidental 1
Frequent 0
Unhappy or anxious Never 2
Accidental 1
Frequent 0
Food restriction No 2
Somewhat 1
Much 0
Peer rejection Never 2
Accidental 1
Frequent 0
NOTE. The higher the scores, the better the quality of life. (Max. score 13)
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Appendix 9 - Pediatric Quality of Life Questionnaire (PedsQL)255
Child report (ages 8-12) (below) Parent report for children (ages 8-12)
Teen report (ages 13-18) Parent report for teens (ages 13-18)
Directions
On the following page is a list of things that might be a problem for you.
Please tell us how much of a problem each one has been for you during the pas
ONE month by circling:
0 if it is never a problem
1 if it is almost never a problem
2 if it is sometimes a problem
3 if it is often a problem
4 if it is almost always a problem
There are no right or wrong answers.
If you do not understand a question, please ask for help.
ABOUT MY HEALTH AND Never Almost Some¬ Often Almost
ACTIVITIES (problems Never times Always
with )
1. It is hard for me to walk 0 1 2 3 4
more than one block
2. It is hard for me to run 0 1 2 3 4
3. It is hard for me to do sports 0 1 2 3 4
activity or exercise
4. It is hard for me to lift 0 1 2 3 4
something heavy
5. It is hard for me to take a 0 1 2 3 4
bath or shower by myself
6. It is hard for me to do chores 0 1 2 3 4
around the house
7.1 hurt or ache 0 1 2 3 4
8.1 have low energy 0 1 2 3 4
ABOUT MY FEELINGS Never Almost Some¬ Often Almost
(problems with ) Never times Always
1.1 feel afraid or scared 0 1 2 3 4
2.1 feel sad or blue 0 1 2 3 4
3.1 feel angry 0 1 2 3 4
4.1 have trouble sleeping 0 1 2 3 4
5.1 worry about what will 0 1 2 3 4
happen to me
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1.1 have trouble getting along 0 1 2 3 4
with other kids
2. Other kids do not want to be 0 1 2 3 4
my friend
3. Other kids tease me 0 1 2 3 4
4.1 cannot do things that other 0 1 2 3 4
kids my age can do
5. It is hard for me to keep up 0 1 2 3 4
when I play with other kids
ABOUT SCHOOL Never Almost Someti Often Almost
(problems with ) Never mes Always
1. It is hard to pay attention in 0 1 2 3 4
class
2.1 forget things 0 1 2 3 4
3.1 have trouble keeping up
with my schoolwork
0 1 2 3 4
4.1 miss school because of not 0 1 2 3 4
feeling well
5.1 miss school to go to the 0 1 2 3 4
doctor or hospital
278





resetting the colonic clock...
TIC
TOC
V\fe are looking for volunteers (aged 8-18) to take part in a study at the Fbyal Children's
Hospital to took at the effectiveness of a new treatment for constipation
Children must have been
diagnosed with Sow Transit
Constipation (SIC) and have
undergone a minimum of 2 years
of treatment
The study involves stimulating the nervesto the bowel to see if this improves the way it
empties
The therapy will take the form of painless
electrical stimulation delivered through the
. skin by electrodes placed on the tummy
and back
This study follows up on a pilot study performed in 2002 from which the results are
encouraging
Anyone interested in finding out more about the study should contact Janet Cha9e or








Thank you for agreeing to take part in the TIC TOC trial. The child whose name
appears on the outside of this envelope has randomly been allocated to receive IFT
from Machine A.
Please do not discuss this information with anyone involved in the trial (including
coordinators and patients/family members) as all involved (apart from yourselves)
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Appendix 13 - Physiotherapist instruction pack






Thank you for agreeing to be part of the TIC TOC trial which is a NHMRC funded
trial aimed at investigating the effect of 2 levels of current (IFT A & B) on bowel
motility in children with slow transit constipation. The trial design is as follows:
An initial assessment is done by Dr Susie Gibb, Janet Chase and Melanie Clarke
followed by 4 weeks of baseline recording of bowel function.
Treatment then occurs in 5 steps:
Step 1-4 weeks of bowel stimulation using one level of current
Step 2-2 months of bowel diary
Step 3-4 weeks of bowel stimulation with the other level of current
Step 4-2 months of bowel diary
Step 5 - Contact at 3, 6 and 12 months after therapy to see how they are progressing
Your role is to administer the IFT according to the directions on the following
pages.
As we are aiming to eliminate any confounding factors in this trial such as
therapist/patient relationship, we are asking you to act as a technician rather than a
therapist, and not to give any advice, other treatment, expectations or feedback as to
whether you think IFT will be, or is being effective.
Our main outcome measure is the child's bowel diary and your encouraging the
child/family to continue to fill this in would be very helpful and very much
appreciated.
If you have concerns about either the child or equipment please contact us on the
following numbers.
Janet Chase: Ph: 92651401 Monday and Tuesday
Ph: 9345 6458 Wednesday and Thursday
or 9345 5805 (and leave a message)
Melanie Clarke: Ph: 9345 6458 or 9345 5522 pager 6655
Susie Gibb: Ph: Paging service 93871000
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Equipment
2 Metron interferential (IFT) machines, labelled A or B on the base of the machines,
will be supplied by the researchers.
You will be contacted by phone to set up appointments for the child, and by letter
with the randomisation results as to whether IFT A or B is to be used.
This must not be discussed with the child/family or the researchers who are to
remain blinded to this information.
Every application must be done the same way as far as possible. One machine has a
standard output (machine A) and the delivers no current (machine B). This means
that during the output check nothing will be felt with one machine whereas the other
will be standard. Note: the output meter on both will still register.
Protocol
(Standard protocol for electrical stimulation as per the APA, EPA Guidelines 2001')
Confirm patient is suitable.
Check skin intact & normally innervated in electrode placement area, no indwelling




Program recall/store Store to recall each time
Output display Either
Patient mode Single
Output mode -IFT, Tens or Russian IFT
Treatment time 20 min
Surge Off
Sweep range 80-150
Output configuration -4 pole or 2 pole 4 pole
Frequency 2.5,4 or 10 4kHz
Vector rotation Off
Output check
Turn on stimulator. Test the stimulator output on operator's hand/forearm. (Note:
Both machines will have an output show on the meter but you will not feel it on
machine B. If you have any concerns, contact Janet Chase).
After testing, leave stimulator on with the output at zero.
1 Robertson, V. J., Chipchase, L., Laakso, E., Whelan, K., & McKenna, L. (2001). Guidelines




Alcohol wipes where electrodes are to go, OR soap and water, rinse & pat dry - for
more details see below.
Electrodes
New, self adhesive sized: 50 x 50 mm (if you consider the size is not large enough
for older children, contact Janet Chase).
Locations: Anterior electrodes - 1 midway along and just below each costal margin.
Posterior electrodes - over erector spinae muscle midway between T9
and L2.
Connect each posterior electrode to a lead to contralateral anterior electrode.
Before beginning treatment
As per usual, warn the patient:
When I turn it up you might feel a tingling or no particular feeling. If you feel
anything or you can feel muscles twitching, let me know immediately as it's
important it stays low and must be comfortable. Do you understand what I have said?
Do you have any questions? Are you happy for me to proceed? (Based on EPA
Guidelines 2001, p7)
Intensity
Gradually turn up intensity until patient says can feel tingling or, if no such feeling,
to no more than halfway on the output dial (ie, 30mA).
Iffeels tingling: check after 2 to 5 minutes and turn up if necessary to maintain that
response. Record the final intensity setting (mA).
Iffeels no tingling: check after 2 to 5 minutes and turn output up to 40mA. Record
this level as max intensity (mA).
Leave on for 20 minutes. Check skin after removing electrodes.
Record
Complete tick box sheet (attached).
Appointments
12 sessions: 3 per week for 4 weeks.
AT THE END OF 12 SESSIONS PLEASE POST THE CHECKLIST IN THE
STAMPED SELF- ADDRESSED ENVELOPE PROVIDED FOR YOU
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DETAILS OF ELECTRODE PLACEMENT AND CARE
Clean the skin where the electrodes go
Use soap & water & pat dry, or, just an alcohol wipe.
Self Adhesive Electrodes
Open the packet and connect one pigtail to a lead.
Gently peel that electrode off its backing and put on the right place on the skin.
[Don't use the pigtail for this as it may pull the wire out of the electrode.]
Smooth the electrode on the skin so it sticks all over and is flat on the skin.
Repeat so you have all 4 electrodes on the skin - 2 paraspinally T10-11 to L2 and 2
on the anterior abdominal wall (attach to contralateral electrodes - usual IFT
arrangement) either side of the umbilicus just below the costal margin. If the child
has a stoma the electrode position may need to be adjusted slightly so it does not lie
directly over the stoma. Leads are attached so that each posterior electrode crosses
diagonally with its anterior "mate".
When it's time to take the electrodes off
Carefully peel off one electrode. Stick back onto its backing plastic. Hold the pigtale
and pull the connection out. Repeat with the other 3 electrodes in turn. Check the
underlying skin. It might be slightly red - that is usual. Anything else, contact Janet
Chase.
Care of self adhesive electrodes
Keep on the plastic backing in its sealable named plastic bag between uses.
After each use - put electrode back onto the backing it came on
- exclude all air bubbles between the electrode and backing
- add 4 or 5 drips of water to the backing - NO more.
Place electrodes in named plastic bag - exclude air and seal. Store flat.
Cared for this way, self adhesive electrodes will last for many uses.
When to throw out an electrode
DO NOT use an electrode if it does not stick all over to the skin.
When a corner starts to peel off it when you put it on the skin, throw it away and use
a new electrode.
Electrodes should only be reused on the same person.
Regarding payment
Your account for each child treated should be sent to:
Dr Bridget Southwell
Murdoch Childrens Research Institute
Flemington Rd
Parkville 3052
We suggest that the easiest way of doing this is at the end of 12 sessions, not after
each treatment.
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Please feel free to contact me at any stage. Thank you very much for participating.
WE ARE VERY GRATEFUL FOR YOUR ASSISTANCE WITH THIS
PROTOCOL
If you have any comments, please let us know. Remember, we need trial
coordinators and the child/family NOT to know which IFT machine is being used.
TIC TOC - FAQs regarding use of IFT
1. There is a problem as no output reading showing (raA)
ANSWER: If no output reading when standard testing on therapist performed there
is a problem. Machine should be checked. Contact Janet Chase.
2. Missed a set appointment. Do we make it up over time or leave it.
ANSWER: If one appointment missed, add an extra as soon as possible so 12
within 4 weeks. No more than 4 IFT treatments in any lweek.
3. Patient thinks there is a problem as cannot feel tingling
ANSWER: This may be 1 of several things:
• cutaneous sensory problem (do sharp/blunt test - if no sensation in electrode
area, patient not suitable for this study);
• the machine being used is a placebo machine (continue treatment as
scheduled but please do not discuss the output level with Janet or the
child/family)
• the intensity level is too low or has dropped since turned on (turn up until
tingling reported again or 40mA if not tingling felt at all)
• there is a problem with the machine (contact Janet Chase).
4. Patient thinks there is a problem as can feel tingling.
ANSWER: This is expected response for an unaltered IFT machine above an
intensity of 5mA.
5. Patient has had no responses after 6 treatments.
ANSWER: This may be 1 of several reasons
• response to IFT is not guaranteed and may not happen
• study is comparing 2 types of stimulation and 1 may be more effective in
some children
• response may take longer than 6 sessions.
Continue until 12 sessions and encourage the child to continue with their diary.
6. What parameters should I be using?
• beat frequency 80-150Hz
• carrier frequency 4kHz
• 4 pole ('true' IFT)
• no surge
• no vector rotation (ie, scanning)
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Appendix 14 - Parent information statement




Title of Project: Colonic manometry and transcutaneous stimulation (using interferential
therapy) in Slow Transit Constipation.
Investigators: B Southwell, J Hutson, S Gibb, A Catto-Smith, J Chase, V Robertson, M
Clarke
Thank you for taking the time to read this Information Statement.
This information statement and consent is 7 pages long. Please make sure you have all the
pages.
For people who speak languages other than English:
If you would also like information about the research and the Consent Form in your
language, please ask the person explaining this project to you.
Your child is invited to participate in a Research Project that is explained below.
What is an Information Statement?
These pages contain information about a research project we are inviting your child to take
part in. The purpose of this information is to explain to you clearly and openly all the steps
and procedures of this project. The information is to help you to decide whether or not you
would like your child to take part in the research.
Please read this information carefully. You can ask us questions about anything in it. You
may also wish to talk about the project with others eg friends or health care worker. Once
you have understood what the project is about, if you would like your child to take part
please sign the consent form at the end of this information statement. You will be given a
copy of this information and consent form to keep
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What is the Research Project about?
Slow Transit Constipation (STC) has been recognised as an important cause of constipation
in children. Treatment is improving but many children still suffer problems on a daily basis.
Children with STC have differences in the nerve systems in their bowel wall and therefore
have abnormal bowel movements. We want to see if stimulating the nerves to the bowel will
improve the way the bowel works. The therapy will be painless electrical stimulation that
will be delivered through the skin by electrodes placed on the tummy and back.
This treatment has already been widely used for a variety of conditions and is very safe. The
machine we are going to use is currently approved by the Australian Government for use in
physiotherapy.
In a similar study at the Royal Children's Hospital in 2002, 6 of 8 children with STC who
had this treatment had a significant improvement in their bowel symptoms. None of these
children had any side effects from the treatment.
We now need to find out just how effective the treatment is and what level of stimulation is
needed to produce results.
We are hoping that 80 children will take part in the study over a 3 year period. We want to
compare the effectiveness of two levels of treatment. They will receive both levels of
treatment in a random order. We will assess their response by a combination of daily bowel
habit recording, answering questionnaires and bowel transit studies.
The exact schedule is explained later under "What does my child need to do to be in this
research project".
Patients with an existing appendicostomy - If your child has an appendix stoma they will be
asked if they are willing to take part in a more involved study of their bowel movements.
This will involve looking at their bowels' ability to squeeze. This can be measured by what
is called manometry. This is explained in more detail under "What does my child need to do
to be in this research project".
The project is not sponsored by the company responsible for the production of the stimulator
machines. The project was started by Ms Janet Chase, Dr Susie Gibb and Profesor John
Hutson. None of them have a financial interest in the project.
Who are the Researchers?
Dr Susie Gibb, who is a Paediatrician from Continence Clinic, will assess children for entry
into the trial.
Ms Janet Chase, who is a continence physiotherapist, will assess children before and during
the trial.
Dr Melanie Clarke, who is a trainee surgeon doing an MD, will perform measurements of
bowel activity.
Regional physiotherapists will perform the stimulations.
This Trial is funded by the National Health and Medical Research Council. Four senior
researchers have designed this trial and raised the funds for the trial. They are Dr Bridget
Southwell, Prof John Hutson, A/Prof Tony Catto-Smith and Prof Val Robertson. Dr Bridget
Southwell, who is a Scientific Research Fellow and expert in the nervous system of the gut,
will coordinate the trial. Prof. John Hutson, who is an expert in intestinal surgery, treats
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many of the patients with STC. A/Prof. Tony Catto-Smith, who is a Gastroenterologist with
experience in measuring bowel activity, will oversee the manometry measurements. Prof.
Val Robertson, who is a physiotherapist expert in measuring the effects of electrical
stimulation and is located in Newcastle NSW, will give independent analysis of the data.
Why is my child being asked to be in this research project?
Your child has been shown to have Slow Transit Constipation (STC). We want to see if this
treatment improves the function of their bowel.
If your child has an existing appendicostomy we would like to measure the ability of their
bowel to squeeze and see if this ability is affected by the treatment.
We would like to talk to you and your child and explain the study in a way that is easy for
you both to understand.
What are my child's alternatives to participating in this project?
The decision to take part in this project is entirely your and your child's own choice. There
are no penalties for deciding not to take part, and their future treatment will not be affected.
If your child has an existing appendicostomy, they can have the stimulation therapy even if
they do not wish to participate in the manometry studies. They will receive the same
treatment as the other children in the study.
What does my child need to do to be in this research project?
Once you have agreed to take part in the research project you and your child will have an
initial assessment with a paediatrician and a physiotherapist. You will both be asked some
questions and your child will have a check-up. Part of this assessment will involve your
child having a heart tracing (ECG) and blood pressure measurements. We will also be
performing an abdominal ultrasound scan. Your child will need to have a bowel transit
study (if they have not already had one). At this stage you and your child will be asked to
start a diary that contains details of their bowel habits and you will need to keep filling this
in every day throughout the study. This is very important.
Your child will then be put into one of two groups by chance (similar to tossing a coin) to
determine in which order they receive their therapy. Neither you nor your child will be able
to tell which level they are getting.
4 weeks after starting the diary, your child will receive their first course of treatment. This
will be 12 half hour sessions (3 times a weeks for 4 weeks).
After the first treatment phase we will reassess your child over a 2 month period. This will
involve a repeat check-up and some more questions. They will also have another bowel
transit study. You will both need to keep filling in their diary.
They will then receive a second session of treatment, but this time at the other level of
stimulation. This will also be 12 half hour sessions (3 times a week for 4 weeks).
After the second treatment phase there will be another 2 month period of reassessment.
During this period you must continue to complete their toilet diary. They will have another
check-up and both of you will again be asked some questions. Your child may be asked to
have another bowel transit study.
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We will contact you and your child at 3,6 and 12 months after finishing the treatment. This
will be your follow-up and we will simply ask you both some more questions.
If your child has an existing appendicostomy and has agreed to take part in the manometry
(pressure recording) studies, this will involve a bit of extra time. Before starting the
treatment (as part of the initial assessment) they will have their first study. For each study
they will need to come into the surgical ward at the Royal Children's Hospital for 2 nights.
In order to measure the squeezing that happens in their bowel, we will put a thin plastic tube
in through their appendicostomy and allow it to travel along the bowel together with any
washout/poo. When the tube is in the right place we will connect the other end to a
recording machine for 24 hours and measure how many times their bowel squeezes and how
strong the squeezes are. During this time they will be able to eat and drink normally but they
will not be able to move around a lot as they are attached to the machine.
We will ask them to have another manometry study after they have had the first course of
therapy so see how it has affected the squeezing ability of their bowel.
The project will undergo continual review and monitoring. We are committed to the safety
and efficiency of this project and will attempt to detect any problems affecting you or your
child. We very much appreciate the considerable time required of you both for your
participation.
Is there likely to be a benefit to my child?
The results of our previous study suggest that this treatment may be effective in managing
bowel symptoms of children with STC. It is possible that the treatment will increase the
ability of their bowel to empty. This could potentially reduce your child's soiling and their
need for medication and, in those with appendicostomies, their need for washouts.
Is there likely to be a benefit to other people in the future?
We hope that electrical therapy will be useful in the treatment of many children with STC.
Current treatment involves frequent visits to hospital and may even involve the need for
surgery. This treatment could improve children's lives.
Even if the treatment proves to be less effective than we expect, the information that we gain
will greatly advance what we know about constipation in children.
What are the possible risks and/or side-effects?
Electrical therapy has no known side effects. To date none of the children who have
received electrical stimulation have experienced any side effects; however there could be as
yet unknown side effects. We will monitor closely for any possibility of these occurring.
All of the children who have had manometry studies have tolerated the procedure very well.
We do not anticipate any risks or side effects.
What are the possible discomforts and/or inconveniences?
The electrical therapy may cause a tingling sensation in the skin under the electrodes. This
stops as soon as the machine is switched off. Your child may find the sensation unusual but
it should not be uncomfortable.
With the manometry study, some children have had some abdominal cramps when the tube
passes around the bowel due to the stimulant that is used to help advance the tube. If at any
stage your child becomes too uncomfortable we will stop the test.
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Taking part does involve a considerable amount of dedication and time. It is essential that
you and your child provide us with as much information as possible so that we can get the
most out of the study.
What will be done to make sure the information is confidential?
All study information will be numbered and kept separately from any names and addresses.
Any results that are published will not include your child's name.
Will I be informed of the results when the research project is finished?
The results of your child's therapy and/or tests will be discussed with you both at the end of
the project. You will also be told about the results of the whole study. We also intend to
publish the results in the NIDKIDs and GGLF newsletters and on the NIDKIDs website.
You can decide whether or not to give permission for your child to take part in this
research project. You can decide whether or not you would like to withdraw your child
at any time without explanation.
You may like to discuss your child's participation in this research project with your family
and with your doctor. You can ask for further information before deciding to take part.
If you would like more information about the study or if you need to contact a study
representative in an emergency, the person to contact is:
Name: Professor John Hutson
Contact telephone: 03 9345 5805 (W)
What are my child's rights as a participant?
1. I am informed that except where stated above, no information regarding my child's
medical history will be released. This is subject to legal requirements.
2. I am informed that the results of any tests involving my child will not be published so as
to reveal my child's identity. This is subject to legal requirements.
3. The detail of the procedure proposed has also been explained to me. This includes how
long it will take, how often the procedure will be performed and whether any discomfort
will result.
4. It has also been explained that my child's involvement in the research may not be of any
benefit to him or her. I understand that the purpose of this research project is to
improve the quality of medical care in the future.
5. I have been asked if I would like to have a family member or a friend with me while the
project is explained to me.
6. I understand that this project follows the guidelines of the National Statement on Ethical
Conduct in Research Involving Humans (1999).
7. I understand that this research project has been approved by The Royal Children's
Hospital Ethics in Human Research Committee on behalf of The Royal Children's
Hospital Board.
8. I have received a copy of this document.
If you have any concerns about the study, and would like to speak to someone
independent of the study, please contact The RCH Consumer Liaison, Clinical Support
Services Team at the Executive Office. Telephone 9345 5676 (Monday to Friday 9am-
5pm).
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The Royal Children's Hospital, Melbourne
STANDARD INFORMED CONSENT FOR PARENT/GUARDIAN TO GIVE






voluntarily consent for my child to take
part in the above titled
Research Project, explained to me by
Mr/Ms/Dr/Professor
• I have received a Parent/Guardian Information Statement to keep and I believe I
understand the purpose, extent and possible effects of my child's involvement
• I have been asked if I would like to have a family member or friend with me while the
project was explained
• I have had an opportunity to ask questions and I am satisfied with the answers I have
received
• I understand that the researcher has agreed not to reveal results of any information
involving my child, subject to legal requirements
• If information about this project is published or presented in any public form, I
understand that the researcher will not reveal my child's identity
• I understand that if I refuse to consent to my child's participation, or if I withdraw my
child from the project at any time without explanation, this will not affect my child's
access to the best available treatment options and care from The Royal Children's
Hospital
• I understand I will receive a copy of this consent form
SIGNATURE Date
I have explained the study to the parent/guardian who has signed above, and believe that
they understand the purpose, extent and possible effects of their child's involvement in this
study.
RESEARCHER'S SIGNATURE Date
Note: All parties signing the Consent Form must date their own signature.
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Appendix 15 - Participant information statement




Title of Project: Colonic manometry and transcutaneous stimulation (using interferential
therapy) in Slow Transit Constipation.
Investigators: B Southwell, J Hutson, S Gibb, A Catto-Smith, J Chase, V Robertson, M
Clarke
Thank you for taking the time to read this Information Statement.
This information statement and consent is 8 pages long. Please make sure you have all the
pages.
For people who speak languages other than English:
If you would also like information about the research and the Consent Form in your
language, please ask the person explaining this project to you.
You are invited to participate in a Research Project that is explained below.
What is an Information Statement?
These pages contain information about a research project we are inviting you to take part in.
The purpose of this information is to explain to you clearly and openly all the steps and
procedures of this project. The information is to help you to decide whether or not you would
like to take part in the research.
Please read this information carefully. You can ask us questions about anything in it. You
may also wish to talk about the project with your parents or guardians, friends or health care
worker. Once you have understood what the project is about, if you wish to take part please
sign the consent form at the end of this information statement. You will be given a copy of
this information and consent form to keep.
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What is the Research Project about?
Slow Transit Constipation (STC) has been recognised as an important cause of constipation
in children. Treatment is improving but many of you still suffer problems on a daily basis.
Children with STC have differences in the nerve systems in their bowel wall and therefore
have abnormal bowel movements. We want to see if stimulating the nerves to the bowel will
improve the way the bowel works. The therapy will be painless electrical stimulation that
will be delivered through the skin by electrodes placed on the tummy and back.
This treatment has already been widely used for a variety of conditions and is very safe. The
machine we are going to use is currently approved by the Australian Government for use in
physiotherapy.
In a similar study at the Royal Children's Hospital in 2002, 6 of 8 children with STC who
had this treatment had a significant improvement in their bowel symptoms. None of these
children had any side effects from the treatment.
We now need to find out just how effective the treatment is and what level of stimulation is
needed to produce results.
We are hoping that 80 children will take part in the study over a 3 year period. We want to
compare the effectiveness of two levels of treatment. You will receive both levels of
treatment in a random order. We will assess your response by a combination of daily bowel
habit recording, answering questionnaires and bowel transit studies.
The exact schedule is explained later under "What do I need to do to be in this research
project".
Patients with an existing appendicostomy - If you have an appendix stoma you will be asked
if you are willing to take part in a more involved study of your bowel movements. This will
involve looking at your bowels ability to squeeze. This can be measured by what is called
manometry. This is explained in more detail under "What do I need to do to be in this
research project".
The project is not sponsored by the company responsible for the production of the stimulator
machines. The project was started by Ms Janet Chase, Dr Susie Gibb and Profesor John
Hutson. None of them have a financial interest in the project.
Who are the Researchers?
Dr Susie Gibb, who is a Paediatrician from the Continence Clinic, will assess children for
entry into the trial.
Ms Janet Chase, who is a continence physiotherapist, will assess children before and during
the trial.
Dr Melanie Clarke, who is a trainee surgeon doing an MD, will perform measurements of
bowel activity.
Regional physiotherapists will perform the stimulations.
This Trial is funded by the National Health and Medical Research Council. Four senior
researchers have designed this trial and raised the funds for the trial. They are Dr Bridget
Southwell, Prof John Hutson, A/Prof Tony Catto-Smith and Prof Val Robertson. Dr Bridget
Southwell, who is a Scientific Research Fellow and expert in the nervous system of the gut,
will coordinate the trial. Prof. John Hutson, who is an expert in intestinal surgery, treats
many of the patients with STC. A/Prof. Tony Catto-Smith, who is a Gastroenterologist with
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experience in measuring bowel activity, will oversee manometry measurments. Prof. Val
Robertson, who is a physiotherapist expert in measuring the effects of electrical stimulation
and is located in Newcastle NSW, will give independent analysis of the data.
Why am I being asked to be in this research project?
You have been shown to have Slow Transit Constipation (STC). We want to see if this
treatment improves the function of your bowel.
If you have an existing appendicostomy we would like to measure the ability of your bowel
to squeeze and see if this ability is affected by the treatment.
We would like to talk to you and explain the study in a way that is easy for you to
understand.
What are the alternatives to participating in this project?
The decision to take part in this project is entirely your own choice. There are no penalties
for deciding not to take part, and your future treatment will not be affected.
If you have an existing appendicostomy, you can have the stimulation therapy even if you do
not wish to participate in the manometry studies. You will receive the same treatment as the
other children in the study.
What do I need to do to be in this research project?
Once you have agreed to take part in the research project you will have an initial assessment
with a doctor and a physiotherapist. You will be asked some questions and will have a
check-up. As part of this assessment we will measure your blood pressure and do a heart
tracing (ECG). We will also be doing an ultrasound scan of your tummy. You will need to
have a bowel transit study (if you have not already had one). You will be asked to start a
diary that contains details of your pooing habits and you will need to keep filling this in
every day throughout the study. This is very important.
4 weeks after starting your diary, you will receive your first course of treatment. This will
be 12 half hour sessions (3 times a weeks for 4 weeks).
After the first treatment phase we will reassess you over a 2 month period. This will involve
a repeat check-up and some more questions. You will also have another bowel transit study.
You will need to keep filling in your diary.
You will then receive a second session of treatment, but this time at the other level of
stimulation. This will also be 12 half hour sessions (3 times a week for 4 weeks).
After the second treatment phase there will be another 2 month period of reassessment. You
must still fill in your diary. You will have another check-up and will again be asked some
questions. You may be asked to have another bowel transit study.
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Toilet Diary - You will start this 4 weeks
before having any therapy and will keep it
going for the whole treatment period
Treatment - This will be a 5-step programme
Step 1 First Course of Bowel Stimulation ■ 12 half-
hour sessions (3 times a week) over 4 weeks.
We will connect you to a machine by wires
applied painlessly to the skin of the tummy
and back
Step 2 Re-Assessment Over 2 Months
Step 3 Second Course of Bowel Stimulation -12
half-hour sessions (3 times a week) over 4
weeks
Step 4 Re-Assessment Over 2 Months
Step 5 Follow Up - Contact at 3, 6 and 12 months
after therapy (questionnaires and
examinations)
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We will contact you at 3, 6 and 12 months after finishing the treatment. This will be your
follow-up and we will simply ask you some more questions.
If you have an existing appendicostomy and have agreed to take part in the manometry
studies, this will involve a bit of extra time. Before starting the treatment (as part of the
initial assessment) you will have your first study. For each study you will need to come into
the surgical ward at the Royal Children's Hospital for 2 nights. In order to measure the
squeezing that happens in your bowel, we will put a thin plastic tube in through your
appendicostomy and allow it to travel along the bowel together with any washout/poo.
When the tube is in the right place we will connect the other end to a recording machine for
24 hours and measure how many times your bowel squeezes and how strong the squeezes
are. During this time you will be able to eat and drink normally but you will not be able to
move around a lot as you are attached to the machine.
We will ask you to have another manometry study after you have had the first course of
therapy to see how it has affected the squeezing ability of your bowel.
The project will undergo continual review and monitoring. We are committed to the safety
and efficiency of this project and will attempt to detect any problems affecting you. We
very much appreciate the considerable time required of you for your participation.
Is there likely to be a benefit to me?
The results of our previous study suggest that this treatment may be effective in managing
your bowel symptoms. It is possible that the treatment will increase your bowel emptying.
This may reduce your soiling and need for medication and, in those of you with
appendicostomies, your need for washouts.
Is there likely to be a benefit to other people in the future?
We hope that electrical therapy will be useful in the treatment of many children with STC.
Current treatment involves frequent visits to hospital and may even involve the need for
surgery. This treatment could improve children's lives.
Even if the treatment proves to be less effective than we expect, the information that you
give us will greatly advance what we know about constipation in children.
What are the possible risks and/or side-effects?
Electrical therapy has no known side effects. To date none of the children who have
received electrical stimulation have experienced any side effects; however there could be as
yet unknown side effects. We will monitor closely for any possibility of these occurring.
All of the children who have had manometry studies have tolerated the procedure very well.
We do not anticipate any risks or side effects.
What are the possible discomforts and/or inconveniences?
The electrical therapy may cause a tingling sensation in the skin under the electrodes. This
stops as soon as the machine is switched off. You may find the sensation unusual but it
should not be uncomfortable.
With the manometry study, some children have had some tummy cramps when the tube
passes around the bowel due to the stimulant that is used to help the tube to move. If at any
stage you become too uncomfortable we will stop the test.
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Taking part does involve a considerable amount of dedication and time. It is essential that
you provide us with as much information as possible so that we can get the most out of the
study.
What will be done to make sure the information is confidential?
Your study information will be numbered and kept separately from any of your names and
addresses. Any results that are published will not include your names.
Will I be informed of the results when the research project is finished?
The results of your therapy and/or tests will be discussed with you at the end of the project.
You will also be told about the results of the whole study. We also intend to publish the
results in the NIDKIDs and GGLF newsletters and on the NIDKIDs website.
You can decide whether or not to take part in this research project. You can decide
whether or not you would like to withdraw at any time without explanation.
You may like to discuss participation in this research project with your family and with your
doctor. You can ask for further information before deciding to take part.
If you would like more information about the study or if you need to contact a study
representative in an emergency, the person to contact is:
Name: Prof. John Hutson
Contact telephone: 03 9345 5805 (W)
What are my rights as a participant?
1. I am informed that except where stated above, no information regarding my medical
history will be released. This is subject to legal requirements.
2. I am informed that the results of any tests involving me will not be published so as to
reveal my identity. This is subject to legal requirements.
3. The detail of the procedure proposed has also been explained to me. This includes how
long it will take, how often the procedure will be performed and whether any discomfort
will result.
4. It has also been explained that my involvement in the research may not be of any benefit
to me personally. I understand that the purpose of this research project is to improve the
quality of medical care in the future.
5. I have been asked if I would like to have a family member or a friend with me while the
project is explained to me.
6. I understand that this project follows the guidelines of the National Statement on Ethical
Conduct in Research Involving Humans (1999).
7. I understand that this research project has been approved by The Royal Children's
Hospital Ethics in Human Research Committee on behalf of The Royal Children's
Hospital Board.
8. I have received a copy of this document.
If you have any concerns about the study, and would like to speak to someone
independent of the study, please contact The RCH Consumer Liaison, Clinical Support
Services Team at the Executive Office. Telephone 9345 5676 (Monday to Friday 9am-
5pm).
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STANDARD INFORMED CONSENT





voluntarily consent for my child to take
part in the above titled
Research Project, explained to me by
Mr/Ms/Dr/Professor
• I have received a Participant Information Statement to keep and I believe I understand
the purpose, extent and possible effects of my involvement
• I have been asked if I would like to have a family member or friend with me while the
project was explained
• I have had an opportunity to ask questions and I am satisfied with the answers I have
received
• I understand that the researcher has agreed not to reveal results of any information
involving me, subject to legal requirements
• If information about this project is published or presented in any public form, I
understand that the researcher will not reveal my identity
• I understand that if I refuse to consent, or if I withdraw from the study at any time
without explanation, this will not affect my access to the best available treatment options
and care from The Royal Children's Hospital
• I understand I will receive a copy of this consent form
I have explained the study to the participant who has signed above, and believe that they
understand the purpose, extent and possible effects of their involvement in this study.
SIGNATURE Date
RESEARCHER'S SIGNATURE Date
Note: All parties signing the Consent Form must date their own signature.
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Age of onset symptoms:
Date of diagnosis of STC:
Transit study: Yes/No Result
Biopsies: Yes/No Result
History














Current bladder symptoms: Day: urgency (Y/N), wetting (Y/N), posturing Y/N),
frequency (Y/N), hesitancy (Y/N), straining to void
(Y/N), infrequent voiding (Y/N)
Night: wetting (Y/N), nocturia (Y/N)













Softeners (Y/N), Osmotic agents (Y/N), Movicol















Abdominal mass - inc faecaloma Yes/No
Palpable bowel loops Yes/No




Sacral dimple/sacral hair tuft
Obvious spinal deformity
Muscle (esp buttock) wasting
Anal inspection:
Site



































In the last week have you had any feeling in your bottom of needing to do a poo?
0 I I 10
none strong and definite
feeling to poo
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Appendix 18 - Bowel diary
WELCOME TO THE TIC TOC TRIAL
and thank you for being part of it. We hope that you enjoy your involvement
and we look forward to getting to know you better.
If at any time you have any questions or problems in regard to the trial, do not hesitate to
phone us.
Janet Chase: Ph: 9345 6458 Wednesday and Thursday
or 9345 5805
Susie Gibb: Ph: Paging service 93871000
On the next page you will find an explanation of how to fill in you bowel diary. You
need to do this every day throughout the trial, so this will take a lot of commitment and
hard work on your part, even though it should only take 1-2 minutes per day to do.
Below is a summary of how the trial works. This is also explained in The Participant
Information Statement that you have already been given.
Initial assessment involves a bowel transit study (if you haven't already had one), and a
check-up by Susie Gibb and a look at your back and tummy muscles and posture by
Janet Chase.
Treatment occurs in 5 steps
Step 1-4 weeks of bowel stimulation using one form of current
Step 2-2 months of bowel diary
Step 3-4 weeks of bowel stimulation with the other form of current
Step 4-2 months of bowel diary
Step 5 - We contact you 6 and 12 months after therapy to see how you are doing.
INSTRUCTIONS FOR COMPLETING THE BOWEL DIARY
In this folder you should find a copy of the Bristol Stool Scale and some of the diary
pages that are colour-coded according to the stage in the trial in which you are using
them - blue for pre-treatment, red for the first 4 weeks of electrical stimulation, yellow
for the following 2 months, purple for the second course of electrical stimulation and
green thereafter. The rest we will give you as you go along.
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1 The diary must be filled in each night before you go to bed, so you can remember what
happened that day.
2 Make sure that each day has a date (day/month/year) and your code name is on it. This
is the name you can choose so that your real name does not appear on any paperwork.
3 Under the column headed "Bowel action and type"
- put a tick (V) for each bowel action you have.
- the tick goes in the 'sit' column if it happened as the result of going to
the toilet to sit without any feeling of needing to poo.
- the tick goes in the 'spontaneous' column, if you went to the toilet
because you had a feeling that you needed to poo.
- 'type' refers to the number that best describes the type of poo on the
Bristol Stool Scale.
4 Under the column headed "Soiline"
- put an 's' for each episode of soiling during the day.
- the's' goes in the 'stain' column if the soiling was just a stain on the
underwear.
- the's' goes in the 'scrape' column if poo had to be scraped off before
the underwear could be washed.
5 The column headed "Tablets, medicines, suppositories, enemas, washouts" is where
you record the medicines etc .you had that day, and whether you had a bowel washout -
just write "w.o." if you did.
6 The column headed "Physio today?" is to record the days that you have electrical
stimulation for your bowel.
7 The next column is to record whether you have "Tummy vain" or not on each
particular day.
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MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY SUNDAY
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Date of first symptoms:-
Date of diagnosis: -












1-3 days 4-7 days 1-2 weeks 2-3 weeks
Initial device used:-
Chait button Silastic catheter Intermittent catheterisation
Other
Please comment:













None Stress/diarrhoea associated Constant
Rectal sensation?
Normal Defective Absent
Ability to hold back defaecation?
Mins Sees Absent
Discrimination between formed, loose or gaseous stools?
Normal Defective Absent




Full time Part time Never
Social limitations?
No limitations Some self imposed or parental restrictions
Very limited or restricted
Toilet free (can be an hour from a toilet)?
Yes No
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Does your child use laxatives?
Yes No Occasionally
What type of laxative?
Does your child require regular suppositories?
Yes No
Does your child require enemas?
Yes No
Does your child ever require disempaction?
Yes No
Is your child on any other treatment?
What food or drinks does you child not tolerate?
Does your child currently suffer from abdominal pain/discomfort?
Yes No
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How frequent is the pain?
Daily 3-6 days/week
1-2 days/fortnight 1-2 days/month





Golytely Phosphate enemas Dulcolax enemas Plain water




How often does your child have episodes of soiling?
Never Daily 3-6 days/week 1-2 days/week
1-2 days/fortnight 1-2 days/month Every 2-3 months
If using an appendicostomy, when are the soiling episodes most common?
Between washouts Just before washouts Only after washouts
Does your child use any protective clothing?
Pads Nappies Others None
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How often does your child wear protective clothing?
All the time Only during daytime Only during night time
Only after washouts Day after washouts Occasionally
Does your child have any problems with urinary incontinence?
Yes No Occasionally
How often does your child have episodes of urinary incontinence?
Daily 3-6 days/week 1-2 days/week
1-2 days/fortnight 1-2 days/month Every 2-3 months
ASPIRATIONS
When do you think that your child will stop requiring medication?
<5 years 5-10 years 10-15 years 15-20 years 20-25years
>25 years Don't know When they don't need it anymore
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Appendix 21 - Instruction letter for manometry
TIC TOC Trial





Tel: (03) 9345 6458
Thank you for enrolling in the TIC TOC trial and for agreeing to take part in the
bowel pressure measurement (manometry) studies.
An appointment has been made for you at the Childrens Hospital on Wednesday
30th August. Please can you present to admissions at 9am on Wednesday and ask
that they page Melanie Clarke or Di Simpson. You will be in hospital for 3 days
(Weds-Fri) with the actual study running for 24hours starting on the Thursday
morning. For the duration of the study (24hrs) you will have to stay in bed and
although you can have your own television and games station, remember to bring
plenty of extra things to do!
You will be free to go home around lunchtime on Friday. We will explain
everything to you before starting the study, and you can ask as many questions as
you like at any time!
Before you attend for the study there are a few things we would like to change with
your washout regime.
(i) No stimulants (ie Bisacodyl, Phosphate/Dulcolax enemas) via your
appendicostomy for 5 days before you come in.
(ii) Perform washouts on the Sunday and Tuesday prior to admission with
water only.
If you have any questions about the manometry or anything else to do with the study,
don't hesitate to contact us.
We look forward to seeing you,
Melanie Clarke





Appendix 22 - Manometry menu choices
24 Hour Colonic Manometry Study Meal Options
Option 1:
Breakfast:
White Bread 2 slices 46g
Margarine 1 tsp 5g
Peanut Butter 1 tbsp 20g
Rice Bubbles 1 cup 30g
Full Cream Milk 1 cup 250mls
Lunch:
Meat Pie or 4 Party Pies 1 or 4 190g
Tomato Sauce 1 tbsp 25g
Iced Donut 1 80g
Chips 1 cup 95g
Dinner:
Spaghetti Bolognese
Spaghetti M cup 90g
Meat Sauce 3 tbsp 60g
Parmesan Cheese 2 tbsp 20g
Self-Saucing Pudding Zi cup 80g
Cream 2 tbsp 40g
Chocolate Milk 2 cup 500mls
Option 2:
Breakfast:
Full Cream Milk 1 cup 250mls
Ham 1 slice 17.5g
Cheese 1 slice 21g
Croissant 1 65g
Margarine 1.5 tbsp 15g
Lunch:
Cheese 2 slices 42g
Tomato 14 35g
Margarine 1 tbsp 20g
White Bread 4 slices 112g
Custard 1 cup 260g
Chocolate Milk 1 cup 250mls
Dinner:
Grilled sausages 4 120g
Tomato sauce 1 tbsp 25g
White bread roll 1 90g
Chips Zi cup 47g
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Canned pears 2 halves 180g




White toast 2 slices 46g
Margarine 1 tbsp 19g
Fried eggs 2 eggs 70g
Chocolate milk 1 cup 250mls
Lunch:
Shepherd's pie 1 200g
Chips 1 cup 95g
Fruit cake 1 slice 50g
Ice cream 2 scoops 48g
Dinner:
Ham and pineapple pizza 2 slices 200g
Chocolate cake 1 slice 55g
Cream 1 tbsp 20g
Chocolate milk 2 cup 500mls
Appendix 23 - Manometry event diary
24 HOUR COLONIC MANOMETRY PATIENT DIARY
PATIENT NAME:
DATE;
Time Started Time Finished Activity Comments
Examples of important activities to record:
Bowel action, bowel urgency, abdominal sensations, passing urine, eating, drinking,
change of posture, change bedhead.
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Appendix 24 - Plain abdominal radiograph demonstrating final position
of manometry catheter and relative positions of the side holes
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